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List of abbreviation 
 
The following acronyms are used in the thesis: 
 
°C     Degree celsius 
ex      Excitation wavelength 
em     Emission wavelength 
µg     Microgram 
µL     Microliter 
µm     Micrometer 
3-NBA 3-Nitrobenzanthrone 
4-ABP 4-Aminobiphenyl 
5-meC     5’-methylcytosine     
5-me-dCMP    5’-methyl-2’-deoxycytosine-3’-monophosphate 
8-oxo-dGMP 8-oxo-2’-deoxyguanosine-3’-monophosphate 
8-OH-dG 8-hydroxy-2’-deoxyguanosine 
8-oxo-dG 8-oxo-2’-deoxyguanosine 
A     Adenine 
AA(s)     Aristolochic acid (s) 
AAN      Aristolochic acid nephropathy 
AP     Apurinic site, 2’-deoxyribose-3’-monophosphate 
ART     Assisted reproduction technologies  
B[a]P      Benzo[a]pyrene 
Bar     Pressure unit 
BEN      Balkan endemic nephropathy  
BER Base excision repair 
BODIPY 4,4-Difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacen-
3-propionylethylendiamine hydrochloride 
Bp Base pair 
BW Body weight 
C     Cytosine 
CE     Capillary electrophoresis 
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CE-LIF Capillary electrophoresis with laser induced fluorescence 
detector 
CE-UV Capillary electrophoresis with ultraviolet detection 
CGE     Capillary gel electrophoresis 
CEC     Capillary electrochromatography 
CH2CL2    methylene chloride 
CHN      Chinese Herbs nephropathy  
CIEF     Capillary isoelectric focusing  
CITP     Capillary isotachophoresis 
cm     Centimeters 
COBRA Combined bisulphite restriction analysis 
CpG-Island    5’-CG-3’-dinucleotides 
CT-DNA    Calf thymus-DNA 
CZE     Capillary zone electrophoresis 
dAMP (or 3’-dAMP) 2’-deoxyadenosine-3’-monophosphate 
dA-AA I,II     7-(2’-deoxyadenosine-N6-yl)-aristolactam I,II 
dC-AAII    7-(2’-deoxycytosine-N6-yl)-aristolactam II 
dG-AA    7-(2’-deoxyguanosine-N2-yl)-aristolactam 
dCMP (or 3’-dCMP) 2’-deoxycytidine-3’-monophosphate 
dG 2’-deoxyguanosine 
dGMP (or 3’-dGMP) 2’-deoxyguanosine-3’-monophosphate 
dTMP (or 3’-dTMP) Thymidine-3’-monophosphate 
Da     Daltons 
DNA     Deoxyribonucleic acid 
DNase I     Deoxyribonuclease I     
Dnmt DNA-methyl transferase 
DZ Dizygotic twins 
e.g. Example 
EDC 1-ethyl-3-(3’-N,N’-dimethylaminopropyl)-carbodiimide 
hydrochloride  
EDTA Ethylene diamine tetraacetic acid 
ESI-MS Electrospray ionisation mass spectrometry 
EtOH Ethanol 
   f Corrrection factor  
  3
FDA Food and drug administration 
Fe2+ Ferrous ion 
Fig Figure 
G Guanine 
h Hours 
H2O Water 
H2O2
     Hydrogen peroxide  
HAAs     Heterocyclic aromatic amines 
HBO     Hyperbaric oxygen 
HC Holstein clones 
HCL     Hydrochloric acid 
HEPES N-(2-hydroxyethyl)-piperazine-N’-2-ethanesulphonic 
acid 
Hpa II    Hpa II Methyl transferase 
HPLC High performance liquid chromatography 
HPLC-ESI-MS High performance liquid chromatography with electros-
pray ionisation mass spectrometry 
HPLC-MS High performance liquid chromatography with mass 
spectrometry  
HPLC -UV High performance liquid chromatography with ultravio-
let detection 
Hupki     Human p53 knock in  
ICSI     Intracytoplasmic sperm injection 
ID     Inner diameter 
ITP     Isotachophoresis 
IVF     In vitro-Fertilisation 
kV     Kilovolts 
L     Liter (s) 
LD     Length of capillary to the detector 
LIF Laser induced fluorescence 
LOS Large Offspring Syndrome 
LT      Total capillary length 
mbar     Millibar 
MEKC    Micellar electrokinetic chromatography 
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MEKC-LIF    Micellar electrokinetic chromatography with laser in-
duced fluorescence detector 
MeOH     Methanol 
mL     Milliliter(s) 
mm     Millimeter 
MN Micrococcal nuclease 
MS Mass spectrometry 
MSREs Methylation sensitive restriction endonuclease 
mW Milliwatt 
MZ Monozygotic twins 
m/z Mass to charge ratio 
N.B. Nota bene 
Na2HPO4    Disodium hydrogen phosphate  
NaH2PO4 Sodium dihydrogen phosphate  
NaHCO3  Sodium bicarbonate 
NaOH Sodium hydroxide 
Na2SO3    Sodium sulphite  
ng Nanogram 
nL     Nanoliter(s) 
nm     nanometer 
NADPH-oxidase   Nicotinamide adenine dinucleotide phosphate oxidase 
NER     Nucleotide excision repair 
OH.     Hydroxyl free radical 
O2
 Oxygen 
O2-
. Superoxide ion 
O3
 Ozone 
OPSL Optically pumped semiconductor laser 
P     Pressure 
PA Peak area 
PAEKI Pressure assisted electrokinetic injection 
PAHs Polycyclic aromatic hydrocarbons 
PCR Polymerase chain reaction 
psi Pound per square inch 
RFU     Relative fluorescence unit 
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RIA Radioimmunoassay 
ROS Reactive oxygen species 
RP Reversed phase 
Rpm Revolutions per minute 
RT     Room temperature 
R.t.     Retention time 
SAM     S-adenosyl methionine 
SC Simmental clones 
SCNT Somatic cell nuclear transfer 
S.D. Standard deviation 
SDS Sodium dodecyl sulphate 
s Seconds 
s.e.m. Standard error of the mean 
S.I. Small intestine 
S/N Signal to noise ratio 
SPD Spleen phosphodiesterase 
SPE Solid phase extraction 
ST Simmental twins 
T     Thymine 
Tab. Table 
TCM Traditional Chinese medicine 
TLC Thin layer chromatography 
tm Migration time 
U     Uracil in case of DNA 
Unit of enzyme activity in case of description MN and 
SPD enzymes 
UV     Ultraviolet 
UV-VIS    Ultraviolet-visible 
V      Volt 
V     Voltage 
VECSEL    Vertically external cavity surface emitting of laser  
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1 Introduction 
 
 
 
1.1 Epigenetics  
The term epigenetics* defines all mitotically and meiotically heritable changes in gene expres-
sion that are not coded by the DNA sequence (1, 2). Epigenetics literally means ‘on top of ge-
netics’. In addition to the DNA sequencing*, epigenetics explains the contribution of another 
system, one that is responsible for the direct translation of the genetic information to control 
the genes influencing our growth and development (2). Additionally, it explains why different 
cell types of an organism share identical DNA sequences but show amazingly diverse func-
tions and phenotypes (2-4). Epigenetics is important for development and cell differentiation 
but could contribute to congenital disorders and health problems (3). Several epigenetic proc-
esses have been described in humans. DNA methylation and histone modifications, main 
components of epigenetic code, are the mechanisms involved side by side for the regulation 
of epigenetic processes (5).  
1.1.1 Histone modification 
 
DNA* is coiled around histones (the main protein components), which means that both to-
gether compose the chromatin (6). DNA is wrapped around nucleosomes (core histones) (7) and 
fixed in place with small proteins called linker histones (Fig. 1). The supercoiling of this 
necklace helps the fitting of DNA into the tiny nucleus (6). Additionally, chromatin controls 
the gene expression, DNA replication and cell functions. Histone modifications including 
methylation, acetylation, phosphorylation and others affect gene expression, DNA replication, 
mitosis and DNA repair mechanism (8-10).  
 
 
 
*: See Appendix 
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Figure 1:  Nucleosome unit of chromatin structure (6) 
 
1.1.2 DNA methylation 
 
DNA methylation is an enzyme-mediated chemical modification involving the covalent addi-
tion of a methyl group to the cytosine nucleotide at the carbon 5’ position of the cytosine ring 
within CpG dinucleotides (11-13) (Fig. 2). 5-methylcytosine is sometimes considered as the 
fifth base of DNA structure. DNA methylation is the unique natural modification of DNA 
revealing that about 3-4% of all cytosines in mammalian DNA are methylated (14). 
Three methyltransferase enzymes are involved in this process: Dnmt3a and Dnmt3b function 
as de novo methyltransferases to introduce methyl group to cytosines as well as Dnmt1 re-
sponsible for maintenance of methylation patterns by acting at the replication forks to intro-
duce CH3 groups on the newly synthesized DNA. 
CpG sites are regions of DNA where a cytosine nucleotide is located next to a guanine nu-
cleotide with the nucleosides linked together by a phosphodiester bond (p). The “CpG is-
lands” are largely localized in the gene promoter* regions of housekeeping genes (which are 
essential for general cell functions) or other genes* frequently expressed in a cell noting their 
evidence in small areas of 300-3000 Bp (12). Almost 50% of the human genes contain CpG 
islands in their promoter regions (15). CpG sites in human DNA are methylated (70-80 %) but 
only in areas where CpG density is low (13). 
For the majority of genes, especially housekeeping genes, the CpG islands in their 5' regions 
are protected from methylation as CpG density is high, and their expressions are switched-on 
(16, 17). That means the methylation-free pattern is important for the transcription of associated 
genes except in case of X-chromosome inactivation and gene imprinting.  
 
 
DNA
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Histone
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Most CpG islands are reported to be unmethylated in healthy tissue (18, 19).  In contrast, the 
CpG sequences in inactive genes as tumour-suppressor genes are usually methylated to sup-
press their expression (20, 21). In consequence, methylation of CpGs in the DNA of humans and 
other vertebrates distinguishes tissues and is involved in the regulation of gene expression and 
cell differentiation (22). The mechanism of switch off of inactive genes leads to permanent si-
lencing of associated genes and then this silencing state is transmitted through mitosis*. From 
this point, DNA methylation represents a basic process of epigenetics by inheriting these 
changes of the gene expression without any alteration of DNA.  
On the other side, DNA methylation plays a fundamental role in carcinogenesis by contribut-
ing to the hypermutability of CpG sequences as there is high probability of the conversion of 
cytosine (C) in the methylated CpGs to thymine (T) by deamination (23). Unlike the cytosine to 
uracil (U) mutation, which is efficiently repaired, the cytosine to thymine mutation can be 
corrected only by the mismatch repair (24). But this repair is inefficient and the conversion of 
the methylated CG sequence to the TG sequence is of high frequency  
(Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Genetic mutation caused 
by DNA-methylation.                                                                     
C: Cytosine; 5-meC: 5-
methylcytosine; U: 
Uracil; T: Thymine (24)  
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1.2 The role of DNA methylation 
Methylation of DNA is the most extensively studied epigenetic modification in mammals (25). 
It is an essential mechanism for regulating embryonic development (26) and influences the 
chromatin structure (27), X-chromosome inactivation (26, 28), imprinting parental genes and pro-
tection of the host organism against expression of undesired sequences, like non-coding or 
repetitive ones (29). It is also essential for epigenetic control of gene expression and the main-
tenance of genomic integrity (30-32). Figure 3 summarises its functions in normal cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The multiple roles of DNA methylation in normal cells 
 
1.2.1 Gene expression 
 
Gene expression is a continuous mechanism throughout the life stages of an organism, which 
makes the cell to gain the control over its morphological and functional characteristics (33). It 
illustrates how our genes work and how they are regulated. Gene expression plays an impor-
tant role in cell differentiation noting some genes are turned on (active) in certain tissues or at 
certain developmental stages and others are turned off (inactive). The alteration of any step of 
the genetic expression process (transcription, translation, posttranslational modification of 
proteins) will lead to change of the function of the gene (33, 34). Different studies like restric-
tion enzyme analysis have established an inverse relationship between gene methylation and 
gene expression (35, 36). In other words, DNA methylation and gene silencing are two faces of 
one coin (37) affecting in consequence the other epigenetic processes (25).  
Between 70-80 % of the CpG sites in the human genome are methylated (38) and the unmethy-
lated CpG regions are found in somatic cells (16). The methylation of CpG islands in promoter 
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regions can suppress the gene expression of the associated gene (34, 39). This gene silencing 
takes place as the methylation within promoter regions is associated with transcriptional re-
pression of the gene (40) and behaves as a switch off for the affected gene. 
 
1.2.2 Chromatin structure and transcription repression 
 
Both DNA methylation and histone modification are the two major mechanisms that regulate 
gene expression, thus it is very important to understand how the histone modification affects 
the chromatin structure that dictates the gene expression pattern emerging from the human 
genome.  
The unmethylated CG dinucleotides in gene promoter regions are free to act as receptors for 
the transcription factors and enable the initiation of the transcription process. However, me-
thylation of CpGs is catalyzed by several DNA methyltransferases as DNMT1 (DNA (cyto-
sine-5-)-methyltransferase-1), DNMT3a and DNMT3b (41) and interferes with the binding of 
many transcription factors (21, 42). But, methylated CpGs facilitate the assembly of transcription 
repressor complexes that include histone deacetylases (HDAC), histone methyl transferases 
and chromatin remodeling ATPase (43). Finally, this represents a connection between three 
mechanisms CpG methylation, chromatin structure modification and gene silencing. Clearly, 
DNA methylation is involved with silencing of the gene, which is suspected to induce a 
higher density of the chromatin structure. This modification of chromatin limits the accessi-
bility to the promoter sites leading to transcription repression  (21, 27, 44).  
This complicated mechanism can be clarified in figure 4. The methylated CpG sites offer 
binding points for m-CpG binding proteins involved in gene repression such as MBD1, 
MBD2 (methyl-CpG binding domain-1 and 2) and MeCP2 (methyl CpG binding protein 2) 
(45). These proteins in turn offer binding sites to transcriptional co-repressors, which finally 
associate with transcription repression mediated factors (histone deacetylase, histone methy-
lases and chromatin ATPases) (46). The deacetylation of histone (47-49) restricts the access to 
promoter regions due to more densely packed nucleosomes and  more condensed chromatin 
structure, leading to repression of gene activity and stop of the transcription (50-52).  
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Figure 4:  Model for methylation-dependent transcription repression (43)  
 
1.2.3 Genomic imprinting 
 
Genomic imprinting is one of the epigenetic phenomena which occur when both maternal and 
paternal alleles are present, but one allele* will be expressed while the other remains inactive. 
The gender of the parent controls the gene expression according to the associated allele (53). 
The mechanism of imprinting of parental genes could be due to the gene silencing by methy-
lation (54). In case of genomic imprinting, either the maternal or paternal homologue of ap-
proximately 0.1 to 1 % of mammal genes is repressed via methylation while the other is ex-
pressed (55). Genomic imprinting process plays a critical role in the regulation of growth in the 
embryo and neonate and is necessary for the development (56). In some cases, aberrant methy-
lation of certain gene results in the expression of the other allele with the susceptibility of 
cancer. This epigenetic phenomenon could be explained by the embryos produced by nuclear 
transplantation, either with two paternal genomes (androgenotes) or with two maternal ge-
nomes (gynogenotes). Although the zygotes could be formed, neither type was able to un-
dergo further development (57, 58).  
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This is due to the natural state which implies a complementary relation between the maternal 
and paternal genomes for the mammalian development and reproduction of species (59). Each 
genome contains different vital characters and necessary properties (60). Large offspring syn-
drome (LOS) is a major problem concerning cloning as well as in vitro fertilization. The over-
size phenomenon of produced animals or humans respectively can be explained by the ge-
nomic imprinting alteration. Some imprinted genes were reported to be connected to human 
diseases (61) when their inactive alleles were expressed. 
 
1.2.4  X-chromosome inactivation 
 
A related mechanism to imprinting is the X chromosome inactivation via gene silencing and 
methylation. The X-chromosome inactivation occurs when one of the two X chromosomes 
(either the maternally or paternally derived X) in every cell in a female is randomly inacti-
vated shortly after fertilization in embryogenesis of females (62). This change is inherited and 
all descendent cells will have the same X-chromosome inactivated as the cell from which they 
arose. Consequently, the male and the female have equal gene expression carried on the X-
chromosome. Thus, the new female population is a mosaic type, composed of two genetically 
different types of cells, one which expresses only the paternal X-chromosome, and another 
which expresses only the maternal X-chromosome. The inactive X chromosome does not ex-
press the majority of its genes (63) due to its silencing by repressive heterochromatin* (64). It 
was found that the inactive X-chromosome is associated with hyper-methylation and histone 
hypoacetylation (65). X-linked genetic diseases are representative to this epigenetic phenome-
non (66, 67).  
 
1.2.5 Cancer 
 
Cancer is one of the diseases that had attracted the attention of the people as well as the scien-
tists in different fields. Excessive researches in oncology had been done in the last decades to 
understand the nature of this disease, recognise its types and to control its invasion.  
Cancer is categorised as a genetic disease (42, 68) caused by somatic mutations* (69), contrary to 
the other genetic diseases caused mainly by germ line mutations* (70). Moreover, the accumu-
lation of mutation* plays a definite role in the progression of the disease. Cancer is mainly 
characterized by multiplication of the cells, cell proliferation and migration from the original 
site to distant sites in case of malignant forms (71). 
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Cancer is classified into benign and malignant* tumours. Metastasis differentiates  between 
malignant and benign* tumours (70), noting that in the malignant tumours, the cancer cells es-
cape through newly formed specific blood vessels and the lymphatic system to spread 
throughout the body and locate in other organs forming metastases. There are different types 
of malignant tumours named according to the affected site: carcinoma*; adenocarcinoma*; 
melanoma*; leukemia*; lymphoma*; sarcoma* and giloma*.  
Although several studies tried to anticipate the mechanism of carcinogenesis, there is no defi-
nite mechanism agreed by all. However, a common argument revealed that cancer is a 
multistep process (72, 73) starting with  ‘Initiation Phase’ to  ‘Promotion Phase’ and end with  
‘Progression Phase’ (74). These stages are characterised by dynamic changes in the genome as 
mutation, chromosome translocation*and gene amplification (75). 
Tumour initiation is the primary phase characterised by the exposure of normal cells to differ-
ent types of carcinogens* that lead to genetic and epigenetic damage in these affected cells. If 
DNA damage is not repaired, an irreversible mutation stage will be developed and in parallel, 
the excessive proliferation of the initiated cells will induce the tumour promotion phase (76) 
provoking changes in the expression of genome (77). The repetitive exposure to carcinogens 
gives raise to the second stage of carcinogenesis to be developed and the accumulation of the 
mutations leads to more expansion of the tumour cells with uncontrollable cell growth. The 
final stage of progression is characterised by malignant growth, invasion of tumour to the sur-
rounding tissues and the development of metastasis. 
Two target genes, oncogenes and tumour suppressor genes, have been clearly identified 
through their involvement in the stages of tumour formation (78). The genetic alterations affect 
the proto-oncogenes (normal cellular genes) or oncogenes (activated counterparts) by exces-
sive gain of their function and the tumour suppressor genes by loss of their function. 
Oncogenes are the activated counterparts of normal cellular genes (proto-oncogenes) formed 
by genomic alterations affecting proto-oncogenes such as point mutation* (79), gene amplifica-
tion or gene fusion. Proto-oncogenes are responsible for the regulation of cell growth, cell 
division and replication. Cell growth is initiated normally by growth factors that are encoded 
by genes and bind to receptor, the trans-membrane protein, giving rise to different signals and 
transcription factors that activate transcription and gene expression. Any mutation of the 
genes involved in this cycle turns them into oncogenes modifying their expressions and func-
tions. Consequently, the cell division could get out of control leading to the transformation of 
a normal cell to a tumour cell (77). Over 80 oncogenes have been defined, among which ras-
oncogene is the most famous one, being identified in third of all human cancers (80). 
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Tumour suppressor genes code for anti-proliferation proteins that suppress mitosis and cell 
growth play a fundamental role in the repairing of DNA mistakes and in apoptosis*. The name 
of these genes refers to their role as brake to prevent cellular proliferation and stop cell divi-
sion through growth inhibitory signals sent by the surrounding cells. Various mechanisms are 
involved in the inactivation of tumour suppressor genes as point mutation, chromosomal dele-
tion or gene conversion. In consequence, they do not work properly and cells can grow out of 
control provoking cancer. Among the tumour suppressor genes, p53 protein is one of the ex-
cessively studied genes, encoded as P53 gene detected in more than 50 % of human cancer, 
e.g. associated with colon, lung, skin, brain tumours and others.  
 
1.2.5.1 DNA methylation: Effective biomarker for tumourigenesis 
 
DNA methylation (81) has a specific meaning and echo in the medical field referring to its fin-
gerprint in several cancer diagnosis researches that conclude DNA methylation patterns in 
tumour cells are altered relative to those of normal cell (82-84). It was interesting to report in 
pioneer works from two decades ago that 5-methylcytosine is identified as a mutational hot-
spot in Escherichia coli (14). Subsequently, the studies had illustrated that abnormal methyla-
tion is closely related to carcinogenesis (85, 86) noting that tumour cells exhibit global hy-
pomethylation of the genome accompanied by region-specific hypermethylation of tumour 
suppressor genes (68, 87).  Both have an active effect for the onset of cancer (88, 89) and have 
been reported in a variety of neoplasm, namely, of the colon and rectum (82, 90-93), lung (94), 
uterine (95), cervix (96) and gastric carcinoma (97). The effect of DNA methylation in cancer cell 
is illustrated in figure 5. 
In case of cancer, hypermethylation occurs to CpG islands in the promoter regions of tumour-
suppressor genes which are then transcriptionally silenced (21). The 'two-hit hypothesis’ im-
plies both alleles of tumour suppressor gene should be mutated to manifest the tumourogene-
sis (98). Gene hypermethylation could be one of these hits contributing to malignancy devel-
opment due to the inactivity of tumour suppressor genes (99). In particular, different studies 
have found relation between the hypermethylation of specific genes involved in DNA repair, 
cell cycle regulation and apoptosis, and certain human tumours (81). In other words, gene hy-
permethylation can result in inactivation of DNA repair, defect of signal transmission be-
tween cells and loss of apoptosis. 
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Figure 5:  The effect of methylation level in tumour cells 
 
On the other hand, the overall genomic hypomethylation was associated with few human ma-
lignancies such as colonic neoplasias (100, 101), lung carcinoma (102) and metastatic prostate car-
cinoma (103). DNA hypomethylation, however, was detected as an important spot in breast 
carcinoma (88). Global hypomethylation affects DNA in repetitive sequences as well as cen-
tromeres* resulting in chromosome instability, loss of imprinting and increased mutation rate. 
A reduction in the genomic content of 5-meC varied from 8% to 31% according to carcinogen 
type was determined in other specific studies concerning bronchial epithelial cells treated with 
a broad range of chemical carcinogens (104). 
Medical researches illustrated that hypomethylation is present at early stages of chronic lym-
phocytic leukaemia (B-CLL) (105).  
In conclusion, DNA methylation can be used as biomarker for diagnosis of cancer because the 
profiles of DNA alterations characterizing a certain cancer type were helpful as cancer diag-
nostics, moreover the inactivated genes by promoter region hypermethylation provide a fun-
damental link of these inactivation patterns corresponding to specific tumours (106). Impor-
tantly, the altered DNA methylation-caused tumour is a reversible epigenetic mutation offer-
ing targets for therapeutic drugs. DNA-methyltransferase inhibitor drugs as 5'-azacytidine, 
decitabine and histone deacetylase inhibitors are being used as chemotherapeutic agents to 
treat some kinds of tumours (1, 107). 
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1.2.6 In-vitro fertilization (IVF)  
 
Several assisted reproduction technologies (ART) were established to solve the infertility 
problems (108). In vitro-fertilisation (IVF), one of the most significant ART had shown success 
to conceive baby in 1976 then the development of its expanded techniques, most importantly 
to be cited the intracytoplasmic sperm injection (ICSI) (109), had really helped the infertile 
couples to conceive infants. However, different birth defects (110, 111) had been remarked in 
some cases like chromosomal abnormalities, cardiovascular defects, growth abnormalities (112, 
113) as well as high risk of low birth weight. Hansen et al (114) had declared that the babies con-
cieved by IVF have twice the rate to develop major birth defects as compared to naturally 
conceived children. Additionally, IVF was reported to be associated with diseases like An-
gelman syndrome (AS) (115) and Beckwith-Wiedemann syndrome (BWS) (116, 117) that etiologi-
cally related to aberrant genomic imprinting (118, 119). The epigenetic modifications of the ge-
nome including DNA methylation and histone modification are linked through their functions 
and synchronously affecting each other. DNA methylation as an important factor in modeling 
the structural patterns of genome was investigated in IVF in different studies. Different me-
thylation status was reported (120, 121) depending on the protocol of in vitro embryo formation 
as well as tissue specificity (120). IVF could affect the DNA methylation via imprinting errors 
that happened during this in vitro reproduction technique (122, 123). 
 
1.2.7 Cloning  
 
Somatic cell nuclear transfer (SCNT), or cloning, is a technique used to create genetically 
identical animals by somatic cell nuclear transfer into unfertilized eggs. In this technique, the 
nuclear genetic material is transferred from the animal that should be cloned (known as ge-
netic donor) into a recipient cell matured oocyte or unfertilised egg (cytoplast) from which the 
genetic material has been removed. Then, the somatic cell taken from genetic donor is in-
serted into the enucleated egg and the fusion of two cells is accomplished by electricity. The 
fused egg is activated for the reproduction.  Then the activated egg is placed in a culture me-
dium. The cellular division is watched till an early-stage embryo (blastocyst) is formed and 
then is transferred to a recipient female (sometimes referred to as ’surrogate mother’) for the 
subsequent development (124).  
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1.2.7.1 Cloning efficiency 
 
The birth of the first mammal cloned from an adult donor cell, ‘Dolly’, proved the success of 
cloning (125) and has initiated a stream of researches to improve cloning technology. However 
the overall efficiency of this technology is low (126-128) noting a success rate ranging from    
0.1 % to 3 % with an exception of 15-20 % success recorded by cattle as a model extensively 
used for mammalian cloning (129). It was estimated that the clones show frequently high mor-
tality rates in utero due to the incomplete reprogramming of nuclear activities (127). 
Normally, somatic nuclei acquire highly specialized DNA and chromatin modifications dur-
ing the differentiation stage in order to support early development (130). Upon somatic nuclear 
transfer into oocytes, the donor nucleus should be remodelled from highly differentiated so-
matic patterns to a totipotent embryonic pattern (zygote that can develop into any sort of cell) 
then to pluripotent pattern (embryo state that gains the capacity to develop to many cell 
types). The end of these development stages is referred to ‘terminal differentiation’ when cells 
gain specific characteristics that allow them to do a specific function. This process is called 
‘epigenetic reprogramming’ occurring in mammalian embryos at two times during their de-
velopment, once soon after fertilization known as preimplantation reprogramming and the 
other takes place during gametogenesis and known as gametogenic reprogramming (Fig. 6). It 
is usually associated with some changes in epigenetic features similar to those that occur  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Overview of epigenetic reprogramming in cloning process and embryo development 
(Figure modified from www.fda.gov/ucm/groups) 
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in normal embryos during early development (131, 132). However, different studies showed an 
evidence that incomplete or inappropriate epigenetic reprogramming of donor cell nuclei is 
the main cause behind the low cloning efficiency, high embryonic and foetal losses after 
SCNT and developmental abnormalities (133, 134). At different stages, inappropriate repro-
gramming occurs leading to failure of cloning. 
Simply talking, other logical reasons rather than the failure of epigenetic reprogramming can 
explain the unsuccessful cloning procedure in the embryonic stage. These reasons could be 
the incompatibility between the enucleated egg and the transferred nucleus, or an egg with a 
newly transferred nucleus may fail to divide or develop properly, or simply the implantation 
of the embryo into the surrogate mother might be impossible. On the other side, the surviving 
clones can exhibit congenital defects (135) such as LOS (126), kidney or brain malformations and 
impaired immune systems. 
 
1.2.7.2 Effect of cloning on epigenetics 
 
High rates of embryonic and foetal mortality (127, 136), and an increased incidence of congenital 
defects (135, 136) have been associated with perturbations in developmentally important epige-
netic marks (127) such as DNA methylation and histone modifications (137-139).  
The methylation of DNA is involved in long-term epigenetic silencing of specific sequences 
(43), including transposons*, imprinted genes and pluripotency-associated genes in the cloning 
process (140). 
Various studies had demonstrated that SCNT procedure can impact on the global DNA me-
thylation status of cloned bovine embryos by insufficient active de-methylation of the nuclear 
donor DNA after transplantation, by delayed or attenuated further passive de-methylation, and 
by precocious de novo methylation before the 16-cell stage (134, 137, 141, 142).  
Other studies had revealed aberrations in global DNA methylation status of cloned embryos 
and fetuses in different species (137, 143-145) . In general, an increase in DNA methylation level 
in cattle clones has been correlated with poor developmental potential of cloned pre-
implantation embryos (137) and with compromised foetal overgrowth (144). The global changes 
in methylation states have also been described for specific genes and non-coding DNA se-
quences under epigenetic control (127, 133, 138, 139, 142, 146). Although the overview of these reports 
shows a relation between the aberrant methylation level and the poor success for the cloning 
process, the genomic methylation status of live offspring was not studied so far. 
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1.2.8 Twins and epigenetics overview 
 
Monozygotic (MZ) twins originate from the same zygote and split into two eggs in the gesta-
tional period and are supposed to share identical epigenomes when the blastocyst splits. Stud-
ies had concluded that the time frame of splitting plays a role whether identical twins or con-
joined twins (splitting after 12 days) are conceived. Surely, dizygotic (DZ) twins developed 
from different zygotes carrying different epigenetic profiles. It was observed that MZ twins 
could show varying behaviour in the incidence of psychiatric diseases such as schizophrenia 
and bipolar disorders as well as other diseases like Parkinson’s and cancer (147-150). This dif-
ferential susceptibility to the diseases was returned to the role of the environmental agents in 
affecting the epigenome (151) and then the twins manifest a difference in phenotype. However, 
the accumulating evidence (152, 153) had recently highlighted that the change in DNA methyla-
tion and chromatin structure of mammalian genome induced due to exposure to the environ-
ment significantly alters the gene function associated with different phenotypic outcomes (149, 
154). Additionally, Kaminsky et al. (155) had proved that the epigenetic profiles are not fully 
determined by DNA sequence, otherwise MZ twins should not show epigenetic differences. 
Most MZ twins showed the same methylation status, whereas few others showed aberrant 
methylation profiles. This epigenetic variation between twins explain the etiology of  the 
complicated diseases developed by one of the traits (149). The correlation between the diver-
sion of the epigenetic profile in the late adolescent and the development of the disease despite 
the same epigenetic status after twin separation is cleared by epigenetic model of twin discor-
dance for psychosis represented by Petronis et al. (147). In conclusion, the DNA methylation, 
this dynamic process throughout the life time, affects the gene expression by shutting some 
genes off or increasing the role of others. The accumulation of these variations of gene ex-
pression in MZ twins contributes to their discordance and their response to the diseases.  Ad-
ditionally, in the recent years there is doubt concerning the assumption that MZ twins are ge-
netically identical organisms due to findings of the researchers about the change on the ge-
netic level associated with the gene sequence. This issue is still under investigation. 
 
 
 
 
Introduction 
15 
1.3 DNA adducts  
1.3.1 DNA adducts and cancer 
 
The formation of DNA adducts is resulted from the covalent interaction of genotoxic carcino-
gens with DNA, derived from exogenous and endogenous sources, either directly or following 
metabolic activation (156, 157). If this DNA modification is not repaired, it will lead to mutations 
in critical genes such as those involved in the regulation of cellular growth and subsequently 
to cancer development ( 1 5 8 )  (Fig. 7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: The pathway of DNA adducts formation 
 
As shown by the Salmonella test established by Ames (159) and by other tests (160-162) , most 
carcinogens are either mutagens (electrophilic reactants that covalently bind to DNA bases) or 
premutagens (chemicals that undergo metabolic conversion to such electrophilic compounds). 
However, the majority of the genotoxic carcinogens require metabolic activation in order to 
form electrophilic reactive species that bind covalently to nucleophilic sites in DNA (161). Gen-
erally speaking, nitrogen and oxygen centres are the prefered nucleophilic sites on DNA to be 
attacked by alkylating and arylating agents (163).  
DNA damage is induced either by normal cellular processes or by some environmental 
agents. Either endogenous or exogenous mediated-DNA damage share similarities in occur-
rence as well as in cell response. The damage is occurred initially either by involvement of 
free radicals (ionizing radiation, UV light, oxidative stress) or adduct formation (mutagenic 
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chemicals, alkylating agents, arylating agents). Unrepaired DNA damage will accumulate and 
contribute to alterations in the DNA sequence leading to mutation upon DNA replication. In 
addition, alterations in the DNA sequence may occur when adducts are subjected to erroneous 
repair. All DNA damage types, especially chemicals-induced DNA damage, are likely being 
the major cause of cancer, aging or other diseases (159, 164). A variety of DNA repair systems 
are involved to keep the integrity of the genetic material. Persistent DNA damage can result in 
induction of both transcription and signal transduction pathways, replication errors and ge-
nomic instability. All these processes are equally associated with cancer. In other words, the 
cellular response to DNA damage could be either positively by repairing approaches or nega-
tively by replication of errors with the induction of diseases.  
Both DNA adducts and DNA methylation that are considered as DNA modifications play an 
important role in monitoring cancer formation. Most studies that consider the association be-
tween cancer at different sites and adduct levels at these sites have shown that cancer cases 
have higher levels of adducts than non-cancer controls (165). These carcinogen-DNA adducts in 
humans are considered as biomarkers of individual exposure and of potential risk for cancer 
development (162). The conclusions illustrated by Buss et al. (166) and Poirier and Beland (167) 
confirm that the adduct formation is directly proportional to the dose, and subsequently any 
traces of adduct exposure present definitely a carcinogenic risk. However, a universal value 
could not be given to such an acceptable level of adducts because their mutational effective-
ness varies according to the nature of the carcinogen as well as the chemical structure of the 
DNA adduct. This was proven by Saffhill et al. (168) as N-7 alkylguanine adducts have consid-
erably less mutagenic potential than O6 alkylguanine adducts. Lastly, different studies had 
argued that genotoxic carcinogens are site selective, for example hepatocellular tumour is as-
sociated with the exposure to aflatoxin B1 which leads to a specific mutation at codon 249 of 
the p53 tumour suppressor gene (169, 170). Furthermore, the spectrum of mutations induced by 
polycyclic aromatic hydrocarbons (PAHs) in the p53 tumour suppressor gene in bronchial 
epithelial cells has been reported to be similar to the major mutational hotspots in human lung 
cancers, indicating that PAHs may be involved in lung carcinogenesis (171-173).  
 
1.3.2 Endogenous adducts 
 
Endogenous mutagens that cause DNA damage are major contributing factors to the onset of 
aging and other degenerative diseases associated with aging, such as cancer (157, 174).  
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Oxidation, methylation, depurination and deamination are the endogenously causative proc-
esses to significant DNA damage. Jackson and Loeb (175) had shown that the endogenous 
DNA damage occurs at a high frequency compared with exogenous damage and the majority 
of damage types induced by normal cellular processes are identical to those caused by some 
environmental agents. The major endogenous sources of DNA damage are those produced by 
ROS and aldehydes derived from lipid peroxidation (176, 177). The former will be discussed 
later in details (Section oxidative stress). The major aldehyde products of lipid peroxidation 
are crotonaldehyde, acrolein and malondialdehyde (MDA) (176, 178). Equally, etheno- (179-182), 
propano- (178, 183), and malondialdehyde- (175, 184) derived DNA adducts are produced by the 
reaction of DNA with epoxyaldehydes, aldehydes and MDA, respectively. These later exo-
cyclic adducts are categorized also as examples of adducts formed by exogenous mutagens 
referring to acrolein and crotonaldehyde as exogenous environmental contaminants (175, 185). In 
addition to oxygen and lipid peroxidation products, DNA damage could occur in living cells 
through other small reactive molecules like alkylating agents or through spontaneous reac-
tions.  
Methylation of DNA bases can occur through the action of environmental chemicals (exoge-
nous) or intracellular (endogenous) agents. For example, N-methyl-N-nitrosoamine which is a 
component of tobacco smoke with powerful alkylating property elevates the mutation rates in 
cultured cells (186). S-adenosylmethionine (SAM) is a reactive methyl group donor found in-
side every cell for normal cellular metabolism (187). It could contribute to methylate inappro-
priate targets, such as adenine (188), guanine (187) and to less extent thymine leading also to mu-
tation (175, 187). The nitrogen atoms of the purine bases (N3 of adenine and N7 of guanine) and 
the oxygen atom of guanine (O6) are particularly susceptible sites to methylation. So the main 
adducts formed are illustrated in figure 8 referring to O6-methylguanine as the most 
mutagenic adduct (187). A minority of endogenous methylation agents such as betaine, choline 
and others, could be generated from endogenous cellular precursors or from exogenous 
sources such as diet, tobacco smoke or environmental pollution (170) and lead to DNA damage 
(189). 
Spontaneous damage contributes to the hydrolysis of DNA with the loss of a base, or deami-
nation, or sugar ring deterioration, or tautomeric shift* (189-191).  
Abasic sites* are among the most frequent endogenous lesions found in DNA, with an esti-
mated 10000 lesions/human cell/day (192). These apurinic / apyrimidinic sites are produced 
from the cleavage of the glycosidic bond present between bases and deoxyribose in DNA due 
to heating, alkylation of  bases or the action of N-glycosylases (190). 
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AP sites are not only produced by spontaneous depurination / depyrimidation but also to a 
large extent by ROS (reactive oxygen species) (193). AP sites can be rapidly and efficiently (192) 
repaired, but mutations and chromosome aberrations occurred in the case when there is no 
damage repair (194).  
Finally, cytosine and its homologue 5-methylcytosine are the main base targets for the hydro-
lytic deamination (192). The fifth distinct base in DNA, 5-methylcytosine, is prone to spontane-
ous deamination more rapidly than cytosine (185) provoking a high degree of mutagenesis 
which results in CG → TA transitions (195).  
It should be mentioned that X-rays could be not only exogenously but also endogenously in-
volved in DNA damage by free radical-mediated reactions and lead to single strand break.  
Of course, endogenous DNA damage can be repaired by ‘Base Excision Repair’ system 
(BER) by removing the damaged base via DNA glycolase then re-synthesising and sealing the 
base by DNA polymerase and DNA ligase, respectively (196). 
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Figure 8:          Examples of endogenous DNA adducts produced by methylation, deamination and oxidation  
                           of corresponding bases (N.B.: They can be also produced by exogenous agents). 
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1.3.2.1 Oxidative stress 
 
Oxidative stress occurs due to an imbalance between the generated and exogenously produced 
oxidants, and the body's natural antioxidant defense mechanisms and different DNA repair 
systems (197). Recently, oxidative stress is defined as altered homeostatic balance resulting 
from oxidant insult (198).  
The reactive oxygen substances (ROS) are the well known drivers of the oxidative stress as 
well as the reactive nitrogen species (199). ROS are continuously formed in living cells as a 
consequence of metabolic and other biochemical reactions (200) as well as by influence of ex-
ternal factors. Most of the ROS species are free radicals (e.g.: O2-
., OH.) characterized by pos-
sessing unpaired free electrons defining their high reactivity. The non free radicals (e.g.: 
H2O2) are able to produce easily free radicals under certain circumstances (201). Among all 
ROS, hydroxyl free radical (OH.) is the most reactive species which diffuses easily towards 
potential targets.  
The free radicals are produced through reactions involving molecular oxygen catalysed either 
by oxidative enzymes or metals. ROS are a double-edged sword as they play an important 
role in physiological processes as in mediating inter- and intra-cellular signaling to highlight 
the pathways regulating proliferation, cell growth and apoptosis (202) as well as in defense 
mechanism against pathogens. When produced in excess, they modify cellular macromole-
cules by oxidizing DNA, proteins and lipids (199, 203-206), evoking vital damage to these bio-
molecules (207). ROS are implicated in a plenty of pathological processes (208) such as chronic 
fatigue, skin disorders, hormonal imbalance, ageing (209), Alzheimer (210), cancer (211), atherosc-
lerosis (212), heart diseases and autoimmune disorders (213).  
The ROS-mediated damage gives rise to different mutation mechanisms which take place 
according to the reactive species involved in the damage (214). Gamma-radiation, superoxide 
and hydrogen peroxide lead to the most mutagenic lesion G:C → A:T transitions. However G: 
C → C:G transversions are arising from transition metals and peroxyl radicals (215). Aging 
(216), as well as the associated degenerative diseases, is attributed to the attack of free radicals 
on different macromolecules and cell constituents (217) and the accumulation of mutations at 
mitochondrial DNA, which can be determined in tissues characterised with many post-mitotic 
cells, like the brain (218). The “Free radical theory” of ageing established by Harman (219) had 
assumed that the generation of intracellular oxygen species is the major limiting factor for the 
life expectancy (220). In agreement with this theory, several studies had confirmed diet in- 
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take (221, 222) and the supplementation of antioxidants (223, 224) reduce the aging process by af-
fecting the rate of  production of mitochondrial ROS.  
So far even under normal aerobic metabolism, active and potentially dangerous oxidants are 
produced leading to vital cellular damage, represented by the production of hundreds of hits 
per cell per day (225, 226). This high endogenous level of oxidative adducts confirms that both 
deficiency of antioxidants  and mitogenesis (227) are important risk factors for cancer (199, 228). 
Two sources are responsible for producing ROS. 
 
- Endogenous ROS 
 
Endogenous ROS are produced in the human body by normal physiological processes as by-
products of several metabolic and enzymatic reactions (217). O2 is of fundamental necessity for 
the life, essential for the respiration in all aerobic organisms as well as for the photosynthesis 
in the plants but it contributes in the production of active and potentially dangerous oxidants 
during normal aerobic metabolism (220). All the biological functions in our body need energy 
which is produced via the electron transport chain in the mitochondria (229). However, danger-
ous metabolic intermediates or by-products are obtained in the electron transfer reactions, 
such as superoxide ion (O2-
.) and hydrogen peroxide (H2O2). Figure 9 illustrates the main 
endogenous source of reactive oxygen species (ROS) (230). Moreover, superoxide radicals and 
H2O2 are particularly produced in peroxisomes during the ROS decomposition, β-oxidation of 
fatty acids and the decontamination of xenobiotics (200). 
 
 
Figure 9: Electron transport chain as source of ROS (230) 
 
Some pathologic systems contribute to oxidative stress by the excessive generation of free 
radicals as result of virus- or bacteria-infected cell phagocytosis process (231). A respiratory 
burst of phagocytes is introduced by NADPH-oxidase generating superoxide ions (213, 231, 232). 
The immune system generates peroxide, superoxide, and singlet oxygen to attack different 
microbes and destroy attacking pathogens. Additionally, the biotransformation of some cyto-
toxic drugs (233) could be accompanied by the generation of toxic intermediates and ROS. 
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Finally, flavo- and heme proteins, involved in the cellular energy processes, give rise to ROS 
derived from molecular oxygen after leak of electrons (197).  
 
- Exogenous ROS 
 
ROS are exogenously introduced by exposure to environmental contaminants like transition 
metals, oxidants and free radicals or exposure to other forms of pollutants. Lifestyle factors 
(234), ultraviolet light (UV) (235), ionising radiations (236), chemotherapeutic agents (237), psycho-
logical stress (238) are the major source to produce oxidants.  
Not only a negative lifestyle, like smoking is as a promoter for oxidative stress but also a 
positive habit can be causative as well. During muscular exercise, the requirement of the body 
for O2 is increased to fulfil the energy demands of this physical activity. Oxygen undergoes a 
four-electron transfer reaction producing ROS. Although it is highly recommended to perform 
muscular exercises to improve a healthy life because the produced ROS are beneficially used 
by the immune system and enhance its activity, the excess of exercises reveal serious adverse 
effects (239). Surprisingly, it was concluded that intense long duration exercises reduce the 
immune function (240) and are associated with high frequency of other diseases as arterioscle-
rosis, cancer and premature ageing (241-243). In contrast, both acute exhaustive and prolonged 
moderate exercises are usually related to the low risk of development of oxidative DNA dam-
age signs and related diseases (244). These conflicts had attracted Poulsen et al. (245) to frame 
the relation between exercise and oxidative DNA modifications. 
The exposure to ionizing radiations and UV light increases the frequency of oxidative stress. 
The tropospheric ozone, found close to the ground, is created through the interactions of vola-
tile organic compounds (VOCs) and nitrogen oxides in the presence of heat and sunlight pro-
ducing harmful health effects. An increased level of oxygen free radical (specially 8-hydroxy-
2’-deoxyguanosine: 8-OH-dG) was recorded in ozone-exposed plants (246, 247), explaining the 
mechanism of ozone-mediated plant injury. Although chemotherapy (anthracyclines, cyclo-
phosphamide, cisplatin, cytarabine, mitomycin, fluorouracil and bleomycin) help in the im-
provement of the health of cancer patients, oxidative stress–mediated injury of normal tissues 
is a significant side effect. Some chemotherapeutic agents, such as bleomycin (248), introduce 
oxidative stress as a mechanism to kill cancer cells. However, other chemotherapeutic agents, 
such as the anthracyclines (249, 250), are more harmful by inducing oxidative stress in non-
targeted tissues. 
 
Introduction 
23 
1.3.2.2 8-oxoguanosine  
 
Among DNA oxidation, one of the most commonly occurred is the hydroxylation of guanine 
in the 8-position and formation of 7,8-dihydro-8-oxoguanosine (225). This oxo-adduct gives 
rise to the most frequent somatic mutation found in human cancers (251) and described by lack-
ing of base pairing and misreading of the modified base, whereas 8-OH-dG can pair with C or 
A. G:C → T:A is a transversion pathway (Fig. 10) which occurs often in association with the 
existence of 8-OH-dG adduct in vivo and in vitro and is confirming the diversity of the muta-
tion forms detected with oxidative stress (252). In most cases, oxidative stress is detected in 
parallel with aging, cancer and other related neurodegenerative diseases (251, 253-255) with rele-
vant level of this adduct. Additionally, increased level of 8-OH-dG had been found in differ-
ent pathological conditions as hepatitis, cardiovascular diseases, skin disorders, breast, lung 
and colon cancers (208). From another side, the detection of 8-OH-dG in urine reflects the oxi-
dative stress case (256) as well as the possible repair by a cellular N-glycolase (257). Therefore, it 
is the most often studied oxidative species as a marker for human biomonitoring of carcino-
genesis (163, 234, 253, 258). 
 
 
 
 
 
 
 
 
 
 
Figure 10:  Mutation by 8-oxoguanosine 
 
 
1.3.2.3 Methods of analysis of 8-oxoguanosine 
 
Determination of 8-OH-dG levels in DNA is of vital importance and requires a sensitive de-
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chromatography with electrochemical detection (HPLC-ECD) (234, 238, 245, 259, 260), 32P post-
labeled HPLC (261), 32P post-labeled-TLC (262), gas chromatography-mass spectrometry (GC-
MS) (263, 264) and LC-MS methods (265, 266). HPLC-ECD and GC-MS had high reputation for 
the quantification of oxo-adducts. However, the levels of 8-OH-dG estimated by the latter 
method were found to be 10-50 folds higher than the levels estimated by the former method. 
The sensitivity recorded by GC-MS is about 1 molecule 8-OH-dG per 106 molecules deoxy-
guanosine (245). However, this technique requires specialized personal and expensive instru-
mentation in addition to the need of derivitization step prior to the analyses which can induce 
an insult of artificially oxidative products explaining the high level of adducts recorded with 
GC-MS. The silylation step and the non-availability of isotopically labeled internal standards 
are the major disadvantages limiting the application of GC-MS technique for the determina-
tion of DNA base modifications. The requirement of specific antibody induces a certain diffi-
culty to apply immunologically based methods. Consequently, HPLC-ECD, the pioneer 
method in this field, is considered so far the only method employed for analysis of 8-OH-dG 
due to its simplicity, sensitivity and availability of its equipments. However, the only draw-
back is the difficulty to estimate exact concentration of 8-OH-dG. 
 
1.3.3 Exogenous DNA adducts 
 
They are formed due to the exposure to genotoxic carcinogens such as polycyclic aromatic 
hydrocarbons (PAHs), UV photoproducts and aflatoxins (267-271) that react with one or more 
DNA bases producing gene mutation (160).  
 
1.3.3.1 Environmental chemicals 
 
Polycyclic aromatic hydrocarbons are the most extensively studied species as they are widely 
found, for example in cigarette smoke (272). They are strongly implicated as causative agents in 
the development of lung cancer (171). 
Among the PAHs, benzo[a]pyrene (B[a]P), which occurs in amounts of 20 to 40 ng per ciga-
rette, is one of the most potent carcinogens. As previously mentioned, the chemicals are not 
the main causative agents for cancers, but they are metabolically activated by cytochrome 
P450 enzyme leading to electrophilic species that can bind to DNA (175). Following this 
mechanism, B[a]P, a bulky adduct, proceeds in a certain metabolic pathway to produce the 
ultimate carcinogenic metabolite of the isomers of 7,8-Diol-9,10-epoxide (BPDE) (273), which 
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is an electrophilic metabolite that attacks preferentially the nitrogen sites of nucleobase result-
ing in the formation of N2-guanine adducts (171, 226) (Fig. 11). Thus, B[a]P leads to the muta-
tions in growth regulatory proto-oncogenes and tumour-suppressor genes and results in cancer 
formation (171, 274, 275). B[a]P was detected along P53 tumour suppressor genes which repre-
sents the major mutational hotspots in two third of detected lung cancers in humans (171). 
Importantly in the pharmaceutical field, B[a]P is present in a high content in coal tars, which 
are the major incorporated ingredients in the preparation of therapeutic ointments used in se-
vere cases of psoriasis (276, 277). Recently, coal tars were estimated as being highly involved in 
the carcinogenicity in humans (278). Different studies performed in vitro as in vivo to provide 
an evident conclusion for the contribution of PAHs in carcinogenesis (171, 274, 277).  
Recently, nitro-PAHs were classified as new mutagens found in some environmental compo-
nents such as diesel exhaust and airborne particles (279). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Proposed metabolic activation pathway of B[a]P (273) 
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One of the most strong and dangerous mutagens reported by Ames test and belonging to ni-
tro-PAHs class is 3-nitrobenzanthrone (3-NBA) noting its mutagenic strength 10000 times 
more than B[a]P. This polycyclic aromatic nitro-ketone is mainly identified in air pollution, 
fuel combustion and soil particles (280, 281). It is metabolically activated by different enzymes 
either in vivo or in vitro (282, 283) producing covalent DNA adducts (279) with subsequent muta-
tions (284) mainly at purine sites (282) at the C8 and N2 position of guanine and at the C8 and N6 
position of adenine (285). Nitroreduction is the initial step of activation of 3-NBA to produce 
N-hydroxy-3-aminobenzanthrone (N-OH-3-ABA) then different pathways can be followed. 
N-OH-3-ABA is metabolised by O- acetyltransferase (286) or sulfotransferase (287) to produce 
N- nitrinium ion yielding non-acetylated DNA adducts (281) or it exerts N-acetylation (286) fol-
lowed by O-esterification to produce N-acetyl-nitrinium ion yielding acetylated DNA  
adducts (288). Or simply, it is reduced to 3-aminobenzanthrone that involved indirectly in the 
formation of both adduct types (Fig. 12). 3-NBA adducts were detected along p53 mutations 
in Hupki mice as well as in lung tumours in mice (289) and rats (171). 
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Figure 12: Proposed metabolic activation pathway of 3-NBA (281) 
 
Heterocyclic aromatic amines (HAAs) represent the second equally important class of exoge-
nous DNA adducts that contribute to human cancer risk ( 2 9 0 ) . They are formed in consequence 
of cooking foods at high temperatures and/or for long period of time (291), especially frying or 
grilling proteinaceous foods such as meat (291, 292), fish and poultry, as products of protein py-
rolysis (293, 294). They are also generated from occupational source (295), environmental source 
(296) and tobacco smoking (290, 297). Many of these HAAs were used in laboratory experiments 
as well as color additives in pharmaceutical preparations and cosmetics, antioxidant in manu-
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facturing of rubbers and plastics and finally in dyes and paints industry. Among 19 structur-
ally determined HAAs (290), 4-Aminobiphenyl (4-ABP) is a major agent investigated for its 
role in the etiology of mainly bladder cancer (298, 299) and breast cancer (297, 300). 4-ABP occurs 
in amounts of 0.2 and 140 ng per cigarette noting the formation of 4-ABP-hemoglobin ad-
ducts in smokers (301). 
It is metabolically activated in a manner like 3-NBA by the cytochrome P450 (294) in liver to 
N-hydroxy-4 ABP which forms covalent DNA adduct and induce mutations at multiples  
sites ( 3 0 2 )  e.g. at the C8 position of guanine by their exocyclic amino group. The latter acti-
vated form enters the circulation and produce haemoglobin adducts or is further transported to 
urinary bladder to react either directly with DNA or after N-acetylation (Fig. 13).  
N-sulphation and N-glucorination are other reported metabolic activation pathways (303).  
4-ABP is also associated with cancer in the fatty sites in the human body as adipose tissue of 
breast due to its lipophilic nature via its activation by peroxidises enzymes in the mammary 
gland following O-esterification pathway to produce adducts with DNA (304) (Fig. 13). 
 
 
 
                                       
 
 
 
 
 
 
 
 
 
 
                                 
 
 
                                      Figure 13:        Proposed metabolic activation pathway of 4-ABP 
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1.3.3.2 Aristolochic acid (AA) 
 
Not only the environmental polluants or food derivative heterocyclic amines form DNA ad-
ducts, but also some fungal products contribute to carcinogenesis (305) such as aflatoxin B1 
which is a fungal metabolite produced by Aspergillus flavus and related fungi that grow on 
improperly stored foods (306-309). In addition, aristolochic acid (AA) is a natural product re-
corded for its carcinogenicity. 
Chinese herbs nephropathy (CHN) (310, 311) is a recently described subacute interstitial fibrosis 
which progress rapidly causing permanent kidney damage, including end-stage of kidney fail-
ure and upper urothelial cancer. It is named also AA nephropathy (312, 313) characterising 
nephrotoxicity disease which is associated with the prolonged use of chinese herbs in the form 
of slimming pills (312, 314-316). This syndrome has been traced to aristolochic acid (AA) which 
is a major alkaloid of isochinoline group extracted from Aristolochica species (316) and other 
plant species. It is consisting of a mixture of structurally related nitrophenanthrene deriva-
tives, AAI and AAII (Fig. 14). They form DNA adducts after metabolic activation by simple 
reduction of the nitro group (315, 316).  
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Figure 14:  Chemical structures of aristolochic acid I (8-methoxy-6-nitro-phenanthro[3,4 -
d][1,3]dioxole-5-carboxylic acid) and aristolochic acid II (6-nitro-phenanthro[3,4-
d][1,3]dioxole-5-carboxylic acid) 
 
Aristolochia is a large genus of plants with over 500 species belonging to the Birthwort fam-
ily. At least 180 kinds of the plant family Aristolochiaceae are well-known over the world. It 
was of great interest by the ancient Egyptians, Greeks and Romans (317, 318). Its nomenclature 
was developed from Greek words (Aristos: best) and (locheia: birth) meaning ‘correct deliv-
ery’. In the Indian folk medicine, it was given to women in labour to expel the placenta (319, 
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320); but due to its poisonous effect, it can lead to the death of the mother. Also, it is highly 
used in traditional Chinese medicine (TCM) (321). AA containing herbs were used for healing 
wounds due to the disinfectant effect of AA which drains off the fluid from the wound (316). 
Consequently, the herbal drugs containing AA were used in the prophylaxis and treatment of 
snake bites (322). It has anti-inflammatory effect (323) and was used for the therapy of chronic 
inflammations such as arthritis, gout and rheumatism (316, 324). In 2001, FDA had released a 
warning to the consumers to stop using herbal medicines containing AA due to the history of 
diseases associated with the use of AA. 
During the 1990s in Belgium, a nephrotoxicity syndrome was initially recorded in group of 
women after ingesting slimming pills. Then importantly, several cases of irreversible renal 
failure and malignant tumours of the urinary tract were reported. This was triggered by chi-
nese herbal drug containing AA used during a slimming regimen (312) with different severity 
of reported cases depending on the taken dosage. This renal disorder was initially called Chi-
nese Herbs Nephropathy (CHN), referring to the origin of herbs used in these remedies im-
ported to Belgium (325, 326). Then this syndrome was also named Aristolochic acid nephropaty 
(AAN) referring to its etiology.  
Identical cases of AAN have been reported in other places out Belgium, especially in Asian 
countries, where traditional medicines are very popular (316, 326). Later, more cases were re-
ported in other European countries (311, 327) as well as Taiwan, China, Japan (311, 328) and in the 
USA.  
The spread of the disease had initiated a stream of researches that had later supported these 
observations as identical renal interstitial fibrosis and urothelial malignancy were reported in 
rabbits and rats treated with AA (325, 329). Finally, the similarity of etiological conditions be-
tween CHN and the case due to AA exposure such as tubular proteinuria, renal glucosuria, a 
progressive rise in serum creatinine (330, 331) and severe anemia at early stage with a great pos-
sibility of development of urothelial tumours (314) had lead to rename the CHN disease as Aris-
tolochic acid nephropathy (AAN). 
Based on clinical characteristics and morphological findings, AAN (321) has major similarities 
with another renal fibrosis disease called Balkan endemic nephropathy (BEN) (332, 333) noting 
the same causative factor later discovered for both diseases (321, 334). BEN was recorded in the 
1920s as the agriculture of Aristolochia clematitis was common in the region of Balkan 
Mountains along the Danube River basin. The oral intake of flour obtained from the growing 
wheat beside which Aristolochia species had grown could explain the exposure of the humans 
in the Balkan regions to AA due to contamination of bread with Aristolochia seeds (335). Mor-
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phologically, both diseases showed extensive hypocellular interstitial sclerosis, tubular atro-
phy, glomerulosclerosis and urothelial atypia associated with the possibility of malignant 
transformation of the urothelium (314, 336, 337). Both are linked to the exposure to AA either 
through the intake of herbal remedies prepared from Aristolochia plants or the ingestion of 
contaminated wheat-made products.  
Aristolochic acids are nephrotoxic and carcinogenic nitroaromatic compounds via the produc-
tion of AA- DNA adducts which were detected in the kidney and ureter of AAN patients (338). 
Different studies had reported AA as nephrotoxic, potent carcinogen in laboratory animals 
(339-342) and man (343) as well as genotoxic mutagen (341, 344, 345). After enzymatic activation (cy-
tochrome P450 and peroxidase) (346) aristolactams (347) are the activated metabolites formed by 
AA nitroreduction (348) and form major DNA adducts (349) through the attack of aristolactam-
nitrinium ion to the exocyclic amino group of adenosine and guanosine (315, 349) (Fig. 15). The 
AA–DNA adducts can be used as potential biomarkers of AA toxicity (167). 
Certain genes are associated with different mutations in response to AA exposure, such as 
TP53 (350). This gene was found to be mutated in 50% of the recorded human cancers (351) and 
was recently identified in some AA-induced tumours (343, 351, 352). The p53 mutational spectra 
of these cancers are dominated by the type of AT-TA transversions (284), resembling the muta-
tional behaviour observed in urothelial cancer patient (353) as well as in H-ras oncogene in ro-
dents exposed to AA dosage (354, 355). 
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Figure 15:   Mechanism of AA-DNA adducts formation (AAI, R : OCH3) and (AAII, R : H) (333) 
 
1.3.3.3 Methods for the determination of AA 
 
Various chromatographic methods were applied for the determination of aristolochic acid in 
various selected herbs and dietary slimming products such as HPLC (356-359) and TLC (360, 361). 
CZE was successfully applied to determine AA in real samples of herbs and dietary natural 
products as an alternative method to HPLC due to its simplicity. CZE-cyclic voltametry 
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method had been used for the determination of AA in medicinal plants using phosphate and / 
or borate as separation buffers (332, 362). Another CE method had been recently published to 
perform the analysis of AA within minutes without any sample pre-treatment (363). The advan-
tage of MEKC principles was also achieved by proposing an on-line concentration method 
using field-enhanced sample injection (FESI) mode for the detection of AAs in chinese medi-
cine preparations (364). Capillary electrophoresis with laser-induced fluorescence detection 
(CE-LIF) were also used for the analysis of the reduced AAs that fluoresce at 477 nm when 
excited at 405 nm using a solid-state blue laser (365). Different detection principles, such as 
UV, MS (366) and NMR (367) were recorded for the analysis of AA in dietary slimming supple-
ments too. DNA adducts formed by AAI and AA II were analysed in vitro and in vivo to 
study their contribution in cancer formation using 32P- postlabelling method (348, 368-370) . 
 
1.4 Methods for determination of the DNA-methylation level 
Some researchers were interested to set different techniques to study the occurrence of methyl 
cytosine and its localization in the genome. Others were interested to measure the level of 
methylcytosine in the genomic DNA either by high-performance separation techniques or by 
enzymatic or chemical means. Although the formers are more sensitive than the latter, enzy-
matic and chemical techniques are favoured due to their simplicity and cheapness. 
  
1.4.1 Gene-specific methylation analysis methods 
 
The analysis of gene specific methylation content implies initially a basic amplification of the 
target sequence. This is achieved by so-called polymerase chain reaction (PCR). Primers 
which are short DNA fragments possessing a sequence complementary to the target sequence 
and DNA polymerase enzymes which are the elemental components of this well-known tech-
nique. By applying PCR specifically to amplify sequence within CpGs, the information on 5-
methylcytosine will be erased as DNA polymerases could not discriminate between cytosine 
and 5-methylcytosine. From here, all the following described methods for the analysis of gene 
specific methylation are focusing on modifying one of these bases to allow differentiation 
between them (371).  
 
 
 
 
Introduction 
34 
- Methylation Sensitive Restriction Endonucleases (MSREs) 
 
The principle of this technique was obtained from the role of 5-meC in prokaryotes as defence 
mechanism against foreign DNA. Simply explained, the ‘bacterial Restriction/modification’ 
system is involving the methylation of the host DNA by DNA methyltransferase enzymes to 
protect it from restriction enzymes which check any DNA in the cell for this ‘methylation 
signature’ and cut the sequence that lacks the correct methylation pattern. In this way, most 
foreign DNA are identified and cleaved before its expression (372). Isoschizomers restriction 
endonucleases have been used to study methylation changes within their specific recognition 
sites noting their different sensitivities to 5-meC. Essentially, one enzyme is insensitive to 5-
meC (e.g.MspI) but the other (e.g.HpaII) does not cut DNA if its cleavage site is occupied by 
5-meC (Fig. 16). 
 
 
 
 
 
 
 
 
Figure 16: Gene-specific methylation analysis using MSREs (371) 
 
The output of this simple technique studying the methylation status can be further identified 
by a southern hybridization gel-electrophoresis technique (MSRE-Southern analysis) involv-
ing the digestion of genomic DNA with the restriction enzyme HpaII and in parallel, another 
part of genomic DNA is digested by MspI enzyme (373). The conclusion is identified from the 
size of the hybridising bands related to the digestion of both enzymes. If the bands are of the 
same size, then this sequence was not methylated. However, larger band detected with HpaII 
means the sequence was methylated (Fig. 17). The drawback of the method is obvious in case 
of incomplete digestion leading to false positive results of restriction-enzyme based methods. 
Moreover, the technique is limited to specific restriction sites and it requires suitable amount 
of pure DNA. This technique can be coupled with PCR (MSRE-PCR) (373) to increase the sen-
sitivity by 1000-fold revealing the amplification of the sequence site if it is not cleaved. The 
inability of restriction enzyme to digest methylated sequences yields longer fragments, indi-
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cating a methylated CpG dinucleotide. The choice of the identification tools either southern 
blot techniques or PCR is dependent on the length of the digested DNA fragment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Representative model of combined MSRE-Southern Blot gel electrophoresis analysis 
The electrophoresis was carried out in 0.8 % (w/v) Agarose in 1 X TAE buffer (triacetic acid + 
EDTA) + Ethidium bromide gel for one hour at 120 V using BioRad Mini –Sub Cell GT Gel 
electrophoresis apparatus. The resulting gel was dried and exposed to x-ray film (Polaroid MP-
4 Land Camera; UV transluminator VVP San Gabriel USA) for 5 min. 
 
- Sodium bisulphite reaction 
 
Treatment of DNA with sodium bisulphite (Na2SO3) will result in a reaction between Na2SO3 
and pyrimidine base (374-376). The sulphonation occurs at position 6 of the pyrimidine ring (376, 
377) and the reaction is reversible (Fig. 18). The amino group at position 4 of C and 5-meC 
becomes non stable by the attack of bisulphite group. Thus, the deamination of these bases 
occurs to either U or T, respectively (374, 376). However, the kinetic rate of deamination reaction 
of both bases distinguishes between C and 5-meC in DNA as the former reaction is faster than 
the latter (378). The reaction is principally dependent on the sequence differences due to 
deamination of unmethylated cytosines to uracil under conditions that methylated cytosines 
escape the reaction (374) (Fig. 19).  
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Figure 18: Bisulphite conversion reaction (374) 
 
 
 
 
 
 
 
 
Figure 19: Gene specific methylation analysis using sodium bisulphite reaction (371) 
 
The difference in methylation status revealed by bisulphite reactivity can be determined and 
quantified by PCR-based technique. Bisulfite sequencing was the universal methodology used 
in the last years providing accurate information about the methylation status. Its limitation is 
dependent on the incomplete conversion of C to U as SO3 2- reacts only with cytosine bases 
not involved in base pairing (371). 
Finally, other methods were literally cited, such as combined bisulphite restriction analysis 
(COBRA) (371, 379, 380), methylation specific PCR (MSP) (381), methylation sensitive single nu-
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cleotide primer extension (Ms-SNuPE) (382, 383) whereas the analysis could be done by means 
of ion pair RP HPLC (383), capillary electrophoresis (384) or MALDI TOF (385), methyl light (386) 
and RNase-T1-MALDI-TOF (387) methods.  
 
1.4.2 Genomic-wide methylation analysis methods 
 
The analysis of genome wide methylation pattern can be performed directly on raw DNA 
samples after its isolation. Its principle is based on the determination of ratio between 5-
methyl cytosine and cytosine. 
 
- Instrumental analysis 
 
Before the determination of DNA methylation by the proposed instrumental technique, it is 
highly required to hydrolyse the DNA molecule to its mononucleotides. This process is suc-
cessfully done by the enzymatic hydrolysis of the genomic DNA by using firstly either De-
oxyribonuclease I (DNase I), nuclease P1 (388) or snake venom phosphodiesterase (389) to pro-
duce deoxyribonucleotides, followed by alkaline phosphatase treatment. The finally produced 
deoxyribonucleosides are subsequently separated by standard reverse-phase HPLC (388, 390-394), 
TLC or CE (395, 396). The separated deoxyribonucleosides can be identified by combining 
HPLC with UV (388, 389, 391, 394) as well as CE with UV (397) or by hyphenating HPLC-MS to 
increase the sensitivity (393). 
HPLC is the oldest and preferred technique for the determination of the genome methylation 
levels of DNA (388). But, HPLC method suffers from the known problems related to the elu-
tion buffer as well as the low amount available of DNA samples. HPLC-UV determination 
method requires at least 10 µg DNA sample, however 1 µg is required for CE-UV (397) and 
HPLC-ESI-MS (393) determination. Alternative method as TLC was prone to the lack of speci-
ficity. 
In the last 10 years, a reproducible electrophoretic method was established and modified (398) 
for accurate determination of the methylation level (394) as well as for detection of DNA ad-
ducts (399). CE-LIF technique had offered an opportunity to analyse 100 ng DNA sample (400) 
after its hydrolysis with micrococcal nuclease and phosphodiesterase II. 
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- Radioactive-mediated SssI methyltransferase assay 
 
This assay is a simple modification of de novo methylation process (376) catalysed by the en-
zyme SssI DNA methyltransferase using S-adenosyl methionine (SAM) as methyl donor. Its 
principle is depending on using the SssI enzyme to transfer a tritium-labelled methyl group 
from SAM to unmethylated cytosines in CpG sites of genomic DNA (401, 402) (Fig. 20). The 
amount of radioactive incorporated labels can be quantified by a scintillation counter. The 
radioactivity is inversely proportional to the CpG methylation and can reverse the extent of 
global changes in methylation pattern. However, the variability of counts recorded from ex-
periment to experiment and from one day analysis to another had influenced the use of this 
assay due to the instability of both SAM and the methyltransferase enzyme.  
 
Figure 20:  Pathway of radioactive-mediated methyltransferase assay. 
 
- Chloracetaldehyde fluorescent assay 
 
Oakeley et al. (403) had developed a method to monitor the changes in genome-wide methyla-
tion levels by labelling the modified DNA by fluorescent tags using chloracetaldehyde. The 
DNA was first depurinated by treatment with sulphuric acid, then the purine bases were re-
moved by precipitation with silver or by column chromatography (404). Then, the depurinated 
DNA was treated with sodium bisulphite that converts C into U leaving the 5-methylcytosine 
unreacted (378). At the end, the sample was incubated with chloroacetaldehyde to produce the 
intensely fluorescent etheno-cytosine derivative of 5-meC, which was quantified by a 
fluorimeter. Thus, this method is providing a tool for the measurement of the level of 5-meC 
in the genome (403). The chloracetaldehyde reaction–dependent assay is a good alternative to 
other methods used for determination of genome-wide methylation because of the non-
fluorescence property of the chloracetaldehyde as well as the DNA molecule. However, the 
toxicity of chloracetaldehyde and the time consumed in this assay could limit its use. The 
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depurination is an important step to prevent the interference from the adenosine purine base 
by forming a fluorescent adduct after reaction with chloracetaldehyde. 
 
1.4.3 Capillary Electrophoresis (CE) 
 
Capillary electrophoresis is one of the most important instrumental techniques applied for the 
determination of genomic methylation level and specifically used in the research work per-
formed in this thesis. It is a powerful separation technique performing the analysis depen-
dently on a unique physicochemical characteristic ‘electrophoretic mobility’. The term elec-
trophoresis, of Greek origin, means electron (electron) and phoresis (carrying) and reflects the 
definition of the process as: the movement of ions under the influence of an electric field 
across buffer-filled capillaries. This phenomenon of electrophoretic transport in an electric 
field has been known by the pioneering work of Kohlrausch (405) in 1897. The history of the 
development of CE is briefly described in the appendix (405-410). CE was popularised after in-
troduction of narrow glass capillaries by Jorgenson and Lukacs enabling the use of high volt-
age with good detection of separated peaks (409-411). Depending on the types of capillary and 
electrolyte used for the analysis, the CE technology can be categorised into several separation 
modes [Capillary Zone Electrophoresis (CZE) (412), Micellar Electrokinetic Chromatography 
(MEKC) (412, 413), Capillary Gel Electrophoresis (CGE), Capillary Isotachophoresis  
(CITP) (414-421), Capillary Isoelectric Focusing (CIEF) and Capillary Electrochromatography 
(CEC)] (422). CE is a flexible technique compatible with several detection modes such as: UV, 
LIF, MS, amperometric, voltammetric and other detectors. CE promises to become an impor-
tant analytical technique, complementary to HPLC. Its applicability covers a broad range of 
entities, from simple ions to high molecular weight species such as DNA and even intact liv-
ing cells. The analysis of ionic species and separation of compounds such as chiral drugs, pes-
ticides, amino acids, peptides, proteins, oligonucleotides and DNA restriction fragments (411, 
423-428) could be performed with CE. 
 
. 
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2 Aim and objectives of the study 
The main objective of this work is the determination of genomic methylation level by capil-
lary electrophoresis so as to better define the molecular-biological relationships associated 
with cancer and other cell abnormalities. 
The first aim of this study is concerned with the assessment of the influence of oxidative 
damage on the methylation level. The CE-LIF method used in the whole work for the analysis 
of DNA modifications requires the presence of the phosphate group in the 3’ position of 2’-
deoxyribose of the nucleotide to be analysed. A synthesis of the modified 8-oxo-2’-
deoxyguanosine-3’-monophosphate (8-oxo-dGMP) nucleotide, its characterisation with ESI-
MS and its detection with CE-LIF should be realised.  
The second aim is the determination of the change in DNA methylation level by CE-LIF in 
several DNA samples treated with carcinogens - aristolochic acid (AA), 3-nitro-benzanthrone 
(3-NBA), benzo[a]pyrene B[a]P and 4-aminobiphenyl (4-ABP) - in either in-vivo or in-vitro 
studies in order to find whether there is a correlation between the methylation level and the 
carcinogen-adduct formation.  
Finally, a great part of this work focuses on the determination of the DNA methylation level 
in clones and twins to clarify some epigenetic approaches toward cloning. Successful somatic 
cell nuclear transfer (SCNT) cloning is compatible with the birth of live offspring in a wide 
range of mammalian species; however the low overall efficiency of the technology could be 
related to the failure of epigenetic reprogramming. Clones that survive into adulthood, in con-
trast, are judged to be normal, and the epigenetic marks required for their normal development 
are assumed to have been retained; however, the epigenetic status of such healthy adult clones 
has never been investigated. The aim of this study is to evaluate the genome-wide 5-meC lev-
els in healthy adult female SCNT clones generated from different genotypes of the Holstein 
and Simmental cattle breeds. In parallel, the genome wide 5-meC levels of experimentally 
generated monozygotic (MZ) twins will be investigated. MZ twins are chosen as comparative 
models in the study because their methylation status is highly similar in adult humans across 
populations. 
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3 Results and Discussion 
3.1 Spectrophotometeric determination of DNA concentration  
The concentration of all DNA samples which were provided and analysed in the course of this 
work was adjusted to give the appropriate quantity for each study and was either 1 or 10 µg. 
This adjustment was accomplished spectrophotometrically. Each dried DNA sample was dis-
solved in 500 μL distilled water. A transmission spectrum of the solution was recorded 
against water in the wavelength region from 200 to 800 nm (See Appendix. Fig. 58). DNA 
shows a relevant absorbance in the UV range. The computation of the DNA concentration 
[μg/mL] was calculated by the Lambert Beer law with the extinction value at 260 nm. The 
purity of the DNA was calculated from the relationship of the difference of the extinction val-
ues at 260 nm and 320 nm to the extinction value at 280 nm. 
 
3.2 Determination of genome wide methylation level with CE-
LIF 
Schmitz et al. (395, 400, 429-432) had developed a sensitive method for the determination of the 
genome-wide methylation level in real samples by CE-LIF. This method was used in all the 
analyses done in this work. The method involved the hydrolysis of the DNA extracted from 
different tissues to modified or unmodified nucleotides (2’-deoxynucleoside-3’-
monophosphate), the derivatisation of the product with BODIPY® FL EDA as fluorescence 
marker, and then the analysis by micellar electrokinetic chromatography using laser induced 
fluorescence detector (Fig. 21). 
   
 
 
 
 
 
 
 
Results and Discussion  
42 
 
 
Figure 21: Outline of the procedure used for the analysis of DNA modifications by means of CE-LIF 
1: Formation of the intermediate product by activation of phosphate moiety of  
       2’-deoxynucleotide with EDC.  
2: Nucleophilic attack by the primary amine of BODIPY on the activated phosphorus moiety. 
 
A mixture of the enzymes micrococcal nuclease (MN: endo- exonuclease enzyme) and spleen 
phosphodiesterase (SPD: exonuclease enzyme) was used to digest DNA to yield mononucleo-
tides with terminal 3’-phosphates (433, 434). Calcium ions were included in the hydrolysis buffer 
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in order to offer a suitable medium for the activity of MN then the hydrolysis took place for 3 
h at 37°C.  
The fluorescence derivatisation of mononucleotides was done with BODIPY FL EDA hydro-
chloride to allow detection of non-fluorescing analytes. The spectroscopic characteristics of 
BODIPY (maximum absorption of 503 nm and maximum emission of 510 nm) make this 
marker suitable for use with the two types of lasers utilised in this study (wave laser excitation 
at 488 nm) (435) and also overcome any interference by native fluorescent matrix comp- 
ounds (432).  
The covalent coupling of the fluorescence marker to mononucleotides took place only in 
presence of water-soluble carbodiimide, as this is essential for the activation of phosphate 
moiety of mononucleotide toward nucleophilic attack by the amino group of the fluorescence 
marker (436). At neutral pH, EDC (1-ethyl-3-(3’-N,N’-dimethylaminopropyl)-carbodiimide 
hydrochloride) possesses a strongly basic tertiary amino group which can be activated through 
intramolecular proton transfer from the tertiary nitrogen atom to the imide nitrogen (436). The 
phosphoamidate is then formed by the nucleophilic attack of the amino linker of BODIPY on 
the phosphorus of the activated phosphate group (Fig. 21). However, this derivatisation re-
quirement excludes the use of fluorescence markers or buffer systems with carboxylic acid, 
primary amino, or phosphate groups (437). Therefore, N-(2-hydroxyethyl)-piperazine-N-2-
ethane sulfonic acid (HEPES) was the only suitable buffer system used for the derivatisa- 
tion (399). 
At the end, a precipitation reaction was mandatory for the stabilisation of the samples to get 
rid of the excess of added BODIPY and EDC. It must be mentioned that the procedure for the 
derivatisation reaction had called for the use of EDC in excess because some of it is lost by 
reaction with water to a urea derivative, and BODIPY must also be used in excess to ensure 
high reaction yield (398). However, this excess of reagents led to great interference from fluo-
rescent signals of BODIPY decomposition products (432). 
Sodium phosphate was chosen as a separation buffer because its high buffer capacity at pH 
9.0 is suitable for a high EOF. The data are displayed as an electropherogram that reports de-
tector response as a function of time. A representative electropherogram of the analysed CT-
DNA sample (10 µg) is illustrated in figure 22. The separated chemical species appeared as 
peaks with different migration times in the electropherogram, i.e., five major signals of the 
derivatised nucleotides in the following order: 2’-deoxyadenosine-3’-monophosphate 
(dAMP), 2’-deoxyguanosine-3’-monophosphate (dGMP), thymidine-3’-monophosphate 
(dTMP), 2’-deoxycytidine-3’-monophosphate (dCMP) and 5’-methyl-2’-deoxycytidine-3’-
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monophosphate (5-me-dCMP). In the early part of the electropherogram, an oligo-zone ap-
pears, representing DNA which was not completely digested by the enzyme mixture 
(MN/SPD). The oligo-zone is dependent on the quantity of SPD used in the enzyme mixture 
as well as the purity of each particular enzyme charge (398). 
Figure 22: Representative electropherogram for the determination of 5-methylcytosine in a 10 µg DNA 
sample by CE-LIF. MEKC operating conditions: separation voltage: 20 kV; T: 20°C; running 
buffer: 90 mM SDS in 18 mM sodium phosphate buffer (pH 9.0) containing 10 % v/v metha-
nol; fused-silica capillary (LT =50 cm; LD =40 cm; ID =50 mm). 
 
The methylation level was determined from the following equation: 
 
 
 
 
 
Where  % 5-meC: methylation level 
 meC:  corrected peak area of 5-me-dCMP 
  C    :  corrected peak area of dCMP 
     f1    :  correction factor of 5-me-dCMP  
    f2        :  correction factor of dCMP 
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Integrated peak areas were used for the routine determination of methylation level (438, 439). 
The correction factor was determined in our group (398) and previously by Stach et al. (395) by 
the analysis of Lambda DNA (unmethylated and enzymatically methylated). This correction 
factor was calculated to be 0.678  0.001 S.D. for dAMP, 1.761  0.001 S.D. for dGMP, 
0.980  0.001 S.D. for TMP, 1.075 0.006 S.D.for dCMP (f2) and 0.910   0.04 S.D. for 5-
me-dCMP (f1) (398). 
 
3.3 Enhancement of the sensitivity of the CE-LIF method  
3.3.1 Comparison of two different LIF-detectors 
 
The sensitive laser-induced-fluorescence detector is the main detection system on which our 
laboratory is dependent for all the CE analyses. However, two detectors are used the argon-
ion laser (em = 488 nm) and the Sapphire TM solid laser. 
First of all, a comparison study was done to choose the more sensitive detector. 
 
- Argon-Ion laser  
 
In different parts of the whole work, the argon-ion laser with power output of 10 mW was 
used for determination of the methylation level (Fig. 23).  
The laser consists of a tube filled with the noble gas argon at a pressure of approximately  
1 mbar as the laser gain medium. In order to generate the 
blue laser light, the gas is exposed to an electrical discharge. 
The Ar+ and Ar2+ ions are produced by this electrical load 
and pass through a laser transition to a lower steady  
state (440, 441).  
 
 
 
 
 
 
Figure 23: Picture of Beckman CoulterTM Argon-Ion Laser 
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- Sapphire TM solid laser 
 
The Sapphire TM solid laser possesses a maximum power output of 20 mW. Figure 24 shows 
the solid laser with its control unit. The laser is placed on a thermoelectric cooler, which en-
sures an effective removal of the excess heat developed and also allows a stabilizing state for 
the diode laser and the resonator (442).  
 
 
 
 
 
 
 
 
Figure 24: Picture of Sapphire solid laser (left) and the control unit (right) 
 
The Sapphire TM solid laser belongs to the class of ‘Optically Pumped Semiconductor Lasers’ 
(OPSL) class. This is similar to the group ‘Vertical-external-cavity surface-emitting of Laser’ 
(VECSEL). The difference between the two groups is that VECSELs are electrically pumped 
while the Sapphire TM solid laser works with optical energy. The optical pumping has the ad-
vantage of producing higher power outputs than the power produced by an injection current-
dependent laser (442).  
A laser is constructed of three components. The energy source, referred to as the pump source 
or diode, provides energy to the laser system. A gain medium, the major determining factor of 
the wavelength of operation, is excited by the pump source to produce a spontaneous and 
stimulated emission of photons leading to the amplification or optical gain. The optical reso-
nator has two parallel mirrors (focusing optics in OPS); one functions as a high reflector and 
the other as a partial reflector for the fundamental wavelength of the OPS. 
The heart of this laser is an OPS chip (Optically Pumped Semiconductor) that functions not 
only as laser medium but also as one of the final mirrors of the linear resonator. The output 
beam of the pump diode is focused onto the OPS chip by a lens. The light from the medium, 
produced by spontaneous emission, is reflected by the mirrors back into the medium, where it 
may be amplified by stimulated emission. The light may reflect from the mirrors and thus 
pass through the gain medium many hundreds of times before exiting the cavity. A curved 
Laser Head
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CDRH Controller
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mirror that is externally arranged completes the resonator for the IR radiation (443). Figure 25 
shows schematically the structure of the resonator containing the gain material (OPS-chip), a 
frequency-doubling crystal and the output coupler.  
 
 
 
 
 
 
 
 
 
Figure 25: Schematic diagram of optically pumped semiconductor laser (OPSL) (443).                            
It is composed of: 1. Pump diode; 2. Focusing optics;  3. OPS chip;                           
4. Doubling crystal; 5. Output coupler 
 
The pumping radiation of the 808 nm diode laser focuses on the OPS chip. The radiation is 
absorbed by the designed structure of the chip (Fig. 25). Thus the OPS chip, as laser medium, 
strengthens the IR wavelength of 976 nm. A non-linear crystal doubles the frequency of the 
IR light to a wavelength of 488 nm (442). The blue beam passes through lenses and exits 
through the window of the output coupler. 
In order to achieve the required detection limit of DNA adducts, a sensitive detection system 
and/or an off-line or on-line enrichment concentration technique is required. Therefore, it was 
necessary to study the characteristics of the Sapphire TM solid laser and to compare its sensi-
tivity with the Beckman laser (Argon ion laser) which was normally used. 
Basically, the Sapphire laser already has advantages over the argon laser. The Sapphire TM 
solid laser has a life time eight times that of the argon laser (444). In addition to this economic 
advantage of the former laser, the Sapphire TM solid laser is relatively small in size which is 
considered an important advantage in the practical work because it is easy either to transfer of 
the laser (if it should be necessary for the work to couple it with other CE equipment in the 
laboratory) or to re-build its units. In order to reach a good decision for the choice of lasers, 
the two lasers: Sapphire laser and Beckman Laser were tested for their sensitivity. Therefore, 
the signal to noise ratios of the lasers were first determined then compared, and comparative 
measurements of standard samples were also performed. 
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3.3.1.1 Determination of signal to noise ratio 
 
Before the two lasers could be compared, the intensity of the Sapphire TM solid laser had to be 
adjusted to be the same as that of the Beckman Coulter TM argon ion laser. This was done by 
analysing the Beckman Coulter test solution (fluorescein solution) as a test solution with the 
argon-ion laser. Then, the same test solution was measured with the Sapphire TM solid laser.  
The power output of the control unit of the solid state laser was adjusted to deliver the same 
signal intensity as obtained from the Beckman laser. 
An equivalency of the two signals was reached with a power output of 16 mW. Both lasers 
experience a power loss within the light conductor as well as within the inter-connections. For 
example, the power loss of the Beckman laser amounted to 6.6 mW (of 10 mW to 3.4 mW) 
within the light conductor and 2 mW (of 3.4 mW to 1.4 mW) in the inter-connections (444). 
After the adjustment of the lasers, the analysis of hydrolysed and derivatised standard CT-
DNA was performed in order to compare accurately the two lasers and the application for the 
analysis of real samples. The results showed good agreement between the two lasers. The 
methylation level of the standard samples deviated less than 1 % between the two lasers 
[Beckman Coulter TM laser 6.07 %  0.08 S.D. (n=10) and Sapphire TM laser 6.06 %  0.15 
S.D. (n=12)].  
The signal to noise ratio (S/N) is an important measurement that should be defined for the 
detector. For the determination of S/N ratio‚ the fluorescein solution was analysed by both 
lasers with sodium tetraborate buffer (20 mM, pH 7.0) for separation. A signal was obtained 
after approximately 4-6 min, and the S/N ratio was computed according to the following for-
mula 2 (445): 
 
      
 
              
 
                     Where S/N:  signal to noise ratio 
H   : peak height of the signal (equivalent to RFU) 
hn    :  height of the noise 
 
 
In order to identify the noise level, the width of the fluorescein signal at its half length was 
recorded (b1/2). The multiplication of b1/2 by 20 resulted in the noise range (tn) (Fig. 26A). 
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Figure 26 (A and B): Electropherogram of fluorescein solution to test the sensitivity of laser induced fluo-
rescence detector. It shows the calculation of signal (A) to noise (B) ratio (S/N) 
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In this range, two lines are drawn through the highest peaks points and lowest through points. 
Then at half distance of tn, a perpendicular line is drawn two peak-through lines, and then the 
point in the middle distance at y axis is taken to calculate accurately hn (Fig. 26B). 
The signal height and the noise strength were measured and the lasers could thus be compared 
objectively with one another. Table 1 shows the calculated S/N ratios of the two lasers. 
The results revealed that the two lasers deviate slightly from each other in the S/N relation-
ship. The Sapphire TM solid laser has a better S/N relationship and therefore gives higher sen-
sitivity than the Beckman TM argon ion laser.  
 
Laser Type Signal to noise ratio (S/N)  
S.D. 
n 
 
Sapphire TM solid laser 
 
             35903  2682 
 
3 
 
Beckman Coulter TM      Ar-
gon-Ion laser 
 
             31945  835 
 
3 
Table 1: Signal to noise ratios of Sapphire TM solid laser and Beckman TM Coulter Argon-Ion laser 
 
3.3.1.2 Reproducibility of the measurements  
 
With the exchange of a fundamental component of the established MEKC-LIF system, the 
reproducibility of the methodology had to be tested. Two aliquots of the standard CT-DNA 
were hydrolysed and derivatised and each was analysed six to eight times with the Sapphire 
solid laser. The methylation levels determined are listed in table 2. The results of the analyses 
showed a very small deviation from each other (S.D. < 1.41 %). This confirms the reproduci-
bility of the method after exchanging the laser detectors. 
 
Sample Methylation level (%)   
S.D. 
n 
 
CT (1) 
 
6.20  0.07 
 
8 
 
CT (2) 
 
6.22  0.07 
 
6 
Table 2:  Determination of the methylation level of CT-DNA samples (10 µg) using 
Sapphire TM solid laser 
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In summary, both laser systems, the solid laser and the argon ion laser, were coupled with CE 
equipment and tested for S/N ratios. The results confirmed the benefit of replacing of argon-
ion laser by the Sapphire solid laser to be used with CE for its higher sensitivity. Also, the 
reproducibility of the measurements recommended the use of the Sapphire laser. In addition, 
the longer life time of the solid laser is definitely a profit, and the analyses costs can be drasti-
cally lowered.  
 
3.4 Synthesis of 8-oxo-2’-deoxyguanosine-3’-monophosphate  
(8-oxo-dGMP) 
The imbalance occurring in the triangle of oxidants, antioxidant systems and DNA repair 
mechanisms favours the status of oxidative stress. Among 20 major defined oxidative DNA 
adducts (260, 446), the 8-oxo-2’-deoxyguanosine adduct is the most investigated oxidative modi-
fication in DNA. It is associated with specific cellular repair mechanism (DNA glycolase en-
zyme: OGG1) (255). Therefore, its existence in urine as a repair product could be used as a 
biomarker for some inflammatory diseases and to lesser extent for carcinogenesis. Its pres-
ence in diverse cancer sites, however, had suggested the role of oxidative stress in the initia-
tion of carcinogenesis. Oxidative stress and aberrant CpG methylation are each associated 
with carcinogenesis. This makes it of interest to find whether there is a correlation between 
oxidative stress and DNA methylation. Firstly, it was important to synthesise 8-oxo-2’-
deoxyguanosine-3’-monophosphate (8-oxo-dGMP) because the analysis of DNA adducts by 
the proposed CE-LIF method needs the availability of well-characterised standards of these 
adducts in the form of 2’-deoxynucleoside-3’-monophosphates. Unfortunately, very few DNA 
adducts are commercially provided in this form. Therefore, different synthesis routes to 8-
oxo-dGMP were tried before its detection and the determination of methylation level in real 
cancer-mediated samples were undertaken. 
 
3.4.1 Optimisation of the synthesis  
 
Because guanine is the nucleobase most prone to oxidation (447), various synthesis pathways 
were tried. First, 25 or 100 µg DNA was dissolved in 330 µL of the freshly prepared ferrous 
sulphate reagent, 1 mM FeSO47 H2O in 10 mM ammonium acetate that was adjusted to pH 4 
with diluted acetic acid buffer, then treated with 13.8 µL of 35 % H2O2. A purification step 
was done in accordance with the Qiagen genomic DNA purification protocols appropriate to 
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the amount of DNA. Unfortunately, the purification was not successful. Therefore, a second 
synthesis pathway was tried using 1 mM hydrogen peroxide with different amounts of  
2’- deoxyguanosine-3’-monophosphate (10, 20 and 100 µg) as starting material. The reaction 
mixture was shaken for 6 hours at 25°C in a covered thermomixer, and kept overnight in the 
dark at the same temperature without shaking. The solutions were then dried using speed vac-
uum, derivatised with BODIPY and precipitated for CE-LIF analysis. Since the analysis of 8-
oxo-dGMP seemed to be very difficult with the CE-LIF due to the unavailability of an inter-
nal standard, the reaction was compared with blank sample using water instead of hydrogen 
peroxide. No difference was observed revealing the detection of a single peak related to the 
starting material. Moreover, the relative fluorescence units (RFU) were found to be (25, 50 
and 153 units) for 10, 20 and 100 µg of 3’-dGMP, respectively (Fig. 27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: CE-LIF analyses of 10 µg, 20 µg and 100 µg of dGMP treated with 1 mM hydrogen 
peroxide. Analysis was done after hydrolysis, derivatisation, precipitation and dilution by a 
factor 1:100. MEKC operating conditions: separation voltage: 20 kV; T: 20°C; running buffer: 
90 mM SDS in 18 mM sodium phosphate buffer (pH 9.0) containing 10 % v/v methanol; 
fused-silica capillary (LT =50 cm; LD =40 cm; ID =50 mm). 
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Different portions of the base line of electropherograms of 10 µg dGMP in presence of either 
peroxide or water were expanded and showed no significant difference in the base line  
(Fig. 28). The CE measurements were performed either directly after sample preparation or 
after 24 h and no extra-peak could be detected to prove the success of the oxidation reaction. 
The electropherograms in figures 27 and 28 are representative of immediate measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: CE-LIF analyses of 10 µg dGMP treated with hydrogen peroxide or water as control sample. 
Analysis was done after hydrolysis, derivatisation, precipitation, and without dilution.     
MEKC operating conditions: the same as previously mentioned. 
 
The simple correlation in figure 27 and the comparison in figure 28 had revealed that the 
starting material 2’-deoxyguanosine-3’-monophosphate (3’-dGMP) was not oxidised by 
H2O2. This suggested pathway was not successful until a catalyst was used because H2O2, 
despite its strong oxidative property, has no hydroxylation activity (448). 
The method of Schuler et al. (258) is another synthesis scheme which we applied to the synthe-
sis of 8-oxo-dGMP with the substitution of CuSO4 for FeSO4. 2’-Deoxyguanosine-3’-
monophosphate was used as the starting material in presence of hydrogen peroxide, copper 
sulphate and sodium ascorbate to synthesise 8-oxo-dGMP (Fig. 29).  
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Figure 29: Proposed scheme of 8-oxo-2’-deoxyguanosine-3’-monophosphate synthesis 
 
Different reaction mechanisms were followed to synthesise the 8-hydroxy-2’-deoxyguanosine 
(8-OH-dG). The Udenfriend system (449) (ascorbic acid, Fe2+- EDTA and O2) has been used 
effectively for hydroxylation of dG, and Fenton’s reaction has also been recorded. Hydrogen 
peroxide can react with transition metal (Fe2+ or Cu+) in the Fenton’s reaction to produce reac-
tive hydroxyl radical (450, 451).  
 
Mn+ + H2O2 → M(n+1)+ + OH− + OH•   
 
Hydrogen peroxide can interact with the resulting OH• to form superoxide anion radical, 
which in turn generates the hydroxyl radical from H2O2 via Haber-Weiss reaction (452). Other 
schemes have been suggested to provide an explanation model for the mechanism of this reac-
tion (453). 
H2O2 + OH• → H2O + O2−. + H+  
H2O2 + O2−. → O2 + OH− + OH• 
 
Then the guanine nucleobase can be attacked at its different sites C (4), C (5) or C (8) by hy-
droxyl radical generated from the incubation of Cu+ / Na ascorbate to produce 4-OH-, 5-OH- 
and 8-OH-dGMP, respectively (454). The isormers 4-OH and 5-OH-dGMP are transformed 
back to guanine by loss of a molecule of water (455). However, 8-OH–dGMP can be either 
reduced with further opening of the imidazole ring to yield 2,6–diamino-5-form-
amidopyrimidine (FAPy-G) or oxidised with further loss of a proton forming 8-OH-dG (456) or 
its tautomer 7,8–dihydro-8-oxo-2’-deoxyguanosine (8-oxo-dG) (455) (Fig. 30). 
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Figure 30: Scheme of oxo-adduct formation after attack of hydroxyl radical on 2’-deoxyguanosine-3’-
monophosphate (455) 
 
Iron (457), copper (458) and chromium (459) are the most common transition metals that partici-
pate in Fenton-like reactions to catalyse DNA oxidation. The oxygen can be obtained by bub-
bling oxygen through the reaction mixture or by adding hydrogen peroxide (H2O2) (460). H2O2 
was chosen in this study to stimulate the production of hydroxyl radical in presence of metal 
because it is an easier procedure with minimum precautions necessary. 
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Various reducing agents such as hydroxylamine, hydrazine, dihydroxymaleic acid, sodium 
bisulphite, sodium ascorbate and acetol were investigated for the hydroxylation reaction (461). 
Sodium ascorbate was chosen for the reaction because the mixture of H2O2 gives the highest 
recorded yield of the oxidised product 8-OH-dG when ascorbic acid is used (460). Sodium 
ascorbate is used in its acid form or its sodium salt to accelerate the production of 8-oxo-
dGMP. However, it should be used in low concentration for the reaction because it possesses 
an antioxidant character (461) which has an inhibiting activity on UV-induced photochemical 
oxidation.  
The reaction mixture was protected from light at low temperature to limit further oxidation 
(462) and the first portion of the solution was injected into the HPLC for the separation after  
15 min reaction. Each injection introduced 100 µL onto the Lichrospher RP-18 HPLC col-
umn, and the peaks corresponding to dGMP and 8-oxo-dGMP were detected by UV system 
and then collected separately. All portions were collected over two and half hours calculated 
from zero reaction time. This time interval was suitable with the yield of 8-oxo-dGMP, which 
is favourably formed in the equilibrium reaction with 3’-dGMP (462).  
The complete separation of 8-oxo-dGMP from 3’-dGMP and its purification were of tremen-
dous importance not only for CE analysis but also for hindrance of the spontaneous oxidation 
of dGMP (463). Equally, the same precautions (low temperature, no light) were observed in the 
storage of collected fractions of 8-oxo-dGMP after its synthesis and separation from the reac-
tants. The preparation of the sample to be analysed by CE-LIF was performed as soon as pos-
sible after collection and purification. 
 
3.4.2 Purification of 8-oxo-2’-deoxyguanosine-3’-monophosphate 
 
Several experiments were performed for the separation of 8-oxo-dGMP from 3’-dGMP and 
the elution was performed at flow rate 0.8 mL/min.  
The time of sample collection was calculated according to the following equation: 
     V = Π r2 l  (3) 
     V = 3.14. (0.025)2. 58 cm = 0.11 cm3 
 Where   V: volume of capillary from detector to collected fraction 
    r: radius of capillary 
    l: length of capillary 
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As the flow rate is 0.8 mL/min, the eluted fraction is collected 8 sec after the peak appear-
ance. Both fractions were identified by their distinctive spectrum ( max 247 nm). 
Eluent system l consisted of 25 mM ammonium formate buffer that was adjusted to pH 4.7 
with diluted formic acid. This buffer has proved its ability to separate 8-oxo-dGMP from  
3’-dGMP with both TLC (464) and HPLC (258, 465). The 2’-deoxyguanosine-3’-monophosphate 
(dGMP) fraction was collected between 12 and 14 min and the 8-oxo-2’-deoxyguanosine-3’-
monophosphate (8-oxo-dGMP) fraction between 16 and 18 min with this buffer system. Frac-
tions of approximately 2 mL dGMP and 1.5 mL 8-oxo-dGMP were collected from each run 
(Fig. 31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Representative HPLC chromatogram for the separation of 8-oxo-dGMP from its starting mate-
rial 3’-dGMP (Eluent: 25 mM ammonium formate buffer pH 4.7). Chromatographic condi-
tions: HPLC analysis was carried out on a reversed phase C 18 column with UV detection at 
247 nm, flow rate (0.8 mL/min). 
 
The collected fractions from several runs were pooled, evaporated by speed vacuum to 2 mL, 
then applied to RP-18 solid-phase extraction columns (SPE) which had previously been con-
ditioned with 5 mL methanol (MeOH) followed by 5 mL water (H2O) and finally eluted with 
1 mL H2O and 1 mL MeOH. The SPE step is important for cleaning up and removal of the 
remaining reactants or side products. First, the collected waste and water fractions (SPE) of 
the portion suspected to contain 3’-dGMP were injected for mass spectrometry (MS) detec-
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tion in the ESI positive mode. Identical mass spectra were observed for the two fractions. The 
ESI-MS has molecular ion peaks at m/z 348.2 [M+H]+ and at m/z 370.2 [M+Na]+, indicating 
the molecular formula to be C10 H14 N5 O7 P. This confirms that the peak detected in figure 31 
(retention time 12-14 min) corresponds to dGMP, which can be collected and lyophilised for 
further utilisation. Also, fragmentation is observed. The N-glycosidic bond is cleaved, so that 
daughter peaks result. These intense peaks were observed at m/z 152.1 and 174.1 correspond-
ing to the protonated guanine nucleobase and the sodium adduct of the guanine nucleobase, 
respectively (Fig. 32), and representing the loss of the neutral 2’-deoxyribose moiety (116 
Da) and the phosphate group (80 Da) (465, 466). 
 
Figure 32:  Mass spectrum ESI-MS positive injection mode of 2’-deoxyguanosine-3’-monophosphate 
(dGMP) in the collected fraction from HPLC (Mobile Phase: 25 mM ammonium formate) at 
m/z 348 
 
Then, the collected waste, water and methanol fractions (SPE) of the portion suspected to 
contain 8-oxo-dGMP were injected for MS detection in the ESI positive mode (Fig. 33). The 
MS analysis had shown that the synthesised 8-oxo-dGMP can be detected in waste and water 
fractions, and its concentration in the former fraction was greater than in the latter one. 
Methanol fractions contain other degraded products which interfere with the determination of 
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8-oxo-dGMP. Therefore, waste and water fractions were further analysed by MEKC to inves-
tigate the electropherograms obtained for the presence of a peak corresponding to 8-oxo-
dGMP. 
 
Figure 33:  Mass spectra. ESI-MS positive ionization mode of 8-oxo-2’-deoxyguanosine-3’-mono-
phosphate in several collected fractions from SPE (waste, water and methanol fractions) 
 
50 µL of each of the collected fractions containing 8-oxo-dGMP from waste and water after 
SPE-mediated purification was added in separate experiments to 10 µg CT-DNA, then hydro-
lysed, derivatised, precipitated and finally measured with CE-LIF. The electropherograms of 
10 µg CT-DNA (CT10) spiked with 8-oxo-dGMP aliquoted from either the waste or water 
solutions after SPE were similar and are illustrated in figure 34. A similar result was observed 
for the electropherograms of CT10 spiked with dGMP fractions from either waste or water 
collections (Fig. 35). Surprisingly, both CT-DNA samples spiked with the two fractions con-
taining 8-oxo-dGMP had revealed two peaks at migration times 12.5 and 16.5 min in addition  
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to the peaks of nucleotides. The appearance of the common peak at 12.5 min either in the 
treated 8-oxo-dGMP fraction or the treated dGMP fraction (Figures 34 and 35) hinders the 
detection of synthesised 8-oxoguanosine. This peak could be related to the ammonium for-
mate buffer, which leads to great interference, since carboxylic acid groups can be also la-
belled by the fluorophore molecule (467). Spiking CT10 sample with dGMP leads to great dif-
ference in the electropherograms.  
Although the synthesis of 8-oxo-dGMP and its complete separation from the starting material 
by HPLC was successful with ammonium formate as eluent, the collected 8-oxo-dGMP was 
not pure enough to be detected as a single peak with the sensitive LIF detector. Also, further 
purification with various SPE columns was not successful (SPE set is illustrated in Appendix. 
Fig. 59).  
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Figure 34: CE-LIF analysis of 10 µg CT-DNA spiked with 8-oxo-dGMP (water fraction) after hy-
drolysis, derivatisation and precipitation. Dilution (1:100). Experimental conditions: the 
same as previously mentioned. 
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Figure 35: CE-LIF analysis of 10 µg CT-DNA spiked with dGMP after hydrolysis, derivatisation and 
precipitation. Dilution (1:100). MEKC operating conditions: the same as previously mentioned. 
 
Therefore, other eluents were tried to achieve better separation as well as to obtain the 8-oxo-
dGMP in pure form. Among the tried mobile phases, eluent system 2 consisting of 15% 
methanol:85 % water, pre-degassed with helium was found to give optimum separation in 
HPLC. Three peaks were detected in the HPLC chromatogram (Fig. 36). Previous studies (258, 
448) had shown that the 8-oxo-dGMP peak is eluted in most cases after the dGMP peak. The 
first broad peak was taken to be the starting material (dGMP) because of its surface area. The 
two successive peaks at migration times 4.53 and 4.90 min were separately collected, evapo-
rated to dryness with the speed vacuum rotator, then detected by MS. 8-Oxo-dGMP was de-
tected at m/z 364 in the MS spectrum of one of these two peaks, confirming that the peak col-
lected at R.t. 4.90 min corresponds to 8-oxo-dGMP. However, the electropherogram obtained 
from the analysis of 10 µg CT-DNA spiked with 8-oxo-dGMP still reveals two peaks that 
were confusing and are still unidentified as previously illustrated in figure 34. 
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Figure 36:  HPLC chromatogram for the detection of 8-oxo-dGMP in the reaction mixture with its starting 
material dGMP (Eluent: 15 % methanol in 85 % water). Chromatographic conditions: the same 
as previously described. 
 
That means the fraction of 8-oxoguanosine (8-oxo-dGMP) is still incompletely pure in that 
more than one peak is detected in MEKC analysis.  
Finally, the best separation was obtained with pure 8-oxoguanosine fraction by using dual 
elution system. It started with 25 mM ammonium formate buffer adjusted to pH 4.7 with for-
mic acid (eluent system 1). 100 µL of reaction sample was injected onto HPLC column. All 
peaks were detected by UV-VIS photodiode array detector. Guanosine (dGMP) had UV ab-
sorbance at λmax 247 nm and its peak was eluted at time interval 12-14 min and 8-oxo-dGMP 
peak was eluted at time interval 16-18 min (λmax 247 nm). 
Then the fractions of 8-oxo-2’-deoxyguanosine-3’-monophosphate pooled from several runs 
were gathered together then evaporated by vacuum speed to 2 mL (8 times concentration).  
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After concentration, this fraction was re-injected on the RP-18 column and re-eluted with 
15 % methanol: 85 % water (eluent system 2). 8-Oxo-dGMP peak had UV absorbance at λmax 
(MeOH) 278 nm and two peaks were detected at retention times 2.87 and 3.25 (Fig. 37). The 
two obtained peaks were separately collected, evaporated till dryness, reconstituted in water 
(500 µL), dried again and stored for further MS detection and CE measurement. 
 
 
 
Figure 37:   HPLC chromatogram of 8-oxo-dGMP in its previously collected HPLC fraction with 25 mM 
ammonium formate buffer (R.t. 16 min) and re-eluted with 15 % methanol:85 % water. Chro-
matographic conditions: the same as previously described. 
 
 
3.4.3 Characterisation of 8-oxo-2’-deoxyguanosine-3’-monophosphate 
 
Dried aliquots of the two collected peaks re-eluted with methanol:water (15:85) were dis-
solved (water:acetonitrile (50:50) + 0.1 % formic acid), then analysed by ESI-MS. The MS 
spectrum of the first collected peak at 2.87 min does not reveal any base peak assigned to  
8-oxo-dGMP (not shown). On the other hand, the ESI-MS of the second collected peak at 
3.25 min shows molecular ion peaks at m/z 364.3 [M+H]+ (base peak) and at m/z 386.2 
[M+Na]+, indicating the molecular formula C10 H14 N5 O8 P, which can be assigned to 8-oxo-
dGMP (Fig. 38). The comparison of the mass spectrum of 8-oxo-dGMP eluted only with elu-
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ent system 1 (See appendix. Fig. 62) with that of 8-oxo-dGMP eluted twice first with ammo-
nium formate buffer then with 15 % methanol:85 % water reveals a smoother trace with 
higher signals for the latter spectrum (Fig. 38). This finding easily confirms the success of 
this dual HPLC elution, first with ammonium formate buffer then with 15 % methanol:85% 
water to obtain pure synthestic 8-oxo-2’-deoxyguanosine-3’-monophosphate. This step can be 
considered a more successful clean-up step than the experiments with various types of SPE. 
 
Figure 38:  Mass spectrum ESI-MS positive injection mode of 8-oxo-2’-deoxyguanosine-3’-
monophosphate (8-oxo-dGMP) in the collected fraction from HPLC (Mobile Phase: 25 mM 
ammonium formate then 15 % MeOH:85 % water) at m/z 364 
 
3.4.4 Analysis of 8-oxo-2’-deoxyguanosine-3’-monophosphate by CE-LIF  
 
A dried aliquot of the collected peak containing 8-oxo-dGMP was derivatised with BODIPY, 
then precipitated and analysed by CE-LIF.  
Finally, the peak corresponding to 8-oxo-dGMP was successfully detected without any inter-
ference from other degraded compounds or impurities (Fig. 39, pink electropherogram: tm 
21.92 min). To test the accuracy of the determination of 8-oxo-dGMP, the signal of  
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Figure 39: MEKC-LIF detection of 8-oxo-dGMP analysed in pure form (pink electropherogram) or  
                          spiked with 10 µg CT-DNA (red electropherogram) in comparison to analysis of 10 µg CT-  
                          DNA (black electropherogram). MEKC operating conditions: the same as previously  
                          mentioned. 
 
synthesised and purified 8-oxo-dGMP was defined by spiking the 8-oxo-dGMP with standard 
CT-DNA. Then, the sample was analysed with the routine CE-LIF after hydrolysis, derivati-
sation and precipitation. The peak corresponding to 8-oxo-dGMP can easily be detected at  
tm: 20.84 min (Fig. 39, red electropherogram). The analysis of the authentic CT-DNA was 
also carried out under the same experimental conditions acting as reference for both previous 
analyses (Fig. 39, black electropherogram). The comparison showed that pure CT-DNA is 
free of the peak detected in the analysis of CT-DNA spiked with the new synthesised 8-oxo-
dGMP confirming the success of synthesis of 8-oxo-dGMP. 
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3.4.5 Detection of 8-oxo-dGMP and determination of methylation level in real 
samples with CE-LIF 
 
It was not possible to use the synthesised 8-oxo-dGMP in standard addition procedure for the 
precise determination of the oxo-adduct in real samples, because the modified nucleotide 
could not be quantified due to different response factors as a result of both the derivatisation 
and the quenching yield (395, 399, 400, 430, 431). But for qualitative analysis, the standard could be 
used. As a practical proof, it was proposed in a double blind study to analyse 8-oxo-dGMP in 
real DNA samples provided from army combat divers. It was found that there is a high risk to 
develop cancer due to oxidative stress during their diving exercises, in which closed-circuit 
re-breathing devices are used. Several NAVY forces over the world use "Closed-Circuit Oxy-
gen Rebreathing Diving Apparatus" (CCORDA). This oxygen re-breather system enables the 
divers to inhale oxygen under high pressure that is suitable for long and deep diving and has 
the additional advantage of low noise with minimal gas escape in comparison with open-
circuit SCUBA. There had been a study involving the navy soldiers who took part in the un-
derwater exercises with the closed-circuit oxygen re-breather equipment for 25 h/week during 
the first year, then 15 h/week during the following three years. Blood samples were taken 
from the soldiers before and after five months training. In this study, samples were taken from 
two soldiers: control samples taken before training and two samples taken five months after 
training. All samples were analysed eight to ten times for accurate results. The 8-oxo-dGMP 
peak was expected to be easily detected, since the previous observations had revealed that it 
appeared earlier than the 3’-dAMP peak. The migration time of 8-oxo-dGMP detection ranges 
from 20-22 min because of changes in the capillary or buffer charge from one analysis to an-
other and/or whether the 8-oxo-dGMP is analysed alone or spiked with CT10. Therefore, the 
location of the peak was referred to 3’-dAMP peak for the easier detection. The electrophero-
grams of samples 1a and 2a are free of the modified nucleotide peak and concluded to be con-
trol samples. The previously described observation that the 8-oxo-dGMP peak appeared be-
fore 3’-dAMP peak made it easy to detect 8-oxo-dGMP peak in the electropherograms of 
samples from soldiers after five months training (1b and 2b). Surprisingly, the peak could not 
be detected in the sample 1b at the matched migration time observed in the analysis of sample 
2b. It seems that the peak is shifted to higher migration time between 3’-dAMP and 3’-dGMP 
peaks (Fig. 40A). 
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The most important observation is concerning the sample 2b because of the appearance of the 
8-oxo-dGMP peak before 3’-dAMP peak (Fig. 40B) as well as the probability of peak  
detection in the position between 3’-dAMP and 3’-dGMP peaks (Fig. 40C). The shift of 8-
oxo-dGMP peak by time in the electropherograms of the analysed sample D24 may be due to 
the formation of two chemical forms, present mainly in 8-oxo-deoxyguanosine and also in its 
minor tautomer 8-hydroxy-deoxyguanosine form (456, 468). Another idea is that 8-oxo-dGMP is 
further oxidised and this product migrates between 3’-dAMP and 3’-dGMP. 
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Figure 40 (A-C):      MEKC-LIF electropherograms for the detection of 8-oxo-dGMP in real samples 
                 [1b (A); 2b (B and C)]. MEKC operating conditions: the same as previously mentioned. 
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3.4.6 Study of the electrophoretic mobility of 8-oxo-dGMP 
 
In consequence of the observation of two peaks for the oxidated dGMP at different migration 
times, it was obviously important to monitor the change in the migration time of the peak in 
subsequent analyses of the same sample. The separation buffer is composed of 20 mM so-
dium phosphate buffer, 95 mM SDS buffer with 10 % MeOH as organic modifier and ad-
justed at pH 9.0. At this basic pH, the keto form of 8-oxo-3’dGMP can be easily converted to 
the enol form through an intermediate step by loss of a proton from N7 of imidazole ring (469). 
The intermediate enolate anion is therefore stabilised by resonance. Therefore the appearance 
of two peaks with two different migration times can be explained by keto-enol tautomerism 
phenomena (456, 468) (Fig. 41). The fluorescence responses of the two tautomers (470) were 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      Figure 41:  Scheme of keto-enol tautomers of 8-oxoguanosine-3’-monophosphate 
 
found to be different; this may be due to effect of the surfactant (SDS) on keto and enol 
forms. But normally, a signal with two peaks is expected for keto and enol forms of one com-
pound. Therefore, a further oxidation process should be a possible explanation. 
For further investigation, a standard addition of definite volume of synthesised and deriva-
tised 8-oxo-dGMP to a derivatised 10 µg CT-DNA sample was performed. The sample was 
analysed in subsequent individual runs. Each run was carefully examined for the existence of 
a small peak corresponding to the oxo-adduct. The 3’-dAMP peak was used as reference for 
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the location of both peaks. The peak defined as 8-oxoguanosine-3’-monophosphate was num-
bered (1) and the peak related to 3’-dAMP was numbered (2) for easily monitoring of the 
migration profile of 8-oxo-dGMP and linking its position to 3’-dAMP peak (Fig. 42). The 
migration times of both peaks are presented in table 3. 
 
Figure 42:  Analysis of 10 µg CT-DNA spiked with 8-oxo-dGMP in successive runs to monitor migration 
times. MEKC operating conditions: the same as previously mentioned. 
 
On analysis of the first run, peak 1 is detected prior to the 3’-dAMP peak in the order of the 
electropherogram as expected from the previous comparative analysis of CT10 spiked with 8-
oxoguanosine to CT10 sample (Fig. 39, red electropherogram). 
The disappearance of peak 1 in the second run (or perhaps a shoulder in front of peak 2) and 
its re-appearance as a shoulder in the third run perhaps can confirm the presence of 8-
oxoguanosine in its tautomeric forms. A number of tautomers can be drawn for 8-oxoguanine 
because of the diversity of sites on the molecule that can be either protonated or ionised. 
Thus, 128 potential tautomeric and ionised forms can be drawn for this oxidised base (468).  
In the third run and successive runs (4 and 5), the re-appearance of peak 1 is observed in an-
other position following the 3’-dAMP peak in the electropherogram. The repeatability of this 
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peak in this position in the electropherogram had suggested that this form may represent the 
major tautomer (468) that corresponds to the detected peak of the pure synthetised 8-oxo-
3’dGMP represented in figure 39 (pink electropherogram).  
The peak areas of peaks 1 and 2 calculated with adjustment for their migration times were 
integrated to correlate the detected 8-oxo-dGMP peak with the 3’-dAMP peak. Accordingly, 
the time-corrected peak area of 8-oxo-dGMP is divided by the time-corrected peak area of  
3’-dAMP and the area/area ratios were calculated as percents as in the determination of me-
thylation level (Table 3). It is observed that the area percentage of the peak detected prior to 
3’-dAMP is lower than that of the peak detected between 3’-dAMP and 3’-dGMP. This can 
be explained by a difference in quenching yields between the two oxidised forms.  
 
 
Run 
number 
Migration time (min)  
PA1 / PA2 % 
n=3 
 
tm Peak 1 / tm Peak 2  
Run 1 0.962   0.02 0.11   0.07 
Run 2 - - 
Run 3 1.011   0.06 - 
Run 4 1.015   0.03           0.14   0.05  
Run 5 1.016   0.03           0.14   0.06 
 
Table 3: Corrected migration times of 8-oxo-dGMP and corrected peak areas percentage in sub-
sequent individual runs. (PA: Peak area. 1: 8-oxo-dGMP. 2: 3’-dAMP)                                                             
 
3.4.7 Correlation between the methylation level, oxidative stress and carcino-
genesis 
 
Several in-vivo studies had detected the production of high levels of ROS in divers or patients 
treated with hyperbaric oxygen (HBO) upon their exposure to HBO (471, 472). Oxidative stress 
mediated by ROS has been attributed to the increased risk of cancer development and diseases 
related to neurological impairment (473). Accordingly, it was hypothesised in this study that 
cancer development and changes in the genome-wide methylation level could be related to the 
oxidative stress generated by hypoxia-reoxygenation during the severe diving training (474-476). 
For this study, four samples were chosen from a set of samples provided to our laboratory; 
these were investigated for the oxo-adduct and the methylation level. As previously demon-
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strated, the 8-oxo-dGMP was found in the samples taken after training (1b and 2b). These 
samples and the samples before training (1a and 2a) were derivatised and analysed eight 
times by CE-LIF. The methylation level percentages of the combat divers are calculated and 
presented in figure 43. A hypomethylation is obvious for the divers after training, since diver 
(1) has higher methylation status in both situations: before and after training than diver (2). 
These analyses highlight an inverse relation between the presence of 8-oxo-dGMP and the 5-
meC level. This finding correlates with the results of the study by Guz et al. (477) study. They 
had suggested that the high level of 8-oxo-dG may induce cancer via the mutagenic potential 
arising through the mispairing of the modified base as well as via its influence on gene ex-
pression by effecting DNA methylation. The explanation of this observation was well illus-
trated by Weizman et al. (478) who concluded that the oxygen radical injury dramatically al-
tered the methylation level. The replacement of guanosine in DNA with 8-oxo-dG had an im-
pact on the activity of the Dnmt1 enzyme responsible for hemimethylation of DNA and sub-
sequently of the Dnmt3a and Dnmt3b enzymes responsible for maintenance of DNA methyla-
tion during replication (479) by methylating cytosine targets. This effect on enzyme activity 
leads to an aberrant methylation level (hypomethylation) which is frequently associated with 
various diseases including ageing, neuro-degenerative diseases and cancer (254, 255).  
In conclusion, our study supports a model linking oxidative stress to the change in methyla-
tion level and cancer development. To verify this conclusion, further analysis of more sam-
ples is necessary. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43:  Methylation level of two divers before and five months after training  
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3.5 Influence of carcinogens on the genomic methylation level 
Several carcinogen-DNA adducts have been used as reflectors of their mutagenic and car-
cinogenic effects. DNA modifications have been generally used as biomarkers of exposure to 
these carcinogens and risk of cancer development. In this work, a number of carcinogens such 
as AA, 3-NBA, B[a]P and 4-ABP were investigated for their effect on the level of 5-meC in 
DNA samples. Although these genotoxic carcinogens belong to different classes of exogenous 
pollutants, they share a common pathway to induce cancer by performing first a metabolic 
activation that results in DNA-bound chemicals and then affecting the functions of the cell 
and possibly leading to cancer. The correlation between the exposure to these different car-
cinogens and the methylation level will contribute to understanding the involvement of the 
environmental pollutants in cancer development via epigenetic modification.  
 
3.5.1 Influence of aristolochic acid treatment on Sprague-Dawley rats 
 
The old herbal drug aristolochic acid (AA), derived from the Aristolochiaceae family (480), has 
recently been associated with the development of nephropathy, designated aristolochic acid 
nephropathy (AAN), as well as urothelial cancer in AAN patients (337, 343, 481). AAN syndrome 
was first reported in a hospital in Brussels, where two young Belgian women were under-
treatment for renal failure. Two years before, both had followed a slimming regimen and had 
taken slimming herbal pills containing AA. The source of the AA in the herbal pills could 
have been the accidental substitution of Stephania tetrandra (Hanfangji or Fenfangji) by Aris-
tolochia fangchi (Guangfangji) during the packaging of the herbal preparations or during the 
marketing of the drugs. The phonetic similarity of fangji and fangchi with the Chinese accent 
was probably the cause of the improper substitution of these Chinese herbs (482). Additionally, 
the roots belonging to the same family (aristolochia) appear very similar, and that could also 
induce confusion (Fig. 44). 
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Figure 44: The roots of two herbs used in the traditional Chinese medicine (483) 
 
It was clearly confirmed in the course of research into the AA toxicity that ingestion of these 
phytotoxins results in nephrotoxicity at mg/kg doses as well as cancers in different tissues. 
Moreover, Grollman et al. (484) have reported the detection of dA and dG aristolactam adducts 
in the renal cortex of the endemic nephropathy patients (484-486). The adducts formed following 
AA exposure were associated with cell cancers. Therefore, it is interesting to test the effect of 
AA on the methylation level by our sensitive method. In this study, DNA methylation was 
determined in several organs taken from rats dosed with aristolochic acid at a daily dose of 30 
mg/kg Body weight (BW, discussed in this section) or from mice dosed with 5 mg AA/kg 
BW (discussed in section 3.5.2). 
 
3.5.1.1 Quantification of DNA in AA-dosed rat samples 
 
The male Sprague-Dawley rats were treated with a single oral dose of 30 mg AAI/kg BW.   
At 24 h after the dosage of AA, the rats were sacrificed. Various tissue samples were col-
lected and stored at -80°C. DNA samples were extracted from these tissues, purified and de-
livered from Hong Kong to our laboratory in Wuppertal. 24 DNA samples were quantified 
spectrophotometrically as previously described under section (3.1), and the calculated DNA 
quantities together with the corresponding purity values of the AA-treated samples and con-
trol samples are presented in table 4. A glance reveals that the colon samples from treated 
animals are the least pure of all the samples because of the impurities probably caused by pro-
Guanfangji Fenfangji  
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teins. The dissolved samples were aliquoted in 10 μg, lyophilised and kept frozen for further 
CE-LIF analysis. 
 
 
Tissue 
Control Treatment with 30 mg AA/kg BW 
Sample 
Code 
DNA-
amount [µg]
Purity Sample 
Code 
DNA- 
amount [µg] 
Purity 
Fore-
stomach 
S 43 41.13 1.42 S 38 24.84 1.43 
S 45 44.84 1.46 S 39 52.67 1.40 
Colon 
Co 11 36.16 1.49 Co 15 35.34 1.33 
Co 12 41.68 1.47 Co 17 23.97 1.37 
Kidney 
K 34 53.75 1.56 K 29 52.18 1.50 
K 35 50.04 1.48 K 32 43.81 1.57 
Small 
intestine 
S.I. 2 37.23 1.52 S.I. 7 25.52 1.48 
S.I. 5 53.27 1.43 S.I. 8 66.83 1.48 
Liver 
L 21 22.26 1.49 L 19 57.79 1.51 
L 26 40.65 1.59 L 27 45.68 1.53 
Bladder 
B 51 20.92 1.52 B 46 18.00 1.41 
B 52 22.31 1.52 B 54 9.70 1.51 
Table 4: DNA quantification in AA-dosed rats and control samples and their purities 
 
3.5.1.2 CE-LIF analysis of methylation level in rats dosed with AA 
 
In order to analyse the samples with CE-LIF, DNA samples were hydrolysed and derivatised 
by the procedure described in the experimental section (section 5.3.1). At that time of the 
study, a special new charge of enzyme mixture was prepared in the laboratory for the analysis 
of these samples. In addition, a mixture of 15 fold enzyme concentration (composition is de-
scribed in the experimental section) was chosen after testing several prepared concentrations 
(5, 10 and 15 fold) that had shown the activity of this chosen mixture was suitable for the hy-
drolysis of AA-DNA-adduct samples. These fundamental changes in the procedure of the 
experiment meant that a correction factor should be reset to overcome the fluctuations that 
could arise from hydrolysis and derivatisation steps. Unfortunately, for reasons of cost, a new 
correction factor with Lambda DNA (unmethylated and enzymatically methylated) could not 
be established during this work. We therefore used the correction factors of dCMP and 5-me-
dCMP previously established in our group for the calculation of the methylation level. With 
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these, a deviation of 8.41 ± 0.05 % (n=8) was found for the methylation level of CT-DNA 
analysed with the new enzyme charge. Therefore, an experiment was performed to estimate 
the methylation level values of all analysed control and AA-treated samples, as well as CT-
DNA samples. The values were calculated using the previous correction factor illustrated in 
equation 1 (above in section (3.2)). Then, a further correction factor was determined by divid-
ing the average value of methylation level of the CT-DNA previously calculated with the es-
tablished correction factor (equivalent to 6.50) by the arithmetic mean value of the methyla-
tion levels of CT-DNA which were analysed in the subsequent hydrolysis sequences. This 
second correction factor was then applied for the calculation of the methylation level values 
of all the analysed (control and AA-dosed) samples in this study. The calculated correction 
factors for each hydrolysis sequence are listed in table 5 for the accurate determination of the 
methylation levels of the samples. 
 
Hydrolysis 
sequence 
Correction 
factor 
1 0.772 
2 0.781 
3 0.774 
4 0.767 
5 0.768 
6 0.778 
7 0.775 
8 0.771 
Table 5:  Calculated correction factors of CT-DNA analysed through MEKC sequences in AA-
dosed rat study (hydrolysis was done with 15- fold enzyme mixture) 
 
In each sequence, CT-DNA samples as well as three dosed-rats and/or control-rats samples 
were hydrolysed, derivatised, analysed with CE-LIF to achieve an accurate analysis. More-
over for accuracy, each sample was analysed six to eight times via a sequence carried out over 
about 24 h (difficulties arising influenced the time needed). From each organ, four samples 
were analysed: two AA-treated rat samples with 30 mg AA/kg BW and two control samples. 
The results of the determination of the methylation level are illustrated in table 6, whereby 
the values represent the arithmetic means of the methylation levels of the individual meas-
urements for each sample and the standard deviations of the individual measurements. The 
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equations used for the calculation of the arithmetic mean (Equation 4) and standard deviation 
(Equation 5) can be summarised as follow (487) : 
 
 
 
 
 
 
 
 
 
Where  x : arithmetic mean of methylation level 
S :  standard deviation 
ix :   methylation level of single measurement 
  n:  number of measurements 
 
 
Organ 
 
AA Treat-
ment  
Methylation level [%] 
± S.D. 
n 
Forestomach 
Control 
2.95 ± 0.05 5 
2.96 ± 0.08 4 
30 mg/kg AA  
3.91 ± 0.02 6 
3.91 ± 0.06 4 
 
Colon 
 
Control 
4.07 ± 0.02 5 
3.95 ± 0.02 6 
30 mg/kg AA  
4.39 ± 0.05 8 
4.52 ± 0.04 8 
Kidney 
Control 
3.40 ± 0.07 5 
3.44 ± 0.03 7 
30 mg/kg AA  
4.25 ± 0.05 6 
3.74 ± 0.06 7 
(4) 
(5) 
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Bladder 
 
Control 
3.48 ± 0.03 6 
3.49 ± 0.04 8 
30 mg/kg AA 
3.69 ± 0.02 8 
3.60 ± 0.05 5 
Small intes-
tine 
Control 
3.57 ± 0.03 5 
3.93 ± 0.04 6 
30 mg/kg AA 
3.73 ± 0.06 6 
3.89 ± 0.03 6 
Liver 
Control 
3.62 ± 0.03 5 
3.73 ± 0.03 6 
30 mg/kg AA 
3.84 ± 0.04 8 
3.73 ± 0.03 6 
 
Table 6: Methylation levels of DNA isolated from different organs of AA-dosed rats       
(n: Number of measurements) 
 
3.5.1.3 Computation and evaluation of data 
 
In the majority of the measurements, the data points do not contribute equally to the final av-
erage. In addition, the illustrated genomic methylation levels in table 7 involve the arithmetic 
means of series of each sample under different sample sizes (number of measurements). The 
overall situation had imposed the necessity of calculating the weighted mean to compare ac-
curately the methylation level data of treated samples with that of control samples. Thus, both 
the weighted mean of the average values of two treated samples and the weighted mean of the 
average values of two control samples for each organ were calculated according to equation 6. 
And, the weighted standard deviation, the square root of the variance, was calculated within 
the series of measurements according to equation 7. The average weighted methylation levels 
of the different organs are listed in table 7. 
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Where  X : weighted mean of methylation level 
x :   arithmetic mean of methylation level 
withinS : standard deviation
 of weighted mean within the series 
S:  standard deviation of single measurements 
k: number of series (animals) 
n:  number of measurements 
 
 
Organ 
 
Methylation level [%] ± S.D.
Control Treated 
 
Forestomach 
 
2.95 ± 0.06 3.90 ± 0.04 
 
Colon 
 
 
4.00 ± 0.01 
 
4.46 ± 0.04 
 
Kidney 
 
3.42 ± 0.05 3.97 ± 0.05 
 
Bladder 
 
3.49 ± 0.03 3.65 ± 0.03 
 
Small intestine
 
3.77 ± 0.03 3.80 ± 0.04 
 
Liver 
 
3.68 ± 0.03 3.80 ± 0.03 
Table 7: Weighted means of methylation levels in different organs from AA-dosed rats  
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A different methylation level behaviour can be observed in the results from the tested organs. 
The methylation values had clearly shown that forestomach, colon and kidney of AA-dosed 
rats are hypermethylated (Fig. 45). In a cooperation with the research group of Prof. Cai in 
the Department of Chemistry at the Hong Kong Baptist University, a parallel study was per-
formed with the same set of samples and tissues with the LC-ESI-MS technique (488) to detect 
DNA adducts. A variety of AA-DNA adducts were quantified, characterised and detected by 
LC-MS, namely dA-AAI, dA-AAII in kidney and liver, dC-AAII in kidney of rats dosed with 
AA at high levels and to a lesser extent dG-AA adduct (only in kidney). Chan et al. (488) pro-
vided the explanation that the exo-cyclic amino group of the aristolactam moiety of the 
guanosine adduct was situated in the narrow minor groove of the DNA strand, in contrast to 
that of adenosine adduct, which was located in the major groove and so easily accessible, so 
that the yield of dA-AA adducts was higher. This is a similar explanation for the A:T to T:A 
mutation scheme associated with the study of mutagenicity of AA in Muta TM Mouse (489).  
Additionally, a previous study performed on rats treated with 0.1, 1.0 or 10 mg AA/kg BW 
over a period of three to six months, had revealed squamous cell carcinoma of the forestom-
ach as well as benign and malignant tumours of kidneys and urinary tract (339, 340). It seems 
that AA stimulate cell proliferation in the forestomach and leads to cancer promotion (490). 
This finding confirms our results that the hypermethylation is a valuable biomarker for the 
possible finding of tumours in both stomach and kidney organs after exposure to AAs. A 
similar approach with the study of Mengs (318) on the effect of AA on the forestomach had 
shown squamous cell carcinoma in the forestomach of 39 female mice treated with 5 mg/kg 
of AA and only one recorded case (318) of adenocarcinoma in the glandular stomach as well. 
This statement affirms our results revealing the risk of tumour development in the stomach 
after AA exposure, whether the experiments were performed on rats or mice. 
Surprisingly, the colon had presented an obvious hypermethylation in the AA-dosed rats, al-
though this is not target tissue for AA, but is a representative organ recommended in the com-
parative studies of normal and tumour cells. Since the colon-cell kinetics in these two cases 
are similar, this represents an advantage in such studies specifically in the determination of 
DNA methylation (491). A similar hypermethylation pattern had been detected in mapping of 
the methylation pattern of specific promoter gene to be associated with the incidence of colon 
cancer (492). This comparison could help to establish a correlation of the probability of the de-
velopment of cancer of the colon with its exposure to AA, in dependence on the dose and the 
time of exposure.  
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On the other hand, neither bladder, nor small intestine nor liver exhibited a tendency toward 
more or less methylation (Fig. 46). 
 
Figure 45: Aberrant methylation level of certain organs taken from rats after AA exposure. The values are 
the weighted mean of the average values ± S.D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46:  Stable methylation level of some organs taken from rats after AA exposure. The values are the 
weighted mean of the average values ± S.D. 
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There have been few reports of liver carcinoma cases due to AA exposure, although hepatic 
foci and nodules formed in consequence to the exposure of rats to 10 mg/kg AA under spe-
cific conditions have been recorded (493). This is consistent with our data received from CE-
LIF analysis, which manifests no change of the methylation status in the rat liver tissue al-
though, the AA-DNA adducts, mainly dA-AAI, were detected in liver by the parallel assay 
performed for these samples with LC-ESI-MS (488). The findings of the hypermethylation 
level in kidney in comparison with control and that there was no change in the methylation 
degree in liver are identical to the gene expression patterns reported in the study of  
Arlt et al. (333), confirming the alteration of the expression levels of more genes in kidney than 
in the liver following 10 mg AA/kg BW treatment of Big Blue rats. In addition, Arlt et al. (333) 
declared that a variety of biological processes related to defence response and immune re-
sponse were changed in kidney, but not in liver. 
Urothelial cell tumours can be induced by a number of chemical carcinogens through envi-
ronmental and/or occupational exposure (295, 494). Recently, AA was also recorded as a causa-
tive factor in the development of urothelial cancer (336, 484, 485). However, the A:T mutations 
caused by specific AA-adenine base adduct were not reported in urothelial cancer. Because of 
this, it was necessary in our study to test the pattern of methylation level in the bladder due to 
its exposure to the carcinogen AA to see whether another part of the urinary tract also under-
goes a change in methylation, as previously mentioned in case of kidney. The analysis of the 
samples taken from the bladder shows no significant difference in the methylation level be-
tween the animals treated with AA and the control animals (Fig. 55). This data is found to be 
consistent with the previous clinical finding that bladder cancer is an invasive form of urothe-
lial cancer (495), and, among urothelial tumours, cancers caused by AA had shown a tendency 
to develop in the upper urinary tract (496). Perhaps the exposure period of the rats used in the 
experiment to AA was not long enough to affect the genomic methylation level. It is highly 
recommended that further study be carried out to monitor the effect of AA in bladder and re-
lated tissues for longer exposure time. In conclusion, these differences clearly suggest that a 
correlation can be established between AA exposure and aberrant methylation level in differ-
ent tissues, which is reported to be associated with gene expression leading to cancer forma-
tion. 
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3.5.2 Influence of aristolochic acid treatment on Hupki mice 
3.5.2.1 CE-LIF analysis of methylation level in mice dosed with AA 
 
P53 is one of the most important genes in carcinogenesis and for this study, Hupki mice were 
used, which are produced by insertion of human p53 gene in place of some parts of murine 
P53 gene in mice (497). The DNA methylation levels in 48 DNA samples from different organs 
(pancreas, stomach, spleen, colon, liver, lung and kidney) of Hupki mice were determined by 
CE-LIF. The Hupki mice were treated daily with an oral dose of 5 mg AA/kg BW. One group 
of mice was sacrificed three weeks after the AA dosage i.e., 24 h after the last treatment with 
AA, and another group was sacrificed 52 weeks after the first treatment. Several DNA sam-
ples were extracted from the collected organs, purified and delivered in aliquots of 10 µg from 
the group of Dr. Arlt at the Institute of Cancer Research in England. The analysis of the sam-
ples was done by Schelle (498) in our Analytical Chemistry department in Wuppertal  
In that study, the hydrolysis of DNA samples involved with AA-adduct formation was obvi-
ously done with a high concentration of enzyme mixture, as previously performed in the hy-
drolysis of AA-dosed rat samples. The factor was calculated for these analysed samples, fol-
lowing the same protocols as were clarified in section 3.5.1.2. The accuracy of measurements 
was controlled by analysing 16 CT-DNA samples in parallel with the 48 Hupki DNA samples 
provided. Each sequence, consisting of a CT-DNA sample and three real samples, was carried 
over a period of 36-45 h, and each sample was analysed twelve to fifteen times. So, the accu-
racy of measurements was definitely assured by this analysis procedure. 
From each organ, the analysis was done for three AA-treated mice samples with 5 mg AA/kg 
BW and three control samples. The methylation levels determined by CE-LIF are illustrated 
in table 8, whereby the values are the arithmetic means of the methylation level of the indi-
vidual measurements for each sample according to equation 4. The errors in the methylation 
level given by the standard deviations of all individual measurements of AA-treated or control 
sampls were calculated with equation 5. 
 
Organ 
Treatment 
with AAI 
Methylation level 
[%] ± S.D.  
n 
 
Pancreas 
 
Control 
4.01 ± 0.10 10 
3.44 ± 0.11 11 
4.00 ± 0.06 12 
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3 Weeks 
3.64 ± 0.08 12 
4.26 ± 0.05 12 
* * 
 
Glandular 
Stomach 
 
Control 
4.30 ± 0.08 11 
4.02 ± 0.09 10 
* * 
3 Weeks 
4.02 ± 0.05 12 
3.95 ± 0.07 12 
4.06 ± 0.06 12 
 
Spleen 
 
Control 
4.31 ± 0.09 10 
4.23 ± 0.05 10 
4.51 ± 0.04 9 
3 Weeks 
3.86 ± 0.06 10 
4.24 ± 0.08 11 
4.26 ± 0.06 13 
 
Kidney 
 
Control 
4.13 ± 0.05 12 
4.25 ± 0.09 12 
4.33 ± 0.08 9 
3 Weeks 
4.24 ± 0.06 12 
4.23 ± 0.05 12 
4.28 ± 0.06 10 
 
Colon 
 
Control 
4.31 ± 0.06 12 
4.21 ± 0.13 12 
4.49 ± 0.08 11 
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3 Weeks 
3.87 ± 0.04 11 
3.92 ± 0.05 10 
4.72 ± 0.09 15 
 
Liver 
 
Control 
4.08 ± 0.10 9 
4.09 ± 0.09 12 
4.46 ± 0.06 7 
3 Weeks 
* * 
4.29 ± 0.12 11 
4.35 ± 0.07 10 
 
 
 
Lung 
 
 
Control 
4.37 ± 0.07 8 
* * 
3.96 ± 0.06 10 
3 Weeks 
3.68 ± 0.09 12 
4.15 ± 0.07 11 
3.74 ± 0.10 9 
 
Kidney 
Control 
3.76 ± 0.10 12 
3.93 ± 0.05 9 
3.98 ± 0.04 10 
52 Weeks 
4.25 ± 0.07 9 
4.36 ± 0.10 12 
4.30 ± 0.11 11 
 
Table 8: Methylation level values of DNA isolated from different organs of AA-dosed Hupki mice 
(n: Number of measurements, * Rejected data) 
 
Some values had shown a large deviation and thus were not taken into consideration in the 
further statistical evaluation of the data. (These values are marked with different colour and in 
italic writing style in table 8). 
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3.5.2.2 Computation and evaluation of data 
 
The mean values of measurements made for each organ were handled for better evaluation of 
data by calculating the weighted mean values from equation 6. In addition, the standard devia-
tion within the series of measurements was calculated from equation 7, taking in considera-
tion the different number of random tests as well as the number of animals. The data pre-
sented in table 9 are obtained on the basis of the formulae used for the weighted methylation 
levels without the red marked values and for the standard deviations. 
 
Organ 
 
Methylation level [%] ± S.D. 
Control (3 weeks ) Treated (3 weeks ) 
 
Pancreas 
 
* 
 
* 
Glandular 
Stomach 
 
* 
 
* 
 
Spleen 
 
4.34 ± 0.06 
 
4.25 ± 0.06 
 
Kidney 
 
4.23 ± 0.07 
 
4.25 ± 0.05 
 
Colon 
 
4.33 ± 0.09 
 
3.89 ± 0.04 
 
Liver 
 
4.09 ± 0.09 
 
4.32 ± 0.09 
Lungs * * 
 Control (52 Weeks ) Treated (52 Weeks ) 
 
Kidney 
 
3.88 ± 0.07 
 
4.31 ± 0.09 
 
Table 9:  Weighted means of methylation level average values of different organs of AA-
dosed mice (* Rejected data due to extreme deviation from the mean) 
 
For a better overview, the methylation levels determined as weighted means of the individual 
values of various organs are presented also in figure 47. This shows clearly that the response 
of several organs in their methylation levels is different upon AA exposure. This difference 
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declares that tissue specificity of the organs plays a fundamental role in the aberrant behav-
iour of the methylation level of the studied organs that distinguish the normal tissues from 
abnormal (499, 500). The colon taken from mice dosed with AAI had shown a hypomethylation, 
while the liver had shown a hypermethylation. Interestingly, both colon and liver had shown a 
great difference between AA-treated samples and controls but in opposite directions. Unfor-
tunately, there are too few measured values for the pancreas, glandular stomach and lungs to 
allow a reasonable conclusion. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47: Methylation level of the individual studied organs taken from AA-dosed mice. The values are 
the weighted mean of the average values ± S.D. 
 
3.5.2.3 Effect of the length of treatment 
 
The change of the average methylation level in the kidney as a function of length of exposure 
of the mice to AA is illustrated in figure 48. No clear deviation in the methylation level can 
be observed between mice treated for three weeks and the untreated mice; while an extreme 
deviation could be determined in case of 52 weeks of mice treatment with AAI. Strong simi-
larity is found to the reported histopathological observations of Mengs (318), that no neoplastic 
signs had been detected in AA-treated mice for weeks, till the manifestation of cystic papil-
lary adenomas in the renal cortex beginning in the 26th week. Equally, this reported observa-
tion supports the dose dependence of the AA effect in the DNA of kidney (488) in terms of 
length of exposure to AA. In addition, it is probable that the clearance of AA-adduct from the 
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body of the mice was variable, since the group treated for three weeks was sacrificed 24 h 
after stoppage of treatment, while the group treated for 52 weeks was sacrificed immediately 
after last AA dosage.  
 
Figure 48: The effect of length of AA-exposure on methylation level of dosed mice. The values are the 
weighted mean of the average values ± S.D. 
 
Additionally, it is remarkable that the genomic methylation level is inversely related to the 
age of control animals. This comparison of data between both controls is congruent with the 
conclusion of research that had found a decline of global DNA methylation with ageing (501), 
while a hypermethylation was determined in gene-specific methylation patterns (502). In my 
opinion, this finding is reinforced by the aberrant methylation level of mice under the influ-
ence of AA. Because the samples taken from treated animals do not agree with this conclu-
sion (501), but exhibit a slight hypermethylation of 52-weeks samples in comparison with 3-
weeks studied samples. The alteration of methylation pattern by the effect of AA had com-
pensated the decrease of methylation level that should be caused by ageing. Additionally, this 
difference might be related to the nutrition regime (503) followed for a longer time for the 
group treated for 52 weeks. It is concluded that AA is a highly dangerous mutagen that vigor-
ously damages DNA and leads to higher methylation levels.  
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3.5.2.4 Correlation between the adduct level and the methylation level 
 
A parallel study was performed by the institute of cancer research in London for the determi-
nation of AA-DNA adducts in the various organs. It is remarkable how different the adduct 
levels, determined per 108 nucleotides, are in the individual organs (Fig. 49). Among adduct 
level patterns of the different organs, the kidney is the outlier, with the highest adduct level 
after three weeks treatment of the mice with aristolochic acid. We found that the kidney sam-
ples are exceedingly highly methylated after 52 weeks treatment of mice with aristolochic 
acid. Although the duration of AA exposure is different in the two findings, both high levels 
of adducts and methylation level are related specifically to kidney.  
It is found that the hypomethylation level detected in case of colon correlates with the low 
adduct levels identified by the 32P-postlabeling assay. On the other hand, the liver also shows 
a low adduct level, but a hypermethylation level is obvious. Thus, a correlation between ad-
duct levels and the genomic methylation level is unlikely and was indeed not found. In con-
clusion, it should be useful to examine the methylation level of the other organs after  
52 weeks AA treatment in future studies. 
 
 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: Methylation levels (CE-LIF method) and adducts levels (32P-postlabeling assay) of various 
organs of Hupki mice dosed with AA 
3.6
3.7
3.8
3.9
4
4.1
4.2
4.3
4.4
Spleen Kidney-3
weeks
Liver Colon Kidney-52
weeks
Organs
M
et
hy
la
tio
n 
le
ve
l [
%
]
0
50
100
150
200
250
300
350
R
A
L/
10
8  u
nm
od
ifi
ed
 n
uc
leo
tid
es
Control Treated Adduct level
 
Results and Discussion  
90 
3.5.3 In-vivo study of the influence of 3-nitrobenzanthrone treatment (3-NBA) 
on Sprague-Dawley rats 
3.5.3.1 Quantification of DNA in 3-NBA-dosed rat samples  
 
In this study, the female Sprague-Dawley rats were treated with a single dose of 0.2 or  
2.0 mg 3-NBA/kg BW by intratracheal instillation under ether anaesthesia. The rats were sac-
rificed 48 h after 3-NBA administration (504). Seven organs were removed (pancreas, heart, 
kidney, urinary bladder, small intestine, liver and lungs) and immediately frozen in liquid 
nitrogen and stored at -80°C; then DNA samples were isolated from these organs. 
For the present work, 36 DNA samples were provided by the German Cancer Research Cen-
tre in Heidelberg (Deutschen Krebsforschungszentrum Heidelberg, DKFZ) and analysed by 
Schiewek (505). The samples were first analysed by UV-VIS spectrophotometry to quantify the 
samples as previously described (section 3.2.). The calculated DNA quantities and the extent 
of purities of the 3-NBA-treated and control samples are summarised in table 10. 
 
 
Organ 
 
Control 
 
Treatment with 3-NBA  
Sample DNA 
amount 
[µg] 
Purity Sample 
from 
animal 
DNA 
amount 
[µg] 
Purity 
Left Lung 
(0.2 mg/kg BW) 
 
 
Control 
 
 
 
10.4 
 
 
1.64 
4 20.4 1.68 
5 27.6 1.74 
Right Lung 
(0.2 mg/kg BW) 
4 32.5 1.76 
5 32.2 1.76 
Small Intestine 
(0.2 mg/kg BW) 
Control 29.2 1.83 4 34.9 1.76 
5 37.8 1.77 
 
Pancreas 
(2 mg/kg BW) 
 
Control 
 
 
28.6 
 
1.79 
 
1 20.0 1.75 
2 23.0 1.76 
3 35.1 1.83 
 
Heart 
(2 mg/kg BW) 
 
Control 
 
 
33.10 
 
1.82 
1 32.5 1.76 
2 25.3 1.76 
3 - - 
    1 27.5 1.84 
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Kidney 
(2 mg/kg BW) 
Control 
 
31.00 1.84 2 25.5 1.83 
3 9.3 1.79 
 
Bladder 
(2 mg/kg BW) 
 
Control 
 
 
15.30 
 
1.84 
1 28.50 1.86 
2 16.70 1.79 
3 14.00 1.78 
 
Small intestine 
(2 mg/kg BW) 
 
Control 
 
 
29.2 
 
1.83 
1 25.1 1.82 
2 28.7 1.81 
3 23.9 1.82 
 
Liver 
(2 mg/kg BW) 
 
Control 
 
 
30.0 
 
1.80 
1 19.2 1.69 
2 22.0 1.67 
3 11.0 1.84 
 
Lungs 
(2 mg/kg BW) 
 
Control 
 
 
10.4 
 
1.64 
1 28.6 1.83 
2 30.1 1.79 
3 39.2 1.84 
 
Table 10: DNA quantification in 3-NBA-dosed rats and control samples and their purities (505) 
 
The dissolved samples were aliquoted in 10 μg then lyophilised under speed vacuum and 
stored at -25°C. 28 samples were taken from three experimental animals (numbered 1, 2 and 
3) treated with 2.0 mg 3-NBA/kg BW and a control animal. In addition, eight samples: six 
were taken from left lung, right lung and small intestine of two experimental animals (num-
bered 4 and 5) treated with the lower dose of 0.2 mg 3-NBA/kg BW and two control samples 
from lung and small intestine were analysed. 
 
3.5.3.2 CE-LIF analysis of methylation level in rats dosed with 3-NBA dosed rats 
 
For the accurate evaluation of measurements, CT-DNA was used as external standard to be 
analysed in parallel with the samples in the same sequence. The accuracy of measurements 
was attained by nine analyses of each sample. The values of methylation level and the stan-
dard deviation of the mean values of individual measurements of each organ for each animal 
were calculated, and the statistic analysis of the methylation levels of the samples was done 
by PD. Dr. Scherer in the Analytical-Biological Research Laboratory in Munich (Analytisch-
Biologisches Forschungslabor München). The mean methylation levels from the experimental 
study for the low and high dose in different tissues are illustrated in tables 11 and 12, respec-
tively. 
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Organ 
 
Animal 
Methylation level [%]
± S.D. 
 
Left lung 
4 3.97 ± 0.15 
5 4.19 ± 0.24 
 
Right lung 
4 4.06 ± 0.20 
5 4.06 ± 0.20 
Lungs (control) 4.01 ± 0.22 
 
Small intestine 
4 * 
5 4.03 ± 0.32 
(control) 4.08 ± 0.30 
Table 11: Methylation levels in two organs of rats dosed with 0.2 mg/kg BW 3-nitrobenzanthrone   
(* No sample was available) 
 
 
 
Organ 
 
Animal 
Methylation level [%] 
± S.D. 
 
 
Pancreas 
1 3.67 ± 0.04 
2 3.65 ± 0.15 
3 3.75 ± 0.12 
(control) 3.62 ± 0.09 
 
 
Heart 
1 3.56 ± 0.04 
2 3.53 ± 0.09 
3 * 
(control) 3.53 ± 0.17 
 
 
Kidney 
1 3.71 ± 0.05 
2 3.72 ± 0.04 
3 * 
(control) 3.71 ± 0.09 
 
 
Bladder 
1 3.38 ± 0.13 
2 3.36 ± 0.08 
3 3.38 ± 0.08 
(control) 3.42 ± 0.18 
 1 3.68 ± 0.14 
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Small intestine 
 
2 3.65 ± 0.14 
3 3.72 ± 0.08 
(control) 3.85 ± 0.09 
 
 
Liver 
1 4.29 ± 0.09 
2 4.32 ± 0.05 
3 4.30 ± 0.10 
(control) 4.29 ± 0.05 
 
 
Lungs 
1 3.59 ± 0.10 
2 3.72 ± 0.06 
3 3.71 ± 0.06 
(control) 3.83 ± 0.05 
Table 12:  Methylation levels in various organs of rats dosed with 2 mg/kg BW 3-nitrobenzanthrone 
(* No sample was available) 
 
3.5.3.3 Computation and statistical analysis of data  
 
Statistical analysis of the results obtained by the CE-LIF analysis has been carried out. No 
significant difference was found between controls and the samples of the different tissues ex-
amined, including the samples of lung and small intestine treated with 0.2 mg/kg BW of 3-
NBA.  
In the high-dose experiment, a significant difference was interestingly observed between the 
samples and controls in case of small intestine and lung; a hypomethylation was revealed with 
a confidence limit of 95 % (Table 12). The appearance of hypomethylation in both S.I. and 
lungs may be explained by the 3-NBA-adduct formation. The presence of such a bulky car-
cinogen (3-NBA) could result in a local change in the structure of the DNA strand similar to 
that caused by BPDE-dG adduct formed in CpG dinucleotide and lead to steric hind- 
rance (506, 507). Because of the reciprocal hydrophobic effect that arises from the aromatic moi-
ety of 3-NBA adduct and the methyl groups of the neighbouring 5-methylcytosines, the  
5-meC could stand out from the DNA strand and thus serves as the substrate of isoforms of 
the DNA methyltransferases in the rats, whereby an aberration could consequently occur to 
the methylation level.  
In conclusion, the lungs and small intestine in the high-dose study differ most in their methy-
lation level from all other tissues after intratracheal exposure to 3-NBA. Accordingly, a com-
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parative overlook between the mean of the methylation levels [%] of the controls in case of 
low-dose analysed samples in small intestine and lungs (4.08 ± 0.30 S.D. and 4.01 ± 0.22 
S.D., respectively) and that of high-dose analysed samples (3.85 ± 0.09 S.D. and 3.83 ± 0.05 
S.D., respectively) had surprisingly revealed a great difference, about 5 %. Although the con-
trol animals were identical in the two cases, this significant difference originates from an ex-
ternal factor, i.e. the two different charges of enzyme mixture used for DNA digestion in the 
two cases due to the differing times of analyses of the two sample sets. The low-dosage sam-
ple set was hydrolysed much later with a fresh charge of the enzyme mixture charge, since the 
charge used for the high-dosage sample set had unfortunately run out. The use of another en-
zyme charge changed the characteristics of the sample matrix and led to larger fluctuations in 
the methylation levels determined. It is highly probable that the diverse enzyme sources gave 
rise to a different distribution in the yield of the individual nucleotides and different data for 
the same controls.  
 
3.5.3.4 Correlation between the adduct level and methylation level  
 
The DNA samples examined in this section were 32P-postlabeled by Bieler et al. (504) for the 
determination of 3-NBA-adduct in the studied organs. All the data obtained from the two 
studies are listed in table 13 in order to establish a meaningful statistical comparison between 
treated samples, control samples and the adduct level. The weighted methylation levels shown 
in the table were computed with equation 6, and the corresponding standard deviation values 
with equation 7, taking in consideration the number of rats used in this experiment. The ad-
duct pattern was identical in all the different tissues described according to the identified ad-
ducts, however different adduct levels were found in all organs. 
It is interesting to observe that the hypomethylation degree detected in small intestine and 
lung does not correlate with the adduct level in these organs (Fig. 50). Although the small 
intestine shows the second lowest adduct level (98.1 ± 5.7 S.D. adducts per 108 unmodified 
nucleotides) determined among the organs examined, the lung tends to show the second high-
est concentration at DNA adduct level (504). Moreover, the highest level of 3-NBA–DNA ad-
ducts was detected in pancreas (619.9 ± 372.2 S.D. adducts per 108 nucleotides), in contrast to 
the lowest level of 3-NBA-DNA adducts, which was detected in liver (59.1 ± 31.1 S.D. ad- 
ducts per 108 nucleotides). However, there is no difference in methylation levels between  
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control and treated samples in the two tissues. Hence, it is concluded that no definite correla-
tion could be established between the adduct concentration in different tissues and the deter-
mined genomic methylation level. 
 
 
 
Organ 
 
Adducts / 108        
unmodified nucleotide 
5-meC [%] of con-
trol ± S.D.  
 
Weighted mean of 5-
meC [%]of samples  
± S.D.  
Small intestine 98.1 ± 5.7 3.85 ± 0.09 3.68 ± 0.01 
Pancreas 619.9 ± 372.2 3.62 ± 0.09 3.69 ± 0.02 
Heart 220.0 ± 101.1 3.53 ± 0.17 3.55 ± 0.01 
Kidney 334.8 ± 50.6 3.71 ± 0.09 3.72 ± 0.002 
Bladder 215.2 ± 56.4 3.42 ± 0.18 3.37 ± 0.004 
Lungs 349.6 ± 138.5 3.83 ± 0.05 3.67 ± 0.02 
Liver 59.1 ± 31.1 4.29 ± 0.05 4.30 ± 0.01 
 
Table 13: DNA-adduct concentration (504) and methylation levels in different organs in the 3-NBA-
dosed rats study (505) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: Methylation levels (CE-LIF method) and adducts levels (32P-postlabeling assay) of various organs 
of Sprague-Dawley rats dosed with AA (398) 
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3.5.3.5 Comparison of the effect of various exogenous carcinogens on the genomic me-
thylation level of Sprague-Dawley rats 
 
Two studies were performed independently on Sprague-Dawley rats to investigate the effect 
of carcinogens belonging either to natural product group (AA) or chemical group (3-NBA) on 
the methylation level of the DNA samples isolated from different organs from the animals. 
The studies were different in some parameters such as the dose and route of administration of 
carcinogens and other factors related to the rats (sex, weight, and age). However, the most 
striking conclusion that imposes itself from this comparison is the tissue specificity of the 
DNA adducts formed, in meaning, first that 3-NBA-DNA adducts are preferentially formed in 
the lung after intratracheal exposure and second that the kidney is the susceptible target tissue 
of AA-DNA adduct formation. Moreover, a hypomethylation level was determined in the case 
of 3-NBA-DNA adducts in lung, in contrast to the hypermethylation level determined in the 
case of AA-DNA adducts in kidney. This observation helps to highlight how useful the aber-
rant genomic methylation level, either hypo- or hyper-status, is as a biomarker for carcino-
genesis and other related dangerous diseases that are due to exogenous chemicals, so that it 
can be a valuable tool to prevent cancer risk. Finally, this comparison reinforces the conclu-
sion that the extent of methylation of cytosine residues varies strongly between tissues and 
can be used as marker to distinguish healthy from unhealthy ones (499). 
 
3.5.4 In-vitro study of various carcinogens on the genomic methylation level 
3.5.4.1 Quantification of DNA in Caco-2 cell samples 
 
In previous parts of this work, the study of the effect of exogenous carcinogens on the methy-
lation level was performed with samples treated in-vivo. Equally important, the study in this 
part was focused on the determination of methylation level in in vitro samples that were under 
the influence of carcinogens for different lengths of time. DNA samples were isolated from 
Caco-2 cells incubated with different carcinogens (B[a]P, 4-ABP or 3-NBA) in the two con-
centrations of 2.5 and 5 µg/kg for 24, 48 and 72 h. Caco-2 cells are derived from human ade-
nocarcinoma of the colon and they differentiate much as epithelial cells of the small intestine 
do (508-510). Therefore, Caco-2 cells are used for in-vitro studies as models of the role of the 
small intestine i.e., drug absorption, transportation (511) and metabolism as well as models to 
investigate the cytotoxic functions of carcinogens (512). 
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The 24 DNA samples were quantified by UV-VIS spectrophotometery as described before 
(section 3.2). The calculated DNA quantities and the extent of purities of the carcinogen-
treated samples and control samples are shown in table 14. The dissolved samples were ali-
quoted in 1 μg, lyophilised under speed vacuum and stored at -25°C. 
 
 
 
Sample treatment 
 
48 hours treatment 
 
72 hours treatment 
Sample 
Code 
DNA-
amount 
[µg] 
Purity Sample 
Code 
DNA-
amount 
[µg] 
Purity 
Control A 7A 9.1 1.76 13A 4.2 1.66 
Control B 7B 10.4 1.75 13B 7.3 1.72 
Control C 7C 3.4 1.67 13C 6.6 1.58 
B[a]P 2.5 µg/kg A 8A 7.8 1.75 14A 7.7 1.58 
B[a]P 2.5 µg/kg B 8B 8.0 1.79 14B 8.9 1.66 
B[a]P 2.5 µg/kg C 8C 7.4 1.76 14C 5.5 1.58 
4-ABP 5 µg/kg A 9A 7.9 1.74 15A 6.0 1.60 
4-ABP 5 µg/kg B 9B 8.3 1.74 15B 5.6 1.61 
4-ABP 5 µg/kg C 9C 7.8 1.79 15C 6.1 1.60 
3-NBA 5 µg/kg A 11A 9.1 1.74 17A 7.1 1.67 
3-NBA 5 µg/kg B 11B 6.5 1.77 17B 7.3 1.62 
3-NBA 5 µg/kg C 11C 6.1 1.77 17C 7.5 1.61 
Table 14: DNA quantification in Caco-2 cells samples and their purities (A,B,C: three different Caco-
2 cells) 
 
3.5.4.2 CE-LIF analysis of methylation level in Caco-2 cells incubated with various 
carcinogens 
 
All the samples were subjected to CE–LIF analysis after hydrolysis, derivatisation and pre-
cipitation of the excess of the fluorescent marker as in the routine method described in the 
experimental section. The accuracy of measurements was guaranteed by carrying the analysis 
procedure so that eight CT-DNA samples were analysed in parallel with the 24 Caco-2 cells 
samples. All the samples were analysed by Klink (513) through successive sequences over  
36-45 hours each. The methylation levels determined are plotted in table 15 as arithmetic 
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means of individual measurements. The correction factor used for the calculation of methyla-
tion level was estimated as previously mentioned (3.5.1.2). The methylation levels and the 
standard deviation of the individual measurements were calculated with equations 4 and 5, 
respectively. 
 
Sample 
Code 
Carcinogen 
treatment 
Dose of 
treatment 
Duration of 
treatment 
Methylation level 
[%] ± S.D. 
n 
7A Control A  
0 
 
 
 
 
 
 
48 h 
3.68 ± 0.06 14 
7B Control B 3.64 ± 0.09 13 
7C Control C 3.55 ± 0.04 11 
8A  
B[a]P 
 
2.5 µg/kg A 3.57 ± 0.09 15 
8B 2.5 µg/kg B 3.62 ± 0.05 14 
8C 2.5 µg/kg C 3.48 ± 0.09 10 
9A  
4-ABP 
 
5 µg/kg A 3.63 ± 0.05 15 
9B 5 µg/kg B 3.59 ± 0.08 14 
9C 5 µg/kg C 3.72 ± 0.06 14 
11A  
3-NBA 
 
5 µg/kg A 3.63 ± 0.07 15 
11B 5 µg/kg B 3.78 ± 0.11 15 
11C 5 µg/kg C 3.72 ± 0.07 12 
13A Control A  
0 
 
 
 
 
 
 
72 h 
3.54 ± 0.11 12 
13B Control B 3.76 ± 0.08 14 
13C Control C 3.48 ± 0.08 15 
14A  
B[a]P 
 
2.5 µg/kg A 3.54 ± 0.07 15 
14B 2.5 µg/kg B 3.66 ± 0.07 15 
14C 2.5 µg/kg C 3.49 ± 0.08 15 
15A  
4-ABP 
 
5 µg/kg A 3.50 ± 0.14 15 
15B* 5 µg/kg B - - 
15C 5 µg/kg C 3.62 ± 0.06 15 
17A  
3-NBA 
 
5 µg/kg A 3.60 ± 0.09 15 
17B 5 µg/kg B 3.72 ± 0.06 15 
17C 5 µg/kg C 3.49 ± 0.09 14 
 
Table 15: Methylation level values of DNA isolated from carcinogens-treated Caco-2 cells                            
(n:  Number of measurements, * Rejected data. A, B and C: Three different Caco-2 cells) (513) 
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3.5.4.3 Computation and statistical analysis of data  
 
No accurate data analysis could be carried out depending on the comparison of arithmetic 
means of samples with those of control due to different sample size (number of measure-
ments). Therefore, the calculation of the weighted mean is helpful to better estimate the prob-
ability of the distribution of data. The weighted means of the methylation level values of con-
trol and carcinogen-incubated Caco-2 cells were calculated with equation 6 as described be-
fore (3.5.1.3). The standard deviation values within the series of measurements were corrected 
by equation 7 under the assumption that the variance of the measurements can be regarded as 
constant because the samples A, B and C are from the same origin. All weighted means of 
methylation levels are plotted in table 16. 
 
Sample description Treatment 
duration 
Methylation level [%] ± S.D 
Control  
 
48 h 
3.63 ± 0.06 
B[a]P (2.5 µg/kg) 3.57 ± 0.08 
4-ABP (5 µg/kg) 3.65 ± 0.07 
3-NBA (5 µg/kg) 3.71 ± 0.09 
Control  
 
72 h 
3.59 ± 0.09 
B[a]P (2.5 µg/kg) 3.56 ± 0.08 
4-ABP (5 µg/kg) 3.56 ± 0.10 
3-NBA (5 µg/kg) 3.61 ± 0.08 
 
Table 16: Weighted means of methylation level average values of Caco-2 cells incubated 
with different carcinogens 
 
The weighted average values of the methylation level determined in DNA of control and 
Caco-2 cell samples incubated with carcinogens (B[a]P, 4-ABP and 3-NBA) for 48 and 72 h 
are graphically represented in figure 51. Surprisingly, a higher methylation level could be 
observed after 48 h incubation with 4-ABP and 3-NBA than that after 72 h incubation with 
the same carcinogens. The explanation may be that DNA repair system plays a role after 
short-term damage by such persistent DNA adducts. Therefore, it is worthwhile in future 
studies to monitor the effect of 3-NBA after incubation times longer than 72 h for the methy-
lation status of Caco-2 cells. 
Among all comparisons between the measurements, the 3-NBA-incubated samples had shown 
the highest deviation of methylation level from that of the corresponding control. Therefore, a 
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further statistical evaluation of control and 3-NBA treated samples after 48 h was performed 
to investigate whether a significant difference exists or not.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51: Methylation level of the studied DNA from Caco-2 cells incubated with different carcinogens.
  The values are the weighted mean of the average values ± S.D. 
 
With the software graph PAD Prism® for comparison of the mean values for the control and 
3-NBA samples, no significant difference between the control and 3-NBA treated Caco-2 
cells (unpaired t test, P < 0.05) was obtained. However on the level of comparing the individ-
ual measurements of the two sample sets and not the means (three samples of each control 
and treated cells, the test does reveal a significant difference between the control and 3-NBA 
treated Caco-2 cells. This confusion raises the important question whether the difference be-
tween the two mean values is due to an insufficient number of studied cells or due to an insuf-
ficient number of measurements, especially since the F test which compares variances had 
indicated that there was no significance difference between the control and the carcinogenic-
mediated Caco-2 cells (Tab. 17). 
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Description Mean values 
 comparison  
Individual measurements 
comparison 
Mean ± s.e.m. 
of control 
3.623 ± 0.03762 
(n= 3) 
3.629 ± 0.01352 
(n= 38) 
Mean ± s.e.m. 
of 3-NBA-treated 
Caco-2 cells 
3.711 ± 0.04307 
(n= 3) 
3.710± 0.0169 
(n= 42) 
 
Unpaired t test  
(P < 0.05) 
 
ns difference 
 
** 
P value 0.1998  
(two tailed) 
0.1998  
(two tailed) 
t, df t = 1.534 , df = 4 t = 3.713 , df = 78 
 
F test 
 
ns 
 
ns 
P value 0.8655 0.111 
 
Table 17: Statistical analysis of 48 hours 3-Nitrobenzanthrone study  
  (ns: non significant. ** significant difference) 
 
3.6 Influence of biological reproduction on DNA methylation 
Nuclear transplantation or cloning is a new technology that attracted great interest not only 
from the researchers but also from people in general because of its potential applications in 
nutrition (514), biomedicine and husbandry (125, 514). Inappropriate or incomplete epigenetic re-
programming has been considered as the major cause for the low success of cloning (127, 135, 
515) as well as for the abnormalities seen in developed clones. Simply explaining, during the 
resetting of the epigenetic marks of terminally differentiated somatic cell, aberrant epigeno-
types of embryos and foetuses could be formed leading to abnormalities such as placental 
dysfunctions or foetal overgrowth phenotypes. Reprogramming of global DNA methylation 
during preimplantation development presents a window for epigenetic perturbation that may 
affect gene expression and phenotype throughout pre-embryo and foetus stages and postnatal 
life (142) from neonatal to adult. DNA methylation is the epigenetic mark of interest in the 
cloning process, and, accordingly, abnormal DNA methylation patterns have been examined 
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in the majority of the studies about epigenetic changes in animal clones. Despite the finding 
of epigenetic perturbations in these studies, the majority of cloned cattle beyond a critical pe-
riod of about six months after birth, if they do not exhibit any health issues of concern, are 
assumed to be normal (515-517). However, the DNA methylation status of the apparently healthy 
adult clones derived from the same nuclear donor has not been yet investigated. Therefore, the 
quantification of global 5-methylcytosine level of healthy adult cloned cattle was performed 
in this double-blinded study by using the former discussed CE technique (395, 399) to measure 
the 5-meC content in DNA extracted from different tissues. 
In cooperation with the Institute of Molecular Animal Breeding and Biotechnology Gene 
Centre at the University of Munich, 84 DNA samples of bovine twins and clones (Simmental 
breed, 1µg) were provided. Also, in cooperation with the Laboratory of Development Biology 
and Reproduction (INRA) in France, 45 DNA samples (1 µg) of bovine clones (Holstein 
breed, 1 µg) were provided. 
 
3.6.1 Accuracy of the measurements 
 
The accuracy of the determination of the methylation level in the provided clones and twins 
samples can be proved by analysing each sample several times. In order to define the mini-
mum number of single measurements that should be applied for all the analyses in this study, 
several random samples were chosen in advance to be hydrolysed, derivatised and analysed 
several times for the determination of the methylation level. The methylation level values of 
the individual measurements of a representative sample from the chosen set are shown in fig-
ure. 52. 
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Figure 52: Multiple measurements of a chosen hydrolysed and derivatised real sample  
 
The mean value of the methylation level of this series of measurements (4.96 ± 0.09 %, n=15) 
was calculated. It was concluded that eight or more individual measurements at least should 
be accomplished in order to obtain a reliable value for the methylation level. 
 
3.6.2 Determination of 5-methyl cytosine level in blood cells of healthy Sim-
mental and Holstein clones 
 
The determination of the methylation level of 51 leukocytes samples isolated either from bo-
vine twins or clones of Simmental breed and of 22 leukocytes samples isolated from bovine 
clones of Holstein breed was done by the established CE-LIF method. Each sample was hy-
drolysed, derivatised and precipitated according to the preparation of 1 µg DNA samples and 
finally analysed 8-15 times. The analysed methylation levels in DNA of leukocytes (white 
blood cells) from 42 healthy female clones at 1- 8 years of age of two different breeds and 13 
pairs of Simmental twins are recorded in tables 18, 19 and 20, noting that the indicated values 
represent the arithmetic means of the methylation level of the individual measurements for 
each sample. The errors of the methylation level are corrected by the factor established by 
Thiemann (398). Statistical analysis was performed to evaluate the efficacy of the method. 
 
 
 
n 
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Sample 
Code 
Methylation level [%] 
± S.D. 
n 
T1 
T2 
T3 
T4 
T6 
T9 
T10 
T11 
T12 
T13 
T14 
T15 
T16 
T17 
T18 
T19 
T20 
T21 
T22 
T23 
T24 
T25 
T26 
T27 
T28 
T29 
T30 
5.35 ± 0.08 
5.26 ± 0.10 
5.07 ± 0.15 
5.10 ± 0.09 
5.60 ± 0.12 
5.43 ± 0.08 
5.29 ± 0.07 
5.51 ± 0.11 
5.47 ± 0.08 
5.00 ± 0.11 
5.53 ± 0.08 
5.32 ± 0.05 
5.20 ± 0.07 
5.38 ± 0.08 
5.54 ± 0.08 
5.43 ± 0.07 
5.52 ± 0.08 
5.36 ± 0.10 
5.35 ± 0.12 
5.61 ± 0.12 
5.46 ± 0.12 
5.35 ± 0.06 
5.64 ± 0.08 
5.46 ± 0.13 
5.57 ± 0.12 
5.36 ± 0.08 
5.21 ± 0.21 
10 
14 
20 
14 
11 
15 
13 
18 
14 
16 
8 
11 
12 
11 
14 
13 
14 
12 
12 
16 
16 
15 
13 
14 
12 
13 
18 
 
Table 18: Determination of methylation level in DNA of leukocytes of Simmental twins 
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Sample 
Code 
Methylation level [%] 
± S.D. 
n 
K1 
K2 
K3 
K4 
K5 
K6 
K7 
K8 
K10 
K11 
K12 
K13 
K14 
K15 
K16 
K18 
K19 
K20 
K21 
6.83 ± 0.09 
6.38 ± 0.14 
6.48 ± 0.13 
6.48 ± 0.12 
6.47 ± 0.15 
6.93 ± 0.13 
6.79 ± 0.04 
6.36 ± 0.08 
6.54 ± 0.12 
6.42 ± 0.08 
5.94 ± 0.11 
6.84 ± 0.11 
6.18 ± 0.16 
6.69 ± 0.13 
6.75 ± 0.15 
6.54 ± 0.13 
6.26 ± 0.13 
6.35 ± 0.07 
6.35 ± 0.17 
12 
6 
12 
12 
10 
13 
11 
9 
9 
9 
10 
11 
12 
13 
8 
9 
13 
11 
11 
 
Table 19:  Determination of methylation level in DNA of leukocytes of Simmental clones 
 
Sample 
Code  
Type Methylation level± 
S.D. 
n 
S2251 Donor cell mother 5.09 ± 0.15 7 
S402  
 
 
Clones genotype 2251 
4.76 ± 0.09 9 
S357 4.80 ± 0.08 8 
S438 5.61 ± 0.13 8 
S448 5.03 ± 0.06 10 
S401 4.43 ± 0.04 7 
S477 5.09 ± 0.06 10 
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S439 4.99 ± 0.05 10 
S474 5.25   0.05 10 
S0029 Donor cell mother 4.80   0.08 11 
S309  
Clones genotype 0029 
4.81   0.05 12 
S437 5.31   0.06 13 
S447 5.13   0.03 15 
S0333 Donor cell mother 4.56   0.04 12 
S0531  
 
Clones genotype 0333 
 
4.78   0.06 10 
S0541 5.29   0.06 10 
S0542 5.09   0.07 13 
S0543 5.66   0.07 13 
S0547 5.61   0.07 10 
S0007  
Clones genotype 7711 
5.69   0.06 13 
S0034 4.43   0.07 12 
S139 5.01   0.07 13 
 
Table 20: Determination of methylation level in DNA of leukocytes of Holstein clones 
 
3.6.2.1 Comparative study of DNA methylation status between clones of the Simmental 
breed and the Holstein breed 
  
The cloned animals were generated by SCNT (518, 519) using fibroblasts from nine adult donors 
that yielded two to nine clones per donor. Of the nine clone genotypes studied, five were from 
the Simmental breed (SC) and four from the Holstein breed (HC) (Fig. 53A-C).  
It was observed that individual 5-meC levels in clones were ranged from 4.4 % to 6.9 %. The 
5-meC content in DNA was ranged from 4.43 % - 5.09 % in clones with Holstein genetics 
(n=19) to 5.94 % - 6.93 % in clones with Simmental genetics (n=19). ANOVA showed unex-
pected significant differences in the mean 5-meC levels of Simmental and Holstein clones 
(mean ± s.e.m. 6.50 % ± 0.01 % and 5.09 % ± 0.02 %, two tailed t-test P < 0.001) (Fig. 53A, 
orange and red crosses). Although the different means of methylation levels were observed, 
the two clones’ breeds exhibit similar mode of variability from their means. 
The variance is the best studied factor to estimate variability, therefore exact restricted likeli-
hood ratio tests were computed on the basis of linear mixed effects models (520) to test for the 
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presence of variability between genotypes. Firstly, the observed variances between clone 
genotypes of both breeds were similar (0.0204 and 0.0164). The distribution of the values 
around the mean is same for both clone breeds (Fig. 53A). Strikingly, the estimated variance 
in 5-meC level within clone genotypes from both breeds (0.104) was markedly higher than the 
estimated variance between clone genotypes (< 10-10), which was not significantly different 
from 0 (exact restricted likelihood ratio test P > 0.99). This estimated variance opposes the 
assumption that clones of the same genotype will show less difference in methylation level. 
The existence of high variability of DNA metylation status in cloned cattle was obvious.  
 
 
Figure 53: Variability in cytosine methylation (5-meC%) of DNA from adult monozygotic twins and 
adult healthy somatic cell nuclear transfer clones 
(A) 5-meC levels as per cent of total cytosine in the DNA of white blood cells 
from individual Simmental breed twins (genotypes ST1-13, n=26), Simmental 
clones (genotypes SC1-5, n=19), and Holstein breed clones (genotypes HC1-4, 
n=19). Nuclear donors for Holstein clone genotypes HC1-3 are indicated as 
non-cloned references in the respective genotypes.  
 
(B) Box plots of the absolute deviations of individual monozygotic Simmental 
twins (ST, n=26), Simmental clones (SC, n=19), and Holstein clones (HC, 
n=19), from their respective genotype means. The two ST outliers represent a 
twin pair.  
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(C) Dot plots of the absolute deviations of genotype means for Simmental twin 
pairs ST1-13, Simmental clone genotypes SC1-5, and Holstein clone genotypes 
HC1-4, from their respective group mean.  
 
3.6.3 Individual and comparative study of DNA methylation status between the 
nuclear mother donor and its clones in Holstein breed. 
  
Clone is assumed to be identical twin of the genetic donor. Consequently, the clones of Hol-
stein (HS) breed were compared in this study to nuclear donor animals. Three Holstein indi-
viduals that served as nuclear donors were analysed for the 5-meC level of their genome to-
gether with their clones. The 5-meC levels of first control group used in this study ranged 
from 4.56 % - 5.09 % in Holstein nuclear donor animals (n=3). Two nuclear donors (Clones 
genotype 029 and 0333) showed the lowest 5-meC levels of the respective genotypes (Fig. 
53A). This provides further evidence that reprogramming of nuclear function by SCNT is 
frequently associated with global DNA hypermethylation that extends from the embryo- 
nic (137, 143) and foetal stages (144) into adulthood. The 5-meC level of the third nuclear donor 
(Clones genotype 2251) was identical to only one of its eight healthy clones but higher than 
five of them and lower than the two remaining ones. This clearly demonstrates that a fully 
functional reprogramming of a given donor genotype is compatible with a highly flexible me-
thylation status of its DNA and that genomic copies (521) of adult animals have to be consid-
ered as epigenome variants. There is an important question which proposed itself after this 
comparison of adult cloned animals with their adult nuclear donors: Is the observation of ab-
errant methylation status in clones resulting from incomplete epigenetic reprogramming of the 
early SCNT embryo or from other factors that affected maintenance methylation during later 
developmental stages (139, 146). In this study, our data offer new insights to this question by 
showing that variability in DNA methylation levels in live clones is not correlated with the 
potential to provide consistently full term reprogramming into live calves as illustrated by the 
comparison between HC1 and HC2 genotypes (5-meC individual levels from 4.43 ± 0.04 S.D. 
to 5.61 ± 0.13 S.D. with 38.77 % blastocysts (per fused embryos) and 8.22 % born calves (per 
transferred embryos), and from 4.81 ± 0.05 S.D. to 5.31 ± 0.06 S.D. with 35.6 % blastocysts 
and 2.4 % born calves, respectively) (Fig. 53A).  
Most importantly, the only true indication of ‘reprogramming’ is the birth of normal off-
spring, as discussed by Campbell (521). Many changes are involved in the mechanisms respon-
sible for the control of gene expression which makes the reprogramming process unclear. 
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Moreover, there was no correlation observed between the proportions of leukocyte subfrac-
tions and the global methylation level, excluding the possibility that the observed variability 
in DNA methylation levels are caused by variation of leukocyte subfractions.  
 
3.6.4 Comparative study of DNA methylation status between clones and 
monozygotic twins of the Simmental breed 
 
Individual genome-wide 5-meC levels were recently shown to be similar in adult human 
across populations (522). Accordingly, monozygotic (MZ) twins are chosen as standard models 
of genetically identical traits as clones concerning the investigation of the methylation status. 
The analyses were performed on several sets of monozygotic twins of HS breed to create a 
reference on the extent of mutations and epigenetic changes occurring during embryonic and 
foetal development of a given genotype produced by sexual production. 
The monozygotic twins used in this study were generated by microsurgical splitting of fertil-
ised embryos (523). Simmental clones were compared with female Simmental monozygotic 
twins to estimate the contribution of SCNT to the observed variability between clones (Fig. 
62A-C). The 5-meC levels of this second chosen control group used in this study ranged from 
5.07% - 5.64% in Simmental MZ twins (n=24) and as previously mentioned the 5-meC levels 
in Simmental clones (n=19) are 5.94 % - 6.93 %. 
The estimated variability of 5-meC levels within 5 genotypes of Simmental clones (0.0636,  
n = 19) was obviously higher than in 13 Simmental twin pairs (0.0193, n=26). When an out-
lier twin pair was excluded, the variability in twins was even lower (0.0091, n=24) (Fig. 53B).  
The variability of 5-meC levels in twins especially detected with the outlier pair could be due 
to either external or internal inherited factors. 
In Simmental clones, the estimated variability within genotypes (0.0636) was thus higher than 
between (< 10-10) clone genotypes. The same finding was previously observed for both 
breeds. In contrast, the variability within twin genotypes (0.0091) was lower than between 
twin genotypes (0.0136), as expected. 
More importantly, the absolute deviations of 5-meC values of individual SCNT clones from 
their respective genotype means were five-fold increased as compared with twins. (Figure 
53B, illustrated as the fractions under the black line in green and light orange boxes). 
While the deviations of genotype means from the respective group means were similar for 
clones and twins (Fig. 53C). 
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On the other hand, when comparison was performed between Holstein clones and twins, the 
difference in absolute deviations of individual 5-meC values from genotype means was even 
more pronounced than the difference between Simmental clones and twins (Fig. 53B, illus-
trated as the fractions under the black line in green and red boxes). The comparison with 
twins had additionally confirms a SCNT cloning effect illustrated by a clone-specific variabil-
ity of DNA methylation. In other words, these epigenome variants highlight that clones are 
only genomic copies of adult animals and not epigenomic ones (521). 
In conclusion, significant genomic DNA hypermethylation in clones was detected in Simmen-
tal clones as compared with Simmental twins (mean ± s.e.m. 6.50 % ± 0.01 % and 5.38 % ± 
0.01 %, two-tailed t-test P < 0.001). Thus, a conclusion can be illustrated in terms that SCNT 
procedure has been shown to affect the DNA methylation status of cloned embryos (137, 145), 
and the effect is remained throughout development till adulthood (Fig. 53A).  
 
3.6.5 Effect of the age, nutrition and cloning process on the epigenetic variabil-
ity of clones 
 
Our study observed epigenetic differences in monozygotic twins that can be due to external 
and internal factors. The former factors can take place through exposure to different environ-
mental conditions that lead to different physiological activities. The internal factors can be 
due to the epigenetic transmission defects through cell divisions that produce an accumulation 
of epigenetic differences by “epigenetic drift” associated with ageing (524), as observed in MZ 
twins in humans. Interestingly, the analysis in this study reveals that the ageing process and 
associated epigenetic drift could act differently in clones.  
The data demonstrate significant differences in means of 5-meC levels between Simmental 
and Holstein clones that arise from breed-specific differences in poorly understood repro-
gramming efficiency and/or differences in donor cell preparation and SCNT procedure. In 
particular, the possibility that these differences were age-related (524) is excluded noting the 
overlapping of the age of Simmental and Holstein clones (unlike DNA methylation levels). 
Furthermore, the mean age of the Simmental clone genotype SC4 (80.5 months ± 1.5 months 
s.e.m.) and the mean age of Holstein clone genotype HC4 (72.0 months ± 5.8 months s.e.m.) 
were very similar (Fig. 54). 
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Figure 54: Correlation between the methylation level and the age of Simmental and Holstein 
clones  
 
The comparison between LMU and INRA cloning procedures (133, 144) shows several differ-
ences. In the LMU cloning procedure, donor cells are subconfluent when used for nuclear 
transfer whereas they are quiescent in the INRA protocol. After fusion between the donor cell 
and the recipient oocyte, the activation process is different and delayed for 1 hour and a half 
in the former protocol compared to the latter. Finally, embryo culture conditions in the LMU 
and INRA protocols were different in terms SOF medium + 10 % serum and O2 control was 
used for the LMU clones and B2 medium + 2.5 % serum and no O2 control for INRA clones. 
This could impact on sequence-specific methylation status and developmental gene expres-
sion in mammals (525, 526). Representative photographs for both breeds are illustrated in figures 
55 and 56. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: Holstein clones from INRA 
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Based on the current data, it is hypothesised that the SCNT cloning procedure induces a “hy-
permethylation drift” protocol in global DNA methylation levels that is within surviving and 
health compatible limits and this deviation is potentially related to breed-specific effects. The 
obtained data do not confirm a normalisation of DNA methylation differences between clones 
and non-clones with advancement of age, as suggested by a study with a limited number of 
SCNT cloned mice (527). Instead, these data support the alternative hypothesis proposed by 
Senda et al. (527) that only cloned animals with a more appropriate methylation status can sur-
vive to adulthood. This assumption is supported by the data from gene-specific analyses that 
suggested more severely altered epigenetic marks in clones that died soon after birth (528) as 
compared with animals that died as juveniles (138). 
 
3.6.6 Determination of 5-methyl cytosine level in liver tissue of healthy and ab-
normal Holstein clones 
 
Researches involving the biochemical properties of food products from cloned and non cloned 
animals had not detected any significant differences (517). Cloned animals and their products 
have recently been declared safe for human consumption by United States FDA (514). It is ob-
vious that the determination of methylation level of critical tissues involved in economically 
important traits (milk and meat) should be included in our study.  
Therefore, the analysis of methylation level in DNA of the liver and muscle samples from HC 
was performed by CE-LIF. The determination of methylation level was done for 10 DNA 
samples extracted from liver cells of female Holstein clones. The evaluated data are recorded 
in table 21 noting that the values are calculated as previously mentioned. 
 
Figure 56 : Simmental clones from LMU 
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Sample 
Code 
 
Type 
State Methylation level 
[%] 
± S.D. 
n 
F6648 Genetic mother Adult mother 4.88   0.12 7 
F2251 Donor cell mother Control 4.04   0.08 10 
F402  
 
Clones 
genotype 
2251(M/C) 
 
YHC 3.98   0.08 8 
F357 YHC 4.33   0.06 8 
F401 YHC 4.83   0.11 7 
F406 PaC 4.12   0.08 7 
F739 PaC 4.13   0.08 13 
F853 PaC 4.64   0.13 9 
F411 PaC 4.82   0.07 8 
F828 PaC 4.93   0.05 13 
Table 21: Determination of methylation level in DNA of liver of healthy and abnomal Hol-
stein clones (YHC: Young healthy clones. PaC: Pathological clones) 
 
The determination of methylation level in the liver cells confirms the epigenetic differences in 
clones. Variable and altered DNA methylation status was detected in young healthy adult 
clones (3 samples) as well as in unhealthy clones (5 samples).  
As in case of leukocytes study, a variability in liver cells of 5-meC between clones of the 
same genotype was also observed. In contrast, the variability is greater with a hypermethyla-
tion in abnormal clones. This finding reflects that living clones without any health problems 
should not be considered normal (515-517). Our data revealed that both normal and abnormal 
clones exhibit an epigenetic variation. 
 
3.6.7 Determination of 5-methyl cytosine level in muscles of healthy and ab-
normal Holstein clones 
 
Muscles are the second important tissue for the economic profit of cattle clones in milk pro-
duction. Therefore, the analysis of methylation level of 13 DNA samples extracted from vol-
untary muscles of healthy clones as well as involuntary muscles (heart) of abnormal clones of 
Holstein breed was performed (later clones were died). The data are evaluated and recorded in 
table 22. 
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Sample 
Code 
Type State Methylation level 
[%] 
± S.D.  
n 
M6648 Genetic mother Adult mother 4.66   0.12 9 
M2251 Donor cell mother Control 4.74   0.04 10 
M477  
 
 
 
Clones 
genotype 
2251(M/C) 
 
YHC 4.65   0.09 8 
M438 YHC 4.74   0.04 5 
M474 YHC 4.77   0.15 8 
M448 YHC 4.77   0.11 10 
M401 YHC 4.84   0.06 8 
M439 YHC 4.85   0.08 9 
C739 HPC 4.25   0.02 12 
C853 HPC 4.67   0.04 11 
C406 HPC 4.74   0.04 13 
C411 HPC 4.76   0.04 14 
C828 HPC 5.09   0.11 7 
Table 22: Determination of methylation level in DNA of muscles of healthy and abnormal Holstein 
clones (YHC: Young healthy clones. PHC: Heart muscles of pathological clones) 
 
The quantification of 5-meC level in muscle samples taken from healthy clones had revealed 
a different observation than the previous studied methylation status in blood samples. No sig-
nificant difference could be detected in healthy adult clones. 
In case of heart muscles, it was observed a significant difference of methylation level between 
the phenotypes (C739 and C828) and the other abnormal clones (C406, C411 and C853). 
However, there is no detected variability between clones when outlier of these 2 phenotypes 
was excluded. In general, the observed variability in muscles is relatively small compared to 
the aberrant methylation level in case of blood and liver samples. The comparison of data 
obtained from the study of methylation status in muscles is not beneficial noting the differ-
ence in muscle types between normal clones and abnormal clones as the analysed DNA sam-
ples are extracted from legs muscles from the former and heart muscle from the latter. The 
heart samples were insufficient to obtain valuable data due to death of clones. 
In conclusion, the reprogramming process establishes first the fully totipotent state and then 
the pluripotent state in the embryo; changes in gene expression during development are asso-
ciated with changes in epigenetic modifications. The reprogramming process could be altered 
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through nuclear transfer procedures, since perturbed DNA methylation patterns could thus be 
responsible for the observed changes in gene expression and may set the embryo or foetus on 
a developmental path that is not compatible with a live and healthy offspring (127, 138, 143). 
However, due to the dynamic nature of DNA methylation that plays a fundamental role in the 
regulation of cellular processes and transgenerational effects, it was not clear how and when 
the methylation pattern is affected in compromised clones. Therefore, long term effects of 
SCNT reprogramming were evaluated by quantifying global epigenetic plasticity in adult 
healthy cloned cattle.  
In fact, clones surviving into adulthood are judged to be normal (515, 529) and their epigenetic 
marks required for normal development are assumed to be maintained. On the other side, the 
clones dying around birth showed a sequence specific variations in DNA methylation (525, 526, 
528). In contrast to this hypothesis, our data highlight SCNT effects on DNA methylation of 
healthy adult clones that are resilient to epigenetic reprogramming during development and 
postnatal exposure to environmental effects. It was concluded that through SCNT cloning 
procedures, functional reprogramming of a donor genome into healthy adults is compatible 
with a highly flexible methylation status of its DNA. The DNA methylation levels in the great 
majority of clones were higher than in the nuclear donors or monozygotic twins (study of 
blood samples). In the Simmental breed, it was detected a 25 % increase in DNA methylation 
levels of clones in comparison with twins. The Clones (mother-genotypes) as well as the 
clone-twin comparisons had provided further confirmation of the previously observed global 
DNA hypermethylation in embryonic (143) and fetal SCNT stages  (144) to healthy adults. 
The global 5-meC variations of such percentage could not be logically originated only from 
the limited number of differentially methylated imprinted genes (530, 531) but other sequence 
elements such as transposons or satellite DNA should be involved in these alteration of DNA 
methylation levels.  
Moreover, the recent data obtained from monozygotic twin studies have highlighted the im-
portant role of epigenome variations as the basis for differences in heritable complex  
traits (155) and new epigenome perspectives show the dynamic interplay of chromatin and 
DNA sequence in heritable traits (532).  
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4 Summary 
DNA methylation is an epigenetic modification established during embryogenesis and reset 
during development. It is an essential process for cell differentiation, gene expression control, 
regulation of vital cell functions and successful mammalian development. Aberrant DNA me-
thylation patterns have frequently been associated with carcinogenesis, with a general loss of 
genomic 5-methylcytosine and a hypermethylation of particular genes. Therefore, the analysis 
of the genomic methylation level would provide a comprehensive tool for the correlation be-
tween 5-meC-mediated biological variations and cancer development as well as other cell 
abnormalities. DNA adducts (another chemical modification of DNA formed via attack of 
exogenous or endogenous chemical reactive agents) have frequently been found to be the first 
step in the development of a cancerous cell and to contribute to tumour aetiology. Thus the 
analysis of DNA modifications is of great importance, as these represent valuable biomarkers 
for exposure to pollutants and carcinogens as well as reflectors of the risk of cancer formation 
or other aging diseases.  
The first section in this study focused on the synthesis of 8-oxo-2’-deoxyguanosine-3’-
monophosphate (8-oxo-dGMP), its detection by the sensitive method CE-LIF and the deter-
mination of the effect of this oxo-compound on the methylation level. The CE-LIF method 
developed by Schmitz et al (395, 399) involves the determination of modified or unmodified nu-
cleotides in form of 2’-deoxyribose-3’-phosphate. Therefore, the hydroxy-nucleotide form of 
the guanine nucleobase was synthesised to enable its detection with CE-LIF via its derivatisa-
tion with the fluorescent marker BODIPY. 8-Oxo-dGMP was successfully synthesised from 
the authentic 3’-dGMP compound by the method of Schuler et al. (258), then was separated 
from the starting material on a C18 column (250 x 4.6 mm, 5 µM) with an ammonium for-
mate buffer (25 mM , pH 4.7). After isolation of the desired fraction, a further purification 
step with 15 % methanol:85 %water was carried out. The pure synthesised 8-oxo-dGMP 
product was characterised with ESI-MS ([M+H]+ at m/z 364.3). A sequence CE-LIF analysis 
of 8-oxo-dGMP had revealed that it exists either in tautomeric forms or a further oxidation 
product of the synthesised 8-oxo-dGMP is formed by time. A double-blind study was carried 
out on leukocytes taken from combat divers who had been subjected to oxidative stress during 
their five months diving training by their exposure to hyperbaric oxygen (HBO). The 8-oxo-
dGMP was detected in the samples from divers after training showing an obvious hypomethy-
lation in comparison to control samples taken from same divers before training. The forma-
tion of the oxoguanosine adduct possibly affects the role of DNA methyltransferase enzymes 
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and leads to a decrease in the genomic methylation level. This study was successful in estab-
lishing a link between the aberrant methylation level, oxidative stress (8-oxo-dGMP) and 
promotion of carcinogenesis, but further studies are necessary to verify these results.  
The second aim of this work was the study of the change of methylation level in response to 
several carcinogens either natural products or environmental pollutants. The effect of aris-
tolochic acid (AA) on the genomic methylation level of treated rats and mice was first exam-
ined. A single oral dose of 30 mg AA/kg BW (body weight) was applied to male Sprague-
Dawley rats, which were sacrificed by decapitation at 24 h after the AA treatment. In addi-
tion, an oral dose of 5 mg AA/kg BW was given daily to female Hupki mice (knock-in mice 
with human p53 gene). One group of mice was sacrificed three weeks after the AA dosage 
i.e., 24 h after the last treatment with AA, and another group was sacrificed 52 weeks after the 
first treatment. DNA samples were extracted from several collected tissues from both studies 
and analysed by CE-LIF. The results showed different patterns in the methylation level ac-
cording to the tested organ, confirming a specificity of the methylation level that can distin-
guish different tissues. In cooperation with a research group in Hong Kong, the highest AA-
DNA adduct concentration was detected in kidneys of the AA-dosed rats (HPLC-ESI-MS 
method). Similarly, a research group in England had detected the highest AA-DNA adduct 
concentration in kidneys of AA-dosed hupki mice among several tissues analysed by the 32P-
postlabeling method. An obvious hypermethylation state was observed in kidney in both 
treated rats (24 h treatment) and treated mice (52 weeks treatment). A hypermethylation was 
also detected with the CE-LIF method in stomach and colon in the former study as well as in 
liver in the latter study (in comparison with their respective controls). Moreover, the compari-
son of data between both controls of mice killed after 3 and 52 weeks had revealed an ex-
pected inverse relation between the animal age and methylation level. In contrast, AA-dosed 
mice did not reveal any hypomethylation related to the exposure length, thus confirming that 
the effect of AA on methylation level had overcome the age effect. Our study had highlighted 
the beneficial use of the aberrant methylation level as helpful biomarker for the promotion of 
carcinogenesis due to AA exposure and had additionally confirmed that kidney is the most 
targeted tissue of AA toxicity. 
Other exogenous chemicals were studied for their carcinogenic effect on the genomic methy-
lation level in both in-vivo and in-vitro studies. In the former study, DNA samples were ex-
tracted from various organs of Sprague-Dawley rats dosed intra-tracheally with 0.2 and  
2.0 mg/kg BW of 3-nitrobenzanthrone [3-NBA] and scarificed 48 h after the treatment. The 
32P-postlabeling method had revealed various DNA-adduct concentrations in specific tissues. 
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The same samples were analysed by CE-LIF and revealed a hypomethylation in small intes-
tine and lungs in the high-dosage study. In the in-vitro study, DNA samples extracted from 
Caco-2 cells incubated with several carcinogens [3-NBA, benzo[a]pyrene (B[a]P) and 4-
amino-biphenyl (4-ABP)] in two concentrations of 2.5 and 5 µg/kg for 24, 48 and 72 h were 
analysed for their methylation level. No significant difference in the methylation level could 
be detected in case of treated Caco-2 cells. This comparison suggests the importance of in-
vivo study of the effect of carcinogens on the methylation level for a reliable conclusion. 
Moreover, the variability of the methylation level among different analysed tissues provides 
insight into the role of related factors such as the cell proliferation rate or the efficiency of 
DNA-repair system in cancer formation via epigenetic modification. 
Finally, DNA methylation as an epigenetic mark was studied in this work for its effect in the 
process of cloning by somatic cell nuclear transfer (SCNT). Epigenetic perturbations are re-
sponsible for foetal and postnatal abnormalities that are frequently observed after SCNT.  
Conversely, the epigenetic status of healthy adult clones is generally considered to be normal, 
although it has never been investigated. The analysis was performed by CE-LIF to determine 
the methylation level from the whole genome of individual animals of each genotype. In order 
to evaluate long-term effects of SCNT reprogramming, the genome-wide methylation level 
was determined in blood samples of 38 healthy adult female SCNT clones generated from 
nine genotypes of the Holstein and Simmental breeds of cattle. Individual methylation levels 
ranged from 4.4 % to 6.9 % with significant differences between the mean 5-meC levels of 
Holstein and Simmental clones (6.50 % ± 0.01 % and 5.09 % ± 0.02 %, P < 0.001). The vari-
ability of methylation level was also found in the case of liver samples in a parallel study per-
formed in ten adult Holstein clones. In addition, in order to judge the contribution of SCNT to 
the variability of individual 5-meC levels, further analysis was carried out to compare Sim-
mental clones with 12 sets of similarly aged female monozygotic Simmental twins experi-
mentally generated from bisected fertilised embryos. In this study, it is concluded that global 
DNA methylation levels of circulating white blood cells of healthy adult bovine clones are in 
fact highly variable between individuals of the same genotype. Also, the methylation level of 
clones is higher than the nuclear donor animals or in contemporary monozygotic twins. The 
absolute deviations of 5-meC values of individual SCNT clones from their genotype means 
were five times as high as in twins. Finally, this study revealed unexpected DNA methylation 
differences between healthy adult clones of the same genotype and between genotypes of dif-
ferent breeds that call for an in-depth analysis of genetic and epigenetic risks associated with 
SCNT cloning and clear guidelines for the use of cloned epigenetics (514). 
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5 Materials and Methods 
5.1 Chemicals 
5.1.1 General laboratory chemicals 
 
1-ethyl-3-(3´-N, N´-dimethylamino-propyl) 
-carbodiimide hydrochloride (EDC)   Fluka, Steinheim, Germany 
2’-thymidine-3’- monophosphate  
(TMP; Na salt)     Sigma, Steinheim, Germany 
4,4-difluoro-5, 7-dimethyl-4-bora-3a, 4a-diaza 
-s-indacene-3-propionyl ethylenediamine 
 hydrochloride (Bodipy-FL-EDA)   Invitrogen, Molecular Probes, Eugene, USA 
Acetone     Merck, Darmstadt, Germany 
Calcium chloride dihydrate   Fluka, Steinheim, Germany 
Calf-thymus DNA (CT-DNA)    
(deoxyribonucleic acid Na salt)  Sigma-Aldrich, Steinheim, Germany 
Dichloromethane HPLC grade  Fischer Scientific, Loughborogh, United King-
dom 
Disodium hydrogen  phosphate  Merck, Darmstadt, Germany 
Fluorescein, Test-mixture, Na salt (water) Beckman Coulter, Krefeld, Germany 
HEPES: N-(2-Hydroxyethyl)-piperazine 
-N´-2-ethane sulphonic acid.    Merck, Darmstadt, Germany  
Hydrochloric acid    Merck, Darmstadt, Germany  
Isopropanol     Chemical unit in Bergische Universität Wupper-     
tal 
Methanol     Merck, Darmstadt, Germany    
Micrococcal nuclease (MN)                          Sigma-Aldrich, Steinheim, 
(Staphylocous aureus)                                   Germany 
Paraffin oil                                                     Fluka, Steinheim, Germany 
Sodium borate     Fluka, Steinheim, Germany 
Sodium dihydrogen phosphate-dihydrate Merck, Darmstadt, Germany 
Sodium dodecyl sulphate, 99 %  Merck, Darmstadt, Germany 
Sodium hydroxide    Carl Roth GmbH Co., Karlsruhe, Germany 
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Sodium tetraphenylborate    Fluka, Steinheim, Germany 
Spleen phosphodiesterase (SPD)  Calbiochem, Darmstadt, Germany 
Water HPLC analysed for 
preparation of derivitisation buffer   JTBaker, Deventer, Holland 
Distilled water was purified through TKA- GenPure water distillation apparatus. 
 
5.1.2 Chemicals for the synthesis of 8-oxo-2’-deoxyguanosine-3’-mono-
phosphate 
 
2’-deoxyguanosine-3’- monophosphate  
(dGMP; Na salt)    Sigma, Steinheim, Germany 
Ammonium acetate     Fluka, Steinheim, Germany 
Ammonium formate    Acrös organics; Geel, Belgium 
Copper sulphate pentahydrate  
(CuSO45 H2O)     Merck, Darmstadt, Germany   
Ferrous Sulphate heptahydrate  
(FeSO47 H2O)      Merck, Darmstadt, Germany   
Hydrogen peroxide solution (35 % H2O2 )  Merck; Darmstadt, Germany   
L-Ascorbic acid Na salt (C6H17O6Na) Acrös organics; Geel, Belgium  
 
5.1.3 Solvents for HPLC separation of 8-oxo-2’-deoxyguanosine-3’-mono-
phosphate from its starting material 
 
Acetonitrile LC-MS grade  Fisher Scientific, Loughborough, UK 
Acetic acid    JTBaker, Deventer, Holland 
Formic acid    Fluka, Steinheim, Germany 
Methanol HPLC grade  Acrös Organics, New Jersey, USA 
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5.2 Experimental preparations 
5.2.1 Standard Preparations 
 
 Hydrolysis buffer (250 mM HEPES in 100 mM CaCl2, pH 6.0) 
3.0 g HEPES and 0.7 g CaCl22H2O were weighed then transferred in a 100-mL screw-cap 
bottle and dissolved in 50 mL water. The solution was then titrated with 1 M NaOH to pH 6.0.  
 
 Derivatisation buffer (50 mM HEPES, pH 6.4) 
Firstly, a stock solution of 800 mM HEPES (pH 6.5) was prepared as the following:  
9.5 g HEPES were weighed in a 100-mL beaker and dissolved in 50 mL water. The solution 
was then titrated with 1 M NaOH to pH 6.5.  
For the preparation of 50 mM HEPES derivatization buffer, 1 mL of the stock solution  
(800 mM) was transferred in a 50-mL centrifuge tube then 15 mL water were added. 
 
 Separation buffer for MEKC-LIF 
90 mM SDS was dissolved in a solution of 90 % v/v sodium phosphate buffer (20 mM,  
pH 9.0) and then 10 % v/v MeOH was added as organic modifier. 
The sodium phosphate buffer was prepared as follow:  
A solution of 20 mM di-sodium hydrogen phosphate (Na2HPO4) and a solution of 20 mM 
sodium dihydrogen phosphate (NaH2PO4) were prepared. The pH of Na2HPO4 solution was 
approximately 10.9 and that of NaH2PO4 solution was approximately 5.6. The desired  
pH 9.0 was obtained by pouring NaH2PO4 solution to Na2HPO4 while the solution was con-
tinuously stirred and monitored with a pH meter at room temperature. The buffer was de-
gassed by sonication before use. 
 
 Separation buffer for CE-LIF (20 mM sodium phosphate buffer, pH 9.0) 
A solution of 20 mM di-sodium hydrogen phosphate (Na2HPO4) and a solution of 20 mM 
sodium dihydrogen phosphate (NaH2P4) were prepared. Then, the latter was added portion-
wise on to Na2HPO4 till pH 9.0 was reached for the solution and finally 10 % v/v MeOH was 
added. 
 
 Sodium tetraphenyl borate 
1.8 g C24H20B Na were weighed and dissolved in 100 mL disodium hydrogen phosphate 
buffer (1 mM, pH 6.0). The solution was stored in a 250-mL screw-cap bottle. 
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 Sodium tetraborate buffer (20mM) 
1.8 g sodium tetraborate were weighed and dissolved in 100 mL disodium hydrogen phos-
phate buffer (1 mM, pH 7.0). The solution was stored in a 250-mL screw-cap bottle. 
 
5.2.2 Preparation of washing solutions for CE 
 
 Preparation of 1M NaOH 
8 g NaOH pellets were weighed and dissolved in 100 mL water. The solution was stored in a 
250-mL screw-cap bottle. 
 
 Preparation of 1M HCL 
210 mL water (measured in a 250-mL graduated cylinder) was poured in a 250-mL screw-cap 
bottle, and then 20 mL of 36 % HCL were added. The solution was shaken after the bottle had 
been sealed. 
 
 Preparation of 200 mM SDS solution 
11.5 g SDS were weighed, transferred to a 250-mL screw-cap bottle, and then 200 mL water 
was added. The solution was stirred slowly after the bottle had been sealed, then allowed to 
stand in order to be used when no foam is seen. 
 
5.2.3 Specific preparation for the synthesis and characterisation of 8-oxo-2’-
deoxyguanosine-3’-monophosphate 
 
 Preparation of 10 mM ammonium acetate buffer: 
0.771 g of ammonium acetate were weighed then transferred to a 1-L volumetric flask and 
dissolved in 1 L distilled water, and then the pH was adjusted to 4 with diluted acetic acid. 
The buffer was degassed before its use. 
 
 Preparation of 25 mM ammonium formate buffer: 
1.576 g of ammonium formate were weighed then transferred to a 1-L volumetric flask and 
dissolved in 1 L distilled water, and then the pH was adjusted to 4.7 with diluted formic acid. 
The buffer was degassed prior to its use. 
 
 
 
 
Experimental part 
 123
 Preparation of 1 mM ferrous sulfate:  
0.0278 g FeSO47H2O were weighed then transferred to a 150-mL beaker and dissolved in 
100 mL 10 mM ammonium acetate buffer (pH 4.0). 
 
 Preparation of 20 mM copper sulfate:  
0.5 mg CuSO45 H2O were weighed on micro-plates of aluminium foil using sensitive balance 
then transferred to an eppendorf capsule and dissolved in 1 mL distilled water. The solution 
was freshly prepared before the reaction. 
 
 Preparation of 170 mM sodium ascorbate:  
0.034 mg C6H17O6Na were weighed on micro-plates of aluminium foil using sensitive balance 
then transferred to an eppendorf capsule and dissolved in 1 mL distilled water. The solution 
was freshly prepared before the reaction. 
 
 Preparation of 1 mM hydrogen peroxide (H2O2): 
800 µL of H2O2 (35 %) were transferred from bottle to an eppendorf capsule and diluted with 
200 µL water. The solution should be freshly prepared before the reaction. 
 
 Preparation of 2 % ammonia:  
8 mL concentrated ammonia (25 %) were diluted with water and the volume was then com-
pleted till 100 mL with water. 
 
5.2.4 Enzyme preparations 
 
The enzyme mixture, consisting of spleen phosphodiesterase (SPD) and micrococcal nuclease 
(MN) enzymes for the hydrolysis, was prepared according to the following steps:  
5.2.4.1 Dialysis of the spleen phosphodiesterase enzyme (SPD) 
 
The enzyme solution (approx. 1 mL), containing a concentration of 10 U SPD enzyme, was 
drawn up with a 2-mL syringe with 0.4 x 20 mm needle (For single use only). Then, the solu-
tion was carefully injected between the diaphragms of the dialysis framework (Slide A Lyz-
ers, 0.5-3 mL volume). The vial of enzyme was washed with water. Then the washing solu-
tion was transferred to the dialysis membrane by means of a needle. Air must be withdrawn 
carefully from the dialysis chamber. After the removal of the syringe, the injection point was 
marked afterwards on the dialysis framework with a water resistant marker. The dialysis 
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framework was fastened to a spongy floater with its marked corner in order to avoid the dan-
ger of the enzyme loss during dialysis. This assembly was transferred to 10-L glass beaker 
filled with millipore cold water. Dialysis was accomplished for 24 h with 4°C in the refriger-
ating chamber. The water was changed after approximately 6 h. One day (24 h) is a sufficient 
time for dialysis to remove low molecular weight compounds. After dialysis, the solution was 
removed with a 5-mL syringe with 0.4 x 20 mm needle from the dialysis membrane and then 
the chamber was rinsed with 500 μL millipore water. The whole collected protein enzyme 
solution was divided on two 1.5-mL eppendorf caps and immediately frozen in liquid nitrogen 
and finally lyophilised in the speed vacuum. 
 
5.2.4.2 Dialysis of the Micrococcal nuclease enzyme (MN) 
 
The dialysis of the Micrococcal nuclease was prepared similar to the dialysis of the SPD en-
zyme, with exception that 500 U MN were dissolved in 500 μL water and were taken with a 
1-mL syringe to be transferred to the dialysis membrane.  
 
5.2.4.3 Production of the MN/SPD enzyme mixture  
 
 Production of the MN-solution: 
The lyophilised protein (500 U) was dissolved in 1667 µL redistilled water; that results in a 
concentration 300 mU/µL. 
 
 Production of the SPD-solution: 
According to the required final concentration of SPD enzyme, the volume of water was calcu-
lated to loosen the lyophilised enzyme described as follow: 
 
 Production of the enzyme mixture 
 
a) MN/SPD mixture with 5 times concentrated SPD:  
 
A final concentration (12.5 mU/μL SPD and of 150 mU/µL MN) was calculated to prepare 5 
times concentrated enzyme-mixture. The lyophilised SPD was first dissolved in 400 μL water 
to produce SPD solution of concentration 25 mU/µL. Then, equal volumes of SPD (25 μL) 
and MN (25 μL) were mixed. In such a way, the prepared 50 μL aliquot of the enzyme mix-
ture was stored at -20°C. 
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b) MN/SPD mixture with 15 times concentrated SPD: 
 
In order to prepare 15 times concentrated enzyme-mixture, a final concentration of 37.5 
mU/μL SPD was calculated. Then, the lyophilised SPD was dissolved in 133 μL water (SPD 
concentration: 75 mU/µL). Finally, equal volumes of SPD (25 μL) and MN (25 μL) were 
mixed. Then, the prepared 50 μL aliquot of the enzyme mixture was stored at -20°C. 
 
5.2.5 Other preparations  
 
Aristolochic acid study 
 
A. Male Sprague-Dawley rats (n=3, BW 180-200 g) were kept in a temperature and hu-
midity controlled room with dark-light cycles. A single oral dose of 30 mg/kg BW of 
AA in 1 % NaHCO3 was given to rats for 24 h. Then, the rats were sacrificed by de-
capitation. Different organs were removed and stored at -80°C then DNA extraction 
was done using Trizol reagent according to the instructions prescribed by the manu-
facturer (Invitrogen, CA, USA). The samples were handled in the department of 
Chemistry of Prof. Zongwei Cai at Hong Kong Baptist University in Hong Kong, 
China. 
 
B. Female Hupki (human p53 knock-in) mice were treated orally with a daily dose of  
5 mg/kg BW of AA according to protocols described to induce tumors in various 
mouse organs. Group of mice was sacrificed three weeks after the AA dosage (24 h af-
ter the last treatment) and another group was sacrificed 52 weeks after the first treat-
ment. Different DNA samples were extracted from the collected organs. The samples 
were handled in institute of Cancer Research by Dr. Volker Arlt, Section of Molecular 
Carcinogenesis in London, United Kingdom. 
 
3-Nitrobenzanthrone study  
 
Female Sprague-Dawley rats (BW 300-380 g) were treated with dose of 0.2 or 2.0 mg/kg BW 
of 3-NBA by intra-tracheal instillation under ether anaesthesia (3 rats/dose). The dose was 
prepared by procedure of Bieler et al.(504). The rats were sacrificed 48 h after 3-NBA admini-
stration. Different organs were collected, frozen immediately in liquid nitrogen and stored at -
80°C then DNA isolation was done following Qiagen genomic DNA Purification procedure 
(Blood & Cell Culture DNA kit, Qiagen, Germany). DNA samples were precipitated by iso-
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propanol and dissolved in distilled water. The samples were handled in the German Cancer 
Research Center, Section of Molecular Toxicology in Heidelberg, Germany 
 
 SCNT and twin study 
 
Animal experiments 
 
Somatic cell nuclear transfer (SCNT) cloned animals were generated by two standard SCNT 
procedures (133, 144, 518, 519) with fibroblasts from nine donors that yielded two to nine clones per 
donor. Monozygotic twins were generated by microsurgical bisection of the fertilised em-
bryos (523). All animal experiments were carried out in accordance with German or French 
legislation on animal ethics and welfare. 
 
DNA samples 
 
DNA samples of Holstein Clones were prepared in INRA (Biologie du dévelopement et Re-
production, Jouy en Josas) in France. DNA samples of Simmental Clones and Twins were 
prepared in Chair for Molecular Animal Breeding and Biotechnology, and Laboratory for 
Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich) in Germany. 
 
 DNA extraction from blood cells 
 
EDTA blood samples were obtained by jugular vein puncture and then leukocytes separation 
was performed by centrifugation (25 min, 1200 x g). The cell fraction was diluted in 10 mL 
PBS and further centrifuged (10 min, 530 x g).  
Cell subfraction counts were performed using the Malassey cell counting method before DNA 
extraction (Blood & Tissue DNA Kit, Qiagen, Germany). DNA samples were dissolved in 
distilled water and stored at -20°C. 
 
DNA extraction from Liver of Holstein Clones 
 
Liver biopsies were taken by surgical needles, cut into very small pieces with a scalpel and 
then crushed using special adapted mixer to enable more efficient lyses. Finally, further cell 
lyses was carried out by addition of Buffer ATL and proteinase Kinase solution followed by 
incubation of the mixture at 56°C. During the incubation time, vortex was occasionally done 
to disperse the sample. The lysate was then treated with 4 µL of RNase (A) to get rid of the 
RNA and incubated for 2 min at RT. Then, Buffer AL and ethanol were added to the sample 
and the mixture was immediately mixed by vortex and applied to DNA easy Mini spin col-
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umn. After centrifugation, the filtrate was discarded. Then, the column was washed first with 
AW-1 buffer followed by centrifugation. The second wash was done with AW-2 buffer fol-
lowed by centrifugation at maximum speed to dry the DNeasy membrane from residual etha-
nol. DNA was finally eluted from the column membrane by addition of small volume of AE 
buffer to increase the final DNA concentration. The column was incubated for 1 min at RT 
and then centrifuged to collect the filtrate containing the required DNA. 
 
DNA extraction from muscles of Holstein Clones 
 
The specimens from muscle tissues were crushed, immediately frozen in liquid nitrogen and 
stored in aluminium foil at -80°C. In order to extract the DNA, the tissues were crushed in 
liquid nitrogen. Then, the powder was incubated overnight in SLB buffer and Proteinase K at 
42°C. The sample was continuously agitated during the incubation period. Then the sample 
was treated with RNase (A) solution (10 mg/mL) and incubated for 1 h at 37°C. The sample is 
treated again with PK in SLB buffer for 1 h and half at 42°C. After incubation, the sample 
was extracted with a mixture of phenol, chloroform and iso-amelic acid, then agitated care-
fully and centrifuged for 6 min at 5000 rpm. After extraction, the DNA was carefully precipi-
tated with NaOH and ethanol. The precipitate was washed 3 times with 70 % EtOH then dried 
(UV lamp, 10 min). Then, the solution was re-suspended in TE (10 mM Tris, 1mM EDTA, 
pH 8.0) and left for agitation at RT over night. 
 
N.B: All the samples analysed in the whole research work were quantified by UV-VIS spec-
trophotometery and subsequently aliquoted in either 1 or 10 µg. 
 
5.3 Methods 
5.3.1 Common methodology for the preparation of DNA samples (1 µg or  
10 µg) 
5.3.1.1 Hydrolysis of genomic DNA samples (1 µg or 10 µg) 
 
1 µg or 10 µg of dried DNA was dissolved in 5 µL water and then hydrolysed to 2’-deoxy-
nucleoside-3’-monophosphate by incubation for 3 h at 37°C with 5 µL of the enzyme solu-
tion. This enzyme solution consists of 5 µL of the enzyme mixture (150 mU/µL MN and  
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12.5 mU/µL SPD) and 1 µL of the hydrolysis buffer (250 mM HEPES in 100 mM CaCl2,  
pH 6.0). The incubation was done while shaking (800 rpm). 
 
5.3.1.2 Derivatisation of genomic DNA samples (1 µg or 10 µg) 
 
DNA hydrolysate (1 µg) was derivatised with 15 µL of 1.8 M EDC (dissolved in 50 mM 
HEPES, pH 6.4), 15 µL of 27 mM Bodipy FLEDA dissolved in the same buffer and 15 µL 
HEPES buffer (50 mM, pH 6.4). Then the sample was incubated for 21 h in the dark at 25°C. 
The incubation was done while shaking (800 rpm). In the case of 10 µg DNA, the hydrolysed 
solution was derivatised with 1.8 M EDC, 27 mM Bodipy FLEDA (20 µL each) and 20 µL 
HEPES buffer. The sample was incubated under the same conditions described for 1 µg DNA 
sample. 
 
5.3.1.3 Precipitation of the excess of Bodipy and EDC (1 µg or 10 µg) 
 
Precipitation of 1 µg DNA sample 
55 µL of the derivatised sample were transferred into a 15-mL cap and then diluted with  
425 µL water. To the solution, 550 µL of 52.5 mM sodium tetraphenylborate (dissolved in  
1 mM sodium phosphate buffer, pH 6.0) were added portion-wise while shaking for the pre-
cipitation of nucleotide. After mixing, 11 mL methylene chloride (CH2Cl2) were added to the 
solution, well mixed and finally centrifuged for 4 min at 3000 rpm and 20°C. The aqueous 
phase was isolated and then centrifuged again for 10 min at 13000 rpm. The supernatant was 
transferred to 1.5-mL cap and stored at -25°C to be analysed by CE. 
 
Precipitation of 10 µg DNA sample 
70 µL of the derivatised sample were transferred into a 50-mL cap and diluted with 630 µL 
water. To the solution, 770 µL sodium tetraphenylborate (52.5 mM solution in 1 mM sodium 
phosphate buffer, pH 6.0) were added portion-wise while shaking for the precipitation of nu-
cleotide. After mixing, 15 mL CH2Cl2 were added to the solution, well mixed and finally cen-
trifuged for 4 min (3000 rpm, 20°C). The aqueous phase was isolated and then centrifuged 
again for 10 min (13000 rpm). The supernatant was transferred to 1.5-mL cap and stored at 
-25°C to be analysed by CE. 
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5.3.1.4 CE-LIF measurement 
 
A definite volume (37.5 or 42 µL) of DNA sample (1 or 10 µg) was transferred to 200 µL 
PCR vial respectively then diluted by a factor 1:100 with distilled water (162.5 or 158 µL) 
which was pre-degassed in case of long sequence-measurements. Finally, two drops of paraf-
fin oil were poured on the surface of the sample to prevent its evaporation during long time 
analysis by CE-LIF. The PCR vial was placed in specific CE vial then closed with rubber cap 
and finally placed in the sample rack of CE (25°C). The sample is hydrodynamically injected 
into the capillary and an electric field is supplied to the electrodes by a high-voltage power 
supply. Then, the ions move through the capillary in the direction of electroosmotic flow to 
the detector placed at the outlet end of the capillary. The ions are separated according to their 
size (r) to charge (q) ratio in terms of their migration due to the electrophoretic velocity. Fi-
nally, the separated ions flow into the laser induced fluorescence detector and their signals are 
transferred to the data system which results in a plot of relative fluorescence unit (RFU) ver-
sus migration time (tm) and the electropherogram is recorded. 
According to the CE mode chosen for the analysis, CZE or MEKC technique, the working 
conditions of CE were adjusted. Tables 23 and 24 summarise the conditions of the used CE or 
MEKC separation techniques respectively. 
 
Condition Value Duration 
(min) 
Solution 
Rinse (Pressure) 20 psi 1.00 SDS 
Rinse (Pressure) 20 psi 1.50 NaOH 
Rinse (Pressure) 20 psi 1.00 H2O 
Rinse (Pressure) 20 psi 2.00 Separation buffer 
for MEKC 
Injection (Pressure) 0.5 psi (forward) 5.00 (sec) Sample 
Separation (Voltage) 20 kV 45 Separation buffer 
for MEKC 
Table 23:  Method of separation of derivatised nucleotide with MEKC-LIF 
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Condition Value Duration 
(min) 
Solution 
Rinse (Pressure) 20 psi 1.50 NaOH 
Rinse (Pressure) 20 psi 1.00 H2O 
Rinse (Pressure) 20 psi 2.00 Separation buffer 
for CZE 
Injection (Pressure) 0.5 psi (forward) 5.00 (sec) Sample 
Separation (Voltage) 28 kV 20 Separation buffer 
for CZE 
Table 24:  Method of separation of derivatised nucleotide with CZE-LIF 
 
5.3.2 Synthesis of 8-oxo-2’-deoxyguanosine-3’- monophosphate 
4 mg of 2’-deoxyguanosine- 3’-monophosphate (dGMP) were dissolved in 400 µL distilled 
water. Then, 160 µL sodium ascorbate freshly prepared solution (170 mM), 160 µL copper 
sulphate pentahydrate solution (20 mM) and 100 µL hydrogen peroxide (28 % H2O2) were 
added. The reaction was left for 15 min at room temperature. Then, the mixture was separated 
on RP-18 column (LichrospherR 100, 250 x 4.6 mm ID, 5 µm). Different eluents were tried: 
25 mM ammonium formate (pH 4.7), acetonitrile:water (different proportions), ammonium 
formate:methanol mixture (1:1) and methanol:water (different percentages). The retention 
times of guanosine and oxoguanosine were identified according to the eluent system (flow 
rate 0.8 mL/min). The HPLC column was prepared at the beginning of every working day; the 
buffer was firstly purged for 2 min (valve is opened) to get rid of air bubbles in the injection 
part then flowed for 20 min to clean the column. The wavelength of UV detector was adjusted 
at 247 nm. Once a stable state of pressure was attained (116 bar), 100 µL of the sample was 
injected onto the column (4 times). 
5.3.3 Electrospray ionisation mass spectrometry (ESI-MS) of 8-oxo-2’-deoxy-
guanosine-3’- monophosphate 
The purified and dried 8-oxo-dGMP fraction was dissolved in water:acetonitrile (50:50,  
0.1 % formic acid) then injected into the ion source where the molecules are ionized.  
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5.3.4 Preparation of the capillary for CE measurement 
 
The fused-silica capillary for the capillary electrophoresis system was prepared from polyim-
ide coated capillaries (type TSP Tubing Fused Silica) with an inner diameter of 50 µm and an 
outside diameter of 375 μm. The steps of the preparation of the capillary were described as 
follows: (See appendix Fig. 57) 
 
 Preparation of the detector window  
The capillary of length more than 50 cm was cut from the stainless steel wire provided in me-
ters using a ceramic capillary cutter. Then, the effective length was measured and the detector 
window was marked within this range. The polyimide sheath covering the capillary should be 
burned in the location of the window which estimated to be 3 mm. To achieve this burning, 
the capillary was inserted into a device designed for the capillary preparation (See Appendix). 
Finally the marked detector window was burned with the gas burner for few seconds to not 
break the fragile glass; afterwards the window was properly cleaned with methanol. The cap-
illary was inserted into the cartouche, and then the inlet and the outlet were cut to the same 
length. In order to avoid high injection fluctuations, about 2 mm of the polyimide coating was 
burned away at the capillary inlet. This heat curing technique improves the long-term stability 
of the capillary by preventing the gradual build-up of welled and frayed polyimide coating 
rests in front of the capillary inlet or outlet after longer contact with CE buffer (533). 
 
 Conditioning of the capillary 
The capillary should be conditioned before its first use. It was rinsed with 1 M NaOH  
(15 min, 20 psi), 1 M HCL (15 min, 20 psi), 1 M NaOH (15 min, 20 psi), water (5 min,  
20 psi) and electrolyte (10 min, 20 psi). Then finally, the electrolyte buffer was injected  
(5 sec, 0.5 psi). The run was performed for 50 min and good base line was obtained by apply-
ing voltage of 20 kV at 20°C. 
 
 Washing of the capillary 
At the beginning of every working day and between each run, the capillary was rinsed with 
200 mM sodium dodecyl sulphate (1 min, 20 psi), 1 M NaOH (1.5 min, 20 psi), water (1 min, 
20 psi) and finally with electrolyte (2 min, 20 psi). Then the electrolyte buffer was injected  
(5 sec, 0.5 psi). 
At the end of the working day, capillary was washed with water (2 min, 100 psi), then both 
inlet and outlet of the capillary is kept overnight in water vials.  
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5.4 Instrumentation 
5.4.1 CE-LIF system specifications are described as follows: 
 
Capillary electrophoresis: P/ACETM MDQ system with a laser-induced-fluorescence (LIF) 
detector (Beckman Coulter, Krefeld, Germany).   
32KaratTM Software, Version 7 (Beckman Coulter, Krefeld, 
Germany) 
LIF detection system: includes LIF detector module (dual wavelength), power supply, 
LIF cartridge plug and probe stabilizer, fibre optic cable, 520 nm 
emission filter and 488 nm notch filter (Beckman Coulter, Kre-
feld, Germany) 
Laser 1:  Argon-ion laser with ex =488 nm (Power: 10 mW output) 
Beckman Coulter (Krefeld, Germany).  
Laser 2:  Sapphire solid-Laser with ex =488nm (Power: 20 mW output) 
Coherent (Dieburg, Germany).  
Capillary:  Fused silica capillary (50 µm ID, 375 µm OD, LT =50 cm, with 
the detection window at LD =40 cm) (BGB-Analytik, Schloß-
böckelheim, Germany). 
 
5.4.2 UV-VIS spectrophotometer specifications for DNA quantification are 
described as follows: 
 
SpecordR 205 UV/VIS spectrophotometer (Analytik Jena, Jena, Deutschland) 
Software WinAspect (Analytik Jena, Jena, Deutschland) 
0.5 mm Suprasil 115-OS Quartz glass cuvettes (Hellma, Mühlheim, Deutschland), measure-
ment at 254 nm 
 
5.4.3 General laboratory instruments 
 
Centrifugation: 
Mini spin-Table centrifuge: Max. 13400 U/min (Eppendorf, Hamburg, Germany) 
AllegraTM 25 R centrifuge:              Beckman CoulterTM, Krefeld, Germany 
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Hydrolysis and derivitisation: 
Thermomixer:  Thermomixer comfort inclusive 0.5 mL- and 2 mL-table with 
aluminium foil cover (Eppendorf, Hamburg, Deutschland)  
 
DNA dryness: 
Speed vacuum:  Jouan SA RC 1022 (Jouan, Saint Herblain, France) 
 
DNA purification:  Qiagen Genomic-Tip 100 / G for mini-preparation volumes 
  Qiagen Genomic-Tip 20 / G for midi-preparation volumes 
 
Enzyme preparation: 
Dialysis membrane: Slide-A-Lyzer dalysis cassette (10.000 Da), 0.5-3 mL capacity (Perbio 
Science, Germany) 
Syringes: 1 mL-, 2 mL-, 5 mL- syringe (Braun, Melsungen, Germany) 
Needles: 0.4 x 20 mm needle (Braun, Melsungen, Germany) 
Water resistant marker, spongy floater, glass beaker (10 L) 
 
pH adjustment of buffers: 
pH-meter:   Beckman 350, (Beckman Coulter, Krefeld, Germany) 
pH-standard electrode:  511275-AB (Beckman Coulter, Krefeld, Germany) 
 
 
Water preparation: 
1. Milli-Q synthesis A10 water ultrapure laboratory water system (Millipore, Schwalbach or 
Eschborn, Germany), and the water quality was 18.2 MOhms × cm with TOC 5-10 ppb.  
2. TKA-GenPure 08.2207 UV-TOC/UF water distillation apparatus (TKA, Niederelbert, 
Germany). 
 
Others equipments: 
 
Balances: Sensitive balance BP 221S [Max 220 g, d = 0.1 mg] (Sartorius, 
Göttingen, Germany)     
Analytical microbalance M2P [Max 2 g, d = 1μg] (Sartorius, 
Göttingen, Germany) 
Beakers:   10 mL, 50 mL, 100 mL, 200 mL, 500 mL, 800 mL beakers. 
Centrifuge tubes:  15 and 50 mL Centrifuge tubes (Sarstedt, Nümbrecht, Germany)  
Gas burner:   MICROFLAM-burner MFB/E (Proxxon, Niersbach, Germany) 
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Graduated cylinders: 25 mL, 50 mL, 100 mL, 250 mL graduated cylinders 
Magnetic stirrer:  IKAMAG RCT (IKA) 
Pipettes: Transfer pipettes in different sizes [0.5 – 10 µL, 10 – 100 µL, 
100 – 1000 µL, 1-5 mL] (Brand, Wertheim, Germany) 
Pasteur pipettes [0.5 and 3 mL] (Sarstedt, Nümbrecht, Germany) 
Pipette micro-tips 0.1-10 μL (Roth, Karlsruhe, Germany) 
Pipette yellow- tips, 200 μL (Sarstedt, Nümbrecht, Germany) 
Pipette blue- tips, 1000 μL (Sarstedt, Nümbrecht, Germany) 
Pipette white- tips, 1250 μL long (Sarstedt, Nümbrecht, Ger-
many) 
Plastibrand 5-mL tips (Roth, Karlsruhe, Germany) 
Reaction capsules:  Eppendorf capsules (Caps 0.5, 1.5 mL), Hamburg, Germany 
Sample vials: 2 mL CE glass vials (Beckmann Coulter, Krefeld, Germany) 
    200 µL PCR vials (Neolab, Heidelberg, Germany) 
Rubber caps REV AA and REV AB for glass and PCR vials 
(Beckman Coulter, Krefeld, Germany) 
Sonicator:   Qualilab USR 54H (Merck Eurolab, Bruchsal, Germany) 
Storage containers:  250 mL screw-cap vials of Duran (C, No: A 359.1) 
Syringe: Glass syringe Luer Lock [20 mL], Fortuna®, (Poulten & Graf, 
Wertheim, Germany)  
Volumetric flasks:  50 mL, 100 mL, 200 mL, 500 mL volumetric flasks. 
Vortexer:   REAX 2000 (Heidolph, Schwabach, Germany) 
 
5.4.4 LC-UV system specifications for HPLC separation of 8-oxo-2’-
deoxyguanosine-3’-monophosphate from its starting material are de-
scribed as follows: 
 
Pump: Merck Hitachi L-6000 A (Tokyo, Japan) 
Column: LichrospherR 100 column (250 x 4 mm, ID), RP- 18 E (5 µm) (Darmstadt, 
Germany)  
Detector: Merck Hitachi L-4250 UV- visible detector: (absorbing band  max 247) (To-
kyo, Japan) 
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5.4.5 SPE system specifications are described as follows: 
 
Solid phase extraction (SPE) vacuum manifold (Merck, Lichrolut) consists of: 
1. Glass chamber to allow easy visual monitoring. 
2. Adjustable racks to accommodate a variety of vials and small-capacity beakers.  
3. Flow control valves to allow easy control of flow through SPE columns. 
4. Vacuum gauge and valve to monitor and release the vacuum during processing. 
5. Different Stationary phase types for SPE columns were used: 
1) LichrolutR RP-18 E (40-63 µm) in plastic column, 3 mL capacity (Merck, Darm-
stadt, Germany).  
2) OasisR HLB (Waters Corporation) solid phase extraction column, a copolymer       
consisting of lipophilic divinylbenzene and hydrophilic N-vinylpyrrolidone, capacity 
60 mg/3 mL (Waters, Eschborn, Germany) 
 3) SPE: StrataTM-X-AW, a Polymeric mixed mode weak anion exchange sorbent 
(modified surface of styrene divinylbenzene sorbent), capacity 200 mg/3 mL (phe-
nomenex, USA).  
 
5.4.6 Mass spectrophotometer:  
 
Micromass Q-Tof ultimaTM API (Waters corporation, Milford massachussets, USA) Capillary 
voltage: 3 kV, source T: 95°C, desolvation T: 180°C, collision Energy: 10 eV. 
 
5.5 Statistical methods 
SCNT and twin study 
Separate models for the 3 experimental groups were run to estimate inter-individual and inter-
genotype variances and another linear mixed effects model for the combined measurements of 
all Simmental animals to estimate the difference in average methylation levels between clones 
and twins. Data analysis was carried out with the statistical software environment R 2.6.2 (534). 
Specifically, the lme4 package (535) was used for the estimation of the linear mixed effects 
models (536) and the RLRsim package (537) to compute exact restricted likelihood ratio tests (538) 
for the presence of between-genotype variation. Reported P-values for the latter are based on 
Monte Carlo samples of 10000 values from the exact sample distribution of the likelihood 
ratio.  
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3-Nitrobenzanthrone-In-vitro study 
Data analysis was carried out with the statistical software graph PAD Prism® version 5.02 for 
comparison of the mean values for the control samples and that of 3-NBA–incubated Caco-2 
cells. 
 
5.6 Software 
o CE measurements:   32 KaratTM version 7.0 (2003), Beckman Coulter, Kre- 
feld, Germany 
o UV measurement:  WinAspect version 2.2.1.0 (2006), Analytik Jena, Jena 
o Mass spectrum:  MassLynx  version 4.0 
o Chemical structures :  ChemDraw Ultra  version 7.0.1 
o Calculations:    Excel-Microsoft Office 2003  
o Text:    Word-Microsoft Office 2003  
o Electropherograms:   Sigma plot 2004 version 9.0 
o HPLC chromatograms:  Paint.NET, Version 3.36 
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6 Appendix 
Glossary 
 
Abasic sites: Sites in DNA from which purine or pyrimidine bases have been lost by cleavage 
of the deoxy ribose N-glycosidic linkage. 
Adenocarcinoma: A tumour developed in an organ or gland. 
Allele: Alternative form of a gene. 
Apoptosis: Programmed cell death. 
Benign tumour: referring to tumour possessing cells that closely resemble normal cells and 
is localised in the tissue where it originates. See also malignant tumour. 
Carcinogen: Any chemical or physical agent that can cause cancer when cells or organisms 
are exposed to it. 
Carcinoma: A malignant tumour derived from epithelial cells.  
Centromere: Constricted portion of a mitotic chromosome where sister chromatides are at-
tached, it is required for proper chromosome segregation during mitosis and meiosis. 
Chromosome translocation: Abnormality caused to the chromosome by rearrangement of 
parts between non homologous chromosomes. 
DNA: Deoxyribonucleic acid; the molecule that carries genetic information. 
DNA adducts: Active metabolites bound covalently to DNA 
DNA sequencing: Methods to determine the order of nucleotide bases. 
Epigenetics: On top of genetics. 
Gene: Fundamental unit of heredity (specific section of DNA within a chromosome). 
Gene conversion: one allele of gene is converted to another during meiotic recombination 
Genome: A full set of chromosomes carried by a particular organism.  
Genotype: The genetic makeup of an individual, also the alleles at one or more specific Loci. 
See also allele. 
Germ line mutation: mutation concerning lineage of germ cells, which give rise to gametes 
and thus participate in formation of the next generation of organisms, and this mutation will 
be transmitted from one generation to the next through gametes. See also mutation. 
Giloma: A malignat tumour derived from nerve tissues. 
Heterochromatin: Regions of chromatin those remain highly condensed and transcription-
ally inactive during interphase. 
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In-vitro: Denoting a reaction or process taking place in an isolated cell-free extract; some-
times used to distinguish cells growing in culture from those in an organism. 
In-vivo: In an intact cell or organism. 
Leukemia: Cancer of white blood cells and its precursors.  
Lymphoma: A malignant tumour developed in lymph glands. 
Malignant tumour: referring to tumour that can invade surrounding normal tissue. See also 
benign tumour. 
Meiosis: Cell division in sexually reproducing organisms that reduces amount of genetic in-
formation by half. 
Melanoma: Cancer involving pigment cells of the skin.  
Mitosis: Simple cell division without a reduction in chromosome number. 
Mutation: A permenant and heritable change in the nucleotide sequence of a chromosome, 
usually in a single gene; commonly leads to change in or loss of the normal function of the 
gene product. 
Phenotype: Physical characteristics of an individual. 
Point mutation: Change of a single nucleotide in DNA, especially in a region coding for pro-
tein, can result in formation of a codon specifying a different amino acid or a stop codon. 
Promoter: Regulatory regions of DNA located towards 5’ region of gene and provide a con-
trol point for regulated gene transcription. 
Sarcoma: A malignant tumour of connective and supporting tissues (blood vessels, bones and 
muscles) 
Somatic mutation: mutation concerning any plant or animal cell other than a germ cell. See 
also mutation. 
Tautomeric shift: spontaneous rearrangement to transient alternative form  
keto (standard)  enol  forms ( G &T amino (standard)  imino forms of A & C) 
Transposon: a relatively long mobile DNA element, in prokaryotes and eukaryotes, that 
moves in the genome by a mechanism involving DNA synthesis and transposition. 
 
N.B: Most of the definitions were structurally modified from the book ‘Molecular Cell Biol-
ogy’, 4th Edition. 
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A brief history of Capillary electrophoresis 
 
1897: Kohlrausch introduced of the basis of the essential characters of the electro-
phoretic transport processes by its law ’’independence of ion migration’’ in and 
proofed mathematically that the passage of an electric current does not change 
the concentration in a system with uniform electrolyte distribution (405).  
1930s: Arne Tiselius introduced the free solution-moving boundary electrophoresis in 
its classical forms (406) for the analysis of complex protein mixtures. 
1948: Tiselius was awarded Nobel Price in Chemistry for his work concluding that 
the direction and the rate of migration of the components were determined by 
their charge and their mobility. 
1960s:  Introduction of classical techniques employing stabilizing media of paper and 
gels of polyacrylamide and agarose. Gel electrophoresis was designed as a mo-
lecular sieve for the size-dependent separation of nucleic acid and proteins.  
1967: Hjertén performs electrophoresis in free solution without any supporting me-
dia to overcome the convection problem and named after him ‘free-zone-
electrophoresis’(407).  
1974:  Virtane applied electrophoresis employing open glass tubes of 200-500 µm 
ID capillaries.  
End of the70's: First steps for the actual development of capillary electrophoresis by Mikkers, 
Everearts and Verheggen (408) using thin capillaries (200 µm ID) made from 
Teflon for zone electrophoresis.  
1981: Rapid advance in CE was achieved by Jorgenson and Lukacs (409-411) and de-
scribed electrophoretic separations of peptides using free zone electrophoresis 
(FZE) in glass capillaries of 75 mm ID employing high voltage of separation 
(30 kV) . 
1984: Terabe (539) introduces micellar electrokinetic chromatography (MEKC) 
1985: Introduction of capillary isoelectric focusing (CIEF) by Hjerten. 
From begining of 1950: Researches about capillary electrochromatography (CEC) 
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Laboratory Document 
Hydrolysis and Derivatisation of DNA Samples 
 
Date: 20.10.08   Operator(s) (Name/Abbreviation): DZ 
 
Sample(s)-Abbreviation: S.I. 2, S.I. 7, S.I. 8 and CT-10 
 
Description: 
 
  
  
Samples: 
1. Hong Kong samples: S.I. 2,7,8 (10µg) 
2. CT-DNA: 10 µg 
 
 
 
1. Hydrolysis 
 
Hydrolysis method: I 
Preparation of DNA at: 01.09.08     Amount: 10 µg 
 
Remarks: 
 
  
 
Hydrolysis with 15 folds enzyme mixture 
 
 
Preparation of DNA by (Operator): Hong Kong and DZ 
 
Enzyme mixture MN/SPD (150mU/ml MN, 2.5U/ml SPD): 
 
Date of preparation: 29.05.08 / 12.08.08    Operator: DZ 
Date of first use of respective aliquot: 20.10.08 
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Hydrolysis buffer (250 mM HEPES, 100 mM CaCl2, pH 6.0): 
 
Description: HB250 DZ (3)     Preparation Date: 16.07.08 
Operator: DZ 
Production of used water: 16.07.08    Charge: G-08-01 
Was the hydrolysis buffer warmed up to R.T. before hydrolysis?           Yes 
 
Water for DNA-dilution (Tridest.): 
Manufactured by processing of demineralized water by means of a water treatment device of the company Milli-
pore 
Equipment designation and technical Data: 
 
Milli-Q SYNTHESIS A-10 ( )   TKA Genpure  (x) 
Charge: H-08-02 
 
 
Information of water quality (See Water-Document) 
 
Hydrolysis conditions: 
 
Temperature: 37°C 
Exact Hydrolysis duration: 3 h 
h x ν:  Yes     ( )  No              (x) 
 
2.Derivatisation: 
 
Derivatisation method: DVI MT 
 
Derivatisation buffer: 
 
Description: DDZ (3)   Composition: 50 mM HEPES, pH 6.36 
Preparation Date: 28.04.08  Operator: DZ 
Production of used water: 21.02.08   Charge: Water for HPLC 
Was the derivatisation buffer warmed up to R.T. before derivatisation?           Yes 
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BODIPY and EDC: 
 
BODIPY =                                       1.25 mg + 125 µL buffer DDZ (3) 
 
Lot & Filling code (Manufacturer): 479175 
1. Date of opening of used aliquot: 131008 
 
Remark: 
  
 
EDC =                                               42.6 mg + 121.5 µL buffer DDZ (3) 
 
Lot & Filling code (Manufacturer): 1251845 / 30307089 
Internal charge / Aliquot description: 02.10.07 / 010 DZ 
1. Date of opening of used aliquot: 10.10.08 
 
Subsequent aliquoting:   Yes (x)     No  ( ) 
 
 
Derivatisation conditions: 
 
Temperature: 25°C 
 
Derivatisation duration: 21 h   Reaction volume [µL]: 70 µL 
 
h x ν:  yes  ( )   No  (x) 
 
Pipettes (Transfer pipette ®, Fa. Brand): 
 
Which Pipettes for hydrolysis were used?? 
 
- Production of enzyme solution:  10-100µL (yellow)   (x) 0.5-10µL (grey)  ( ) 
 
-DNA-transfer and enzyme addition: 10-100µL (yellow) ( ) 0.5-10µL (grey)  (x) 
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Which Pipettes for derivatisation were used? 
 
- HEPES addition to hydrolysate: 10-100µL (yellow) (x) 0.5-10µL (grey)  ( ) 
 
-Production BODIPY-solution:  10-100µL (yellow) (x) 0.5-10µL (grey)  ( ) 
 
- Production EDC-solution:  10-100µL (yellow) (x) 0.5-10µL (grey) ( )  
 
Last calibration of pipettes is done at: March 2007 
 
Subsequent treatment of derivatised sample(s): 
 
1. Aliquot: 
 
 
---------------------------------------------------------- 
 
 
 2. Storage (Temp. / Location): - 20°C / Laboratory H11.16 
 
Conclusion: 
 
 
 
After derivatisation, precipitation of sample was done by tetraphenylborate. Then centrifuga-
tion was done for 10 min. 
 
 
 
 
Date: 21.10.08    Signature of Operators: ……. 
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Description of sequence 
 
Run 
number 
Sample  Capillary Laser Dil. Buffer Data file 
001-003 T1 WNI 05A 
DZ 140309 
Sapphire 
solid 
laser 
1:100 20 mM sodium 
phosphate buffer 
(pH 9.0) in 10 % 
MeOH 
140309DZ001-003 
004-006 T2 same same same same 140309DZ004-006 
007-009 T3 … … … … 140309DZ007-009 
010-012 CT 1 … … … … 140309DZ010-012 
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Figure 57:  Steps of capillary preparation 
 
 
 
Removal of polyimide isolation layer A 
Adjust capillary inlet and 
outlet to this end
Capillary was cut to acquire
total length of 50 cm
B 
Burning the polyimide layer from
inlet and outlet ends
Transparent inlet or outlet end
   C    
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Figure 58: Transmission spectrum of CT-DNA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59:  Solid phase extraction manifold 
 
 The illustrated solid phase extraction (SPE) set was used for cleaning purposes of the synthe-
sised 8-oxo-dGMP. 
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Figure 60:  LC chromatogram-UV–VIS spectrum of 2’-deoxyguanosine-3’-monophosphate (3’-dGMP). 
Chromatographic conditions: The analysis was performed on Knauer column (125 X 4 mm, 
ID), prepacked with Eurosphere 100 C18 (5 µm), with integrated Knauer pre-column (Berlin, 
Germany), Dionex pump P580A LPG , Dionex  Photodiode Array Detector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61:  LC chromatogram-UV–VIS spectrum of 8-oxo-2’-deoxyguanosine-3’-monophosphate (8-oxo-
dGMP). Chromatographic conditions: same as in previous figure 
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Figure 62:  Mass spectrum ESI-MS positive injection mode of non purified 8-oxo-dGMP in the collected 
fraction from HPLC after its separation from the starting material (Mobile Phase: 25 mM am-
monium formate) 
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